var title_f18_51_19248="Medial patellar plica test";
var content_f18_51_19248=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F83265&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F83265&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 560px\">",
"   <div class=\"ttl\">",
"    Medial patellar plica test",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 540px; height: 377px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    With the patient supine, the examiner first applies pressure with the thumb over the inferior and medial apsect of the patellofemoral joint to interpose the medial plica between the medial patellar facet and the medial condyle. While maintaining this pressure, flex the knee passively from full extension to 90 degrees of flexion. In patients with plica syndrome, pain and popping occurs when the knee is between 30 and 45 degrees of flexion.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_51_19248=[""].join("\n");
var outline_f18_51_19248=null;
var title_f18_51_19249="Ring cutter";
var content_f18_51_19249=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F53966&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F53966&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 586px\">",
"   <div class=\"ttl\">",
"    Ring cutter method of ring removal",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 566px; height: 230px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Use ring cutters with care in patients with lacerations because metal filings may cause foreign body reaction and/or chronic synovitis. Check the saw blade to ensure it is sharp and clean. Note that standard ring cutters are usually not effective for removing hardened steel rings (eg, steel nuts, washers). Place the guard of the ring cutter under the ring on the plamar aspect of the hand or plantar aspect of the foot. Apply the saw blade to the ring using the lever (large arrow) and turn the wheel of the blade using the handle (lines). Heat from friction may develop and necessitate periodic cooling with cold water or ice. Once the ring is cut, remove it from the finger by pulling it apart with hemostats. Two cuts may be necessary to permit removal.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Fuchs SM. Ring removal. In: Textbook of Pediatric Emergency Procedures, 2nd ed, King C, Henretig FM (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2008. Copyright &copy; 2008 Lippincott Williams &amp; Wilkins.",
"    </div>",
"    <div class=\"contractual\">",
"     <br/>",
"     <a href=\"file://www.lww.com\">",
"      file://www.lww.com",
"     </a>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_51_19249=[""].join("\n");
var outline_f18_51_19249=null;
var title_f18_51_19250="Medium chain triglycerides: Drug information";
var content_f18_51_19250=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Medium chain triglycerides: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?29/29/30164?source=see_link\">",
"    see \"Medium chain triglycerides: Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"UTD.htm?13/55/14195?source=see_link\">",
"    see \"Medium chain triglycerides: Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F191959\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      MCT Oil&reg; [OTC]",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F191960\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      MCT Oil&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F191967\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Nutritional Supplement",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F191961\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cystic fibrosis: 45 mL/day in divided doses",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Malabsorption syndromes: Oral: 15 mL 3-4 times/day",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F191964\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?13/55/14195?source=see_link\">",
"      see \"Medium chain triglycerides: Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Nutritional supplement:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Infants:",
"     </i>",
"     Oral: Initial: 0.5 mL every other feeding, then advance to every feeding, then increase in increments of 0.25-0.5 mL/feeding at intervals of 2-3 days as tolerated",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Seizures:",
"     </b>",
"     Oral: About 40 mL with each meal or 50% to 70% (800-1120 kcal) of total calories (1600 kcal) as the oil will induce ketosis necessary for seizure control",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Cystic fibrosis:",
"     </b>",
"     Oral: 45 mL/day in divided doses",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F191962\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F191949\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Oil, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     MCT Oil&reg;: 14 g/15 mL (960 mL) [gluten free; contains coconut oil; 115 cal/15 mL]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F191939\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F191951\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Prepared mixture should be sipped slowly; administer no more than 15-20 mL at any one time (up to 100 mL may be administered in divided doses in a 24-hour period); formulas should not be cold. May also be used on salads or vegetables; may incorporate into sauces or used in cooking or baking.",
"    </p>",
"    <p style=\"text-indent:0em;margin-left:0em;margin-top:2em;text-align:justify;\">",
"     Possible gastrointestinal side effects from medication can be prevented if therapy is initiated with small supplements at meals and gradually increased according to patient's tolerance.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F191950\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Dietary supplement for those who cannot digest long chain fats; malabsorption associated with disorders such as pancreatic insufficiency, bile salt deficiency, short bowel syndrome, and bacterial overgrowth of the small bowel; induce ketosis as a prevention for seizures",
"    </p>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F191965\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Frequency not defined.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Endocrine &amp; metabolic: HDL serum levels decreased and triglycerides serum levels increased (&gt;6 months daily use)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Abdominal pain, bloating, cramping, diarrhea, nausea",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F191954\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     May be taken with meals (115 calories/15 mL); derived from coconut oil. Possible gastrointestinal side effects from medication can be prevented if therapy is initiated with small supplements at meals and gradually increased according to patient's tolerance",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F191942\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     MCTs are saturated fatty acids in chains of 6-12 carbon atoms. They are water soluble and can pass directly through intestinal cell membranes and blood stream. Once taken up by the liver, they are used for metabolic energy before being stored.",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Huttenlocher PR, Wilbourn AJ, and Signore JM, &ldquo;Medium-Chain Triglycerides as a Therapy for Intractable Childhood Epilepsy,&rdquo;",
"      <i>",
"       Neurology",
"      </i>",
"      , 1971, 21(11):1097-103.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?18/51/19250/abstract-text/5166216/pubmed\" id=\"5166216\" target=\"_blank\">",
"        5166216",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 10132 Version 29.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0502-1.234.2.38-DECD7EA589-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_51_19250=[""].join("\n");
var outline_f18_51_19250=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F191959\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F191960\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F191967\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F191961\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F191964\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F191962\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F191949\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F191939\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F191951\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F191950\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F191965\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F191954\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F191942\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/10132\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/10132|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?29/29/30164?source=related_link\">",
"      Medium chain triglycerides: Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?13/55/14195?source=related_link\">",
"      Medium chain triglycerides: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f18_51_19251="Cryptococcus neoformans in CSF";
var content_f18_51_19251=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F58455%7EID%2F63752%7EID%2F75483&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F58455%7EID%2F63752%7EID%2F75483&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Cryptococcus neoformans in cerebrospinal fluid",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 368px; height: 240px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Gram stain of cerebrospinal fluid (x1000) shows likely yeast forms, a few with cell walls and budding. These forms can be confused with host cells on the Gram stain and are more easily identified by India ink. The most definitive procedures are testing for cryptococcal antigen and culture. Cryptococcus neoformans grew from this specimen.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Harriet Provine.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Cryptococcus neoformans in an India ink preparation",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 360px; height: 240px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    India ink preparation of cerebrospinal fluid (x400) shows a prominent clear zone around individual yeasts, consistent with the capsule of Cryptococcus neoformans. The yeast in the center of the slide is budding.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Harriet Provine.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Cryptococcus neoformans on Sabouraud's agar",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 378px; height: 240px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Culture of Cryptococcus neoformans on Sabouraud's agar.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Harriet Provine.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_51_19251=[""].join("\n");
var outline_f18_51_19251=null;
var title_f18_51_19252="Bleeding diverticulum endosc";
var content_f18_51_19252=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F52254&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F52254&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic2\" style=\"width: 1057px;\">",
"  <div class=\"figure\" style=\"width: 487px\">",
"   <div class=\"ttl\">",
"    Blood vessel within a colonic diverticulum",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 467px; height: 210px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Endoscopy showing a blood vessel within a diverticulum. The blood vessel is separated from the bowel lumen only by mucosa. Over time, the vessel wall is exposed to injury along its luminal aspect, possibly leading to segmental weakness which predisposes to rupture into the lumen.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of James B McGee, MD.",
"    </div>",
"   </div>",
"  </div>",
"  <div class=\"figure\" style=\"width: 450px\">",
"   <div class=\"ttl\">",
"    Normal sigmoid colon",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 216px; height: 216px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Endoscopic appearance of the normal sigmoid colonic mucosa. The fine vasculature is easily visible, and the surface is shiny and smooth. The folds are of normal thickness.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of James B McGee, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_51_19252=[""].join("\n");
var outline_f18_51_19252=null;
var title_f18_51_19253="Complications of gastroesophageal reflux in adults";
var content_f18_51_19253=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Complications of gastroesophageal reflux in adults",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?18/51/19253/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?18/51/19253/contributors\">",
"     Peter J Kahrilas, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?18/51/19253/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?18/51/19253/contributors\">",
"     Nicholas J Talley, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?18/51/19253/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?18/51/19253/contributors\">",
"     Shilpa Grover, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?18/51/19253/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Nov 3, 2011.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The complications of gastroesophageal reflux disease (GERD) can be broadly divided into three categories:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Esophagitis, which can be associated with a variety of symptoms, including heartburn, regurgitation, and dysphagia (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?21/41/22168?source=see_link\">",
"       \"Clinical manifestations and diagnosis of gastroesophageal reflux in adults\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Consequences of the reparative process of esophagitis (peptic stricture and Barrett's metaplasia)",
"     </li>",
"     <li>",
"      Extraesophageal manifestations of reflux, such as asthma, laryngitis, and cough",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    This topic review will discuss the complications of reflux other than esophagitis, each of which occurs in a continuum of severity. The pathophysiology of this disorder, the consequences of Barrett's metaplasia, and the medical and surgical management of esophagitis are presented separately.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     PEPTIC STRICTURE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Strictures are a result of the healing process of ulcerative esophagitis. Collagen is deposited during this phase and, with time, the collagen fibers contract, narrowing the esophageal lumen. The strictures are usually short in length and contiguous with the gastroesophageal junction; endoscopy may also reveal adjacent areas of reflux esophagitis (",
"    <a class=\"graphic graphic_picture graphicRef51348 \" href=\"UTD.htm?14/29/14815\">",
"     picture 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_diagnosticimage graphicRef73360 \" href=\"UTD.htm?2/38/2671\">",
"     image 1",
"    </a>",
"    ). The main symptoms that they produce are solid food dysphagia and episodic esophageal obstruction.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Many reports have confirmed the benefit of conservative management of benign strictures by dilation [",
"    <a class=\"abstract\" href=\"UTD.htm?18/51/19253/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. Dramatic relief of dysphagia can be attained by mechanical dilation with mercury-filled, rounded, or tapered dilators. This generally requires dilation to a lumen diameter &ge;14 mm (44 French). Unyielding, tortuous, or tight strictures may require an endoscopically positioned balloon dilator or a dilator passed over an endoscopically or fluoroscopically positioned metal guide wire (",
"    <a class=\"graphic graphic_picture graphicRef61943 \" href=\"UTD.htm?10/51/11071\">",
"     picture 2",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/24/39305?source=see_link\">",
"     \"Management of benign esophageal strictures\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Severe strictures invariably require several dilations. The schedule for serial dilations should be based upon the type of stricture, its response to initial and subsequent dilation, and the patient's tolerance of the procedure. Treatment with a proton pump inhibitor can prevent the recurrence of strictures once they have been adequately dilated [",
"    <a class=\"abstract\" href=\"UTD.htm?18/51/19253/abstract/3,4\">",
"     3,4",
"    </a>",
"    ]; the benefit is greater than that achieved with H2 blockers [",
"    <a class=\"abstract\" href=\"UTD.htm?18/51/19253/abstract/4\">",
"     4",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/53/42840?source=see_link\">",
"     \"Medical management of gastroesophageal reflux disease in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Although effective, surgery is only rarely required for peptic strictures. One report evaluated 160 patients who underwent an antireflux operation and dilation for peptic stricture; the results of early operation appeared to be comparable to, or better than, those of conservative treatment by dilation alone [",
"    <a class=\"abstract\" href=\"UTD.htm?18/51/19253/abstract/5\">",
"     5",
"    </a>",
"    ]. However, this conclusion was obtained prior to the availability of proton pump inhibitors.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     COMPLICATIONS OF EXTRAESOPHAGEAL REFLUX",
"    </span>",
"    &nbsp;&mdash;&nbsp;Gastroesophageal reflux followed by regurgitation",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    aspiration of gastric juice has been associated with several extraesophageal complications including asthma, posterior laryngitis, chronic cough [",
"    <a class=\"abstract\" href=\"UTD.htm?18/51/19253/abstract/6\">",
"     6",
"    </a>",
"    ], dental erosions [",
"    <a class=\"abstract\" href=\"UTD.htm?18/51/19253/abstract/7\">",
"     7",
"    </a>",
"    ], chronic sinusitis [",
"    <a class=\"abstract\" href=\"UTD.htm?18/51/19253/abstract/8,9\">",
"     8,9",
"    </a>",
"    ], recurrent pneumonitis, nocturnal choking, chronic hoarseness, pharyngitis, subglottic stenosis, and laryngeal cancer.",
"   </p>",
"   <p>",
"    Convincing evidence exists linking each of these entities to reflux in some patients. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/18/5418?source=see_link\">",
"     \"Evaluation of subacute and chronic cough in adults\"",
"    </a>",
"    .) However, it remains difficult to establish a causal relationship in an individual patient because, even if pathologic reflux can be documented from an esophageal perspective, rarely can one convincingly demonstrate pathologic regurgitation or aspiration. Since gastroesophageal reflux is so common, it may simply be a coexisting condition without a causal relationship.",
"   </p>",
"   <p>",
"    The two extraesophageal manifestations of reflux that have been subject to the most investigation are asthma and otolaryngologic manifestations; the following discussion will emphasize these entities.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Reflux-induced asthma",
"    </span>",
"    &nbsp;&mdash;&nbsp;Epidemiologic evidence suggests that 15 million Americans suffer from asthma, that 34 to 89 percent of asthmatics have gastroesophageal reflux disease (GERD) (irrespective of the use of bronchodilators), and that up to 40 percent of asthmatics have peptic esophagitis [",
"    <a class=\"abstract\" href=\"UTD.htm?18/51/19253/abstract/10,11\">",
"     10,11",
"    </a>",
"    ]. Two major mechanisms of reflux-induced asthma have been proposed:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Aspiration of gastric contents into the lung with consequent bronchospasm",
"     </li>",
"     <li>",
"      Reflux-induced activation of a vago-vagal reflex arc from the esophagus to the lung causing bronchoconstriction",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The association between reflux and asthma is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/56/39816?source=see_link\">",
"     \"Gastroesophageal reflux and asthma\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Otolaryngologic manifestations",
"    </span>",
"    &nbsp;&mdash;&nbsp;Otolaryngologic manifestations of GERD can result from the esophagopharyngeal reflux of gastric contents with subsequent contact injury of the pharyngeal and laryngeal mucosa [",
"    <a class=\"abstract\" href=\"UTD.htm?18/51/19253/abstract/12-15\">",
"     12-15",
"    </a>",
"    ]. The term \"laryngopharyngeal reflux\" has been used to describe this process. Pathophysiologic data suggest that what discriminates reflux patients with otolaryngologic manifestations of GERD from those without these symptoms is a propensity for the refluxate to reach the proximal esophagus with consequent regurgitation, often with minimal esophageal symptoms, and usually without esophagitis [",
"    <a class=\"abstract\" href=\"UTD.htm?18/51/19253/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Laryngitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several studies have suggested a relationship between acid reflux and laryngitis. Issues related to its diagnosis and treatment are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/10/33960?source=see_link\">",
"     \"Laryngopharyngeal reflux\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Laryngeal and tracheal stenosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most common cause of laryngeal and tracheal stenosis in adults is prolonged endotracheal intubation. The pathogenesis begins with mucosal injury to the trachea, which is followed by inflammation and a hyperplastic reparative process [",
"    <a class=\"abstract\" href=\"UTD.htm?18/51/19253/abstract/16\">",
"     16",
"    </a>",
"    ]. The vocal process of the arytenoids and the posterior cricoid are the sites most often injured by intubation. Several animal studies have demonstrated the development of subglottic stenosis when disruption of the mucosa is followed by periodic exposures of the exposed cartilage to gastric secretions [",
"    <a class=\"abstract\" href=\"UTD.htm?18/51/19253/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Patients intubated beyond 48 to 72 hours are most prone to develop laryngeal mucosal injuries, and esophageal pH recordings suggest that pharyngeal reflux of gastric contents is common in recumbent intubated patients [",
"    <a class=\"abstract\" href=\"UTD.htm?18/51/19253/abstract/17\">",
"     17",
"    </a>",
"    ]. These two factors may explain the incidence of subglottic stenosis in patients intubated for prolonged periods.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Laryngeal cancer",
"    </span>",
"    &nbsp;&mdash;&nbsp;The worst potential risk of laryngopharyngeal reflux is the development of squamous cell cancer of the larynx. The larynx is the most common site of head and neck squamous cell carcinoma, accounting for 26 percent of all cases [",
"    <a class=\"abstract\" href=\"UTD.htm?18/51/19253/abstract/18\">",
"     18",
"    </a>",
"    ]. The overwhelming majority of these cases can be linked to cigarette smoking [",
"    <a class=\"abstract\" href=\"UTD.htm?18/51/19253/abstract/19\">",
"     19",
"    </a>",
"    ]. Excessive alcohol consumption may be an independent or potentiating factor. However, laryngopharyngeal reflux has also been invoked in the pathogenesis of some cases of laryngeal cancer [",
"    <a class=\"abstract\" href=\"UTD.htm?18/51/19253/abstract/20-23\">",
"     20-23",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/43/36537?source=see_link\">",
"     \"Overview of the diagnosis and staging of head and neck cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, \"The Basics\" and \"Beyond the Basics.\" The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on \"patient info\" and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?24/2/24610?source=see_link\">",
"       \"Patient information: Acid reflux (gastroesophageal reflux disease) in adults (The Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?10/19/10546?source=see_link\">",
"       \"Patient information: Esophageal stricture (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?37/30/38373?source=see_link\">",
"       \"Patient information: Acid reflux (gastroesophageal reflux disease) in adults (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22813261\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Gastroesophageal reflux disease (GERD) may be associated with esophageal complications including esophagitis, peptic stricture, and Barrett's metaplasia, and a number of extraesophageal complications. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Peptic stricture'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H4\">",
"       'Complications of extraesophageal reflux'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Peptic strictures are a result of the healing of ulcerative esophagitis and may result in dysphagia. Relief of dysphagia can be attained by mechanical dilation of strictures. In some cases, serial dilations may be needed. Treatment with a proton pump inhibitor can prevent the recurrence of strictures once they have been adequately dilated. Surgery is only rarely required for peptic strictures. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Treatment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Gastroesophageal reflux followed by regurgitation",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      aspiration of gastric juice has been associated with several extraesophageal complications. These complications include asthma, posterior laryngitis, chronic cough, dental erosions, chronic sinusitis, recurrent pneumonitis, nocturnal choking, chronic hoarseness, pharyngitis, subglottic stenosis, and laryngeal cancer.",
"      <br/>",
"      <br/>",
"      Reflux-induced asthma may result from aspiration of gastric contents into the lung with consequent bronchospasm, and reflux-induced activation of a vago-vagal reflex arc from the esophagus to the lung, causing bronchoconstriction.",
"      <br/>",
"      <br/>",
"      Otolaryngologic manifestations of GERD can result from the esophagopharyngeal reflux of gastric contents with subsequent contact injury of the pharyngeal and laryngeal mucosa. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Complications of extraesophageal reflux'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/51/19253/abstract/1\">",
"      Wesdorp IC, Bartelsman JF, den Hartog Jager FC, et al. Results of conservative treatment of benign esophageal strictures: a follow-up study in 100 patients. Gastroenterology 1982; 82:487.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/51/19253/abstract/2\">",
"      Patterson DJ, Graham DY, Smith JL, et al. Natural history of benign esophageal stricture treated by dilatation. Gastroenterology 1983; 85:346.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/51/19253/abstract/3\">",
"      Klinkenberg-Knol EC, Festen HP, Jansen JB, et al. Long-term treatment with omeprazole for refractory reflux esophagitis: efficacy and safety. Ann Intern Med 1994; 121:161.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/51/19253/abstract/4\">",
"      Marks RD, Richter JE, Rizzo J, et al. Omeprazole versus H2-receptor antagonists in treating patients with peptic stricture and esophagitis. Gastroenterology 1994; 106:907.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/51/19253/abstract/5\">",
"      Mercer CD, Hill LD. Surgical management of peptic esophageal stricture. Twenty-year experience. J Thorac Cardiovasc Surg 1986; 91:371.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/51/19253/abstract/6\">",
"      Ing AJ, Ngu MC, Breslin AB. Pathogenesis of chronic persistent cough associated with gastroesophageal reflux. Am J Respir Crit Care Med 1994; 149:160.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/51/19253/abstract/7\">",
"      Schroeder PL, Filler SJ, Ramirez B, et al. Dental erosion and acid reflux disease. Ann Intern Med 1995; 122:809.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/51/19253/abstract/8\">",
"      DiBaise JK, Huerter JV, Quigley EM. Sinusitis and gastroesophageal reflux disease. Ann Intern Med 1998; 129:1078.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/51/19253/abstract/9\">",
"      DiBaise JK, Olusola BF, Huerter JV, Quigley EM. Role of GERD in chronic resistant sinusitis: a prospective, open label, pilot trial. Am J Gastroenterol 2002; 97:843.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/51/19253/abstract/10\">",
"      Sontag SJ, O'Connell S, Khandelwal S, et al. Most asthmatics have gastroesophageal reflux with or without bronchodilator therapy. Gastroenterology 1990; 99:613.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/51/19253/abstract/11\">",
"      Harding SM, Richter JE, Guzzo MR, et al. Asthma and gastroesophageal reflux: acid suppressive therapy improves asthma outcome. Am J Med 1996; 100:395.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/51/19253/abstract/12\">",
"      Jacob P, Kahrilas PJ, Herzon G. Proximal esophageal pH-metry in patients with 'reflux laryngitis'. Gastroenterology 1991; 100:305.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/51/19253/abstract/13\">",
"      Koufman JA. The otolaryngologic manifestations of gastroesophageal reflux disease (GERD): a clinical investigation of 225 patients using ambulatory 24-hour pH monitoring and an experimental investigation of the role of acid and pepsin in the development of laryngeal injury. Laryngoscope 1991; 101:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/51/19253/abstract/14\">",
"      Shaker R, Milbrath M, Ren J, et al. Esophagopharyngeal distribution of refluxed gastric acid in patients with reflux laryngitis. Gastroenterology 1995; 109:1575.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/51/19253/abstract/15\">",
"      Poelmans J, Feenstra L, Demedts I, et al. The yield of upper gastrointestinal endoscopy in patients with suspected reflux-related chronic ear, nose, and throat symptoms. Am J Gastroenterol 2004; 99:1419.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/51/19253/abstract/16\">",
"      Cote DN, Miller RH. The association of gastroesophageal reflux and otolaryngologic disorders. Compr Ther 1995; 21:80.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/51/19253/abstract/17\">",
"      Gaynor EB. Gastroesophageal reflux as an etiologic factor in laryngeal complications of intubation. Laryngoscope 1988; 98:972.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/51/19253/abstract/18\">",
"      Vaezi MF. Laryngitis and gastroesophageal reflux disease: increasing prevalence or poor diagnostic tests? Am J Gastroenterol 2004; 99:786.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/51/19253/abstract/19\">",
"      Cann CI, Fried MP, Rothman KJ. Epidemiology of squamous cell cancer of the head and neck. Otolaryngol Clin North Am 1985; 18:367.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/51/19253/abstract/20\">",
"      Olsen NR. Effects of stomach acid on the larynx. Proc Am Laryngol Assoc 1983; 104:108.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/51/19253/abstract/21\">",
"      Morrison MD. Is chronic gastroesophageal reflux a causative factor in glottic carcinoma? Otolaryngol Head Neck Surg 1988; 99:370.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/51/19253/abstract/22\">",
"      Ward PH, Hanson DG. Reflux as an etiological factor of carcinoma of the laryngopharynx. Laryngoscope 1988; 98:1195.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/51/19253/abstract/23\">",
"      Wynder EL, Stellman SD. Comparative epidemiology of tobacco-related cancers. Cancer Res 1977; 37:4608.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 2263 Version 9.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-203.80.222.8-8F853297CB-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_51_19253=[""].join("\n");
var outline_f18_51_19253=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H22813261\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      PEPTIC STRICTURE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      COMPLICATIONS OF EXTRAESOPHAGEAL REFLUX",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Reflux-induced asthma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Otolaryngologic manifestations",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Laryngitis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Laryngeal and tracheal stenosis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Laryngeal cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22813261\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"GAST/2263\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/2263|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?2/38/2671\" title=\"diagnostic image 1\">",
"      Peptic esophageal stricture",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/2263|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?14/29/14815\" title=\"picture 1\">",
"      Peptic eso stricture Endosc",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?10/51/11071\" title=\"picture 2\">",
"      Dilation esophageal stricture",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/41/22168?source=related_link\">",
"      Clinical manifestations and diagnosis of gastroesophageal reflux in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/18/5418?source=related_link\">",
"      Evaluation of subacute and chronic cough in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/56/39816?source=related_link\">",
"      Gastroesophageal reflux and asthma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/10/33960?source=related_link\">",
"      Laryngopharyngeal reflux",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/24/39305?source=related_link\">",
"      Management of benign esophageal strictures",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/53/42840?source=related_link\">",
"      Medical management of gastroesophageal reflux disease in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/43/36537?source=related_link\">",
"      Overview of the diagnosis and staging of head and neck cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?37/30/38373?source=related_link\">",
"      Patient information: Acid reflux (gastroesophageal reflux disease) in adults (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?24/2/24610?source=related_link\">",
"      Patient information: Acid reflux (gastroesophageal reflux disease) in adults (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?10/19/10546?source=related_link\">",
"      Patient information: Esophageal stricture (The Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f18_51_19254="Clinical manifestations and diagnosis of hyperprolactinemia";
var content_f18_51_19254=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Clinical manifestations and diagnosis of hyperprolactinemia",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?18/51/19254/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?18/51/19254/contributors\">",
"     Peter J Snyder, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?18/51/19254/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?18/51/19254/contributors\">",
"     David S Cooper, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?18/51/19254/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?18/51/19254/contributors\">",
"     Kathryn A Martin, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?18/51/19254/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Nov 29, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The clinical manifestations of hyperprolactinemia are relatively few and usually easy to recognize. Once the presence of prolactin excess is identified, further evaluation to establish the underlying cause is usually straightforward. The clinical manifestations and diagnosis of hyperprolactinemia are reviewed here. The causes and treatment of hyperprolactinemia are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/41/22167?source=see_link\">",
"     \"Causes of hyperprolactinemia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/52/31561?source=see_link\">",
"     \"Treatment of hyperprolactinemia due to lactotroph adenoma and other causes\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     CLINICAL PRESENTATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hyperprolactinemia causes typical symptoms in premenopausal women and in men, but not in postmenopausal women.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Premenopausal women",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hyperprolactinemia in premenopausal women causes hypogonadism, manifested by infertility, oligomenorrhea, or amenorrhea [",
"    <a class=\"abstract\" href=\"UTD.htm?18/51/19254/abstract/1,2\">",
"     1,2",
"    </a>",
"    ], and less often by galactorrhea.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h3\">",
"     Hypogonadism",
"    </span>",
"    &nbsp;&mdash;&nbsp;Excluding pregnancy, hyperprolactinemia accounts for approximately 10 to 20 percent of cases of amenorrhea. The mechanism appears to involve inhibition of luteinizing hormone (LH), and perhaps follicle-stimulating hormone (FSH) secretion, via inhibition of the release of gonadotropin-releasing hormone (GnRH). As a result, serum gonadotropin concentrations are not supranormal, typical of other causes of secondary hypogonadism.",
"   </p>",
"   <p>",
"    The symptoms of hypogonadism due to hyperprolactinemia in premenopausal women correlate with the magnitude of the hyperprolactinemia. In most laboratories, a serum prolactin concentration above 15 to 20",
"    <span class=\"nowrap\">",
"     ng/mL",
"    </span>",
"    (15 to 20",
"    <span class=\"nowrap\">",
"     mcg/L",
"    </span>",
"    SI units) is considered abnormally high in women of reproductive age.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A serum prolactin concentration greater than 100",
"      <span class=\"nowrap\">",
"       ng/mL",
"      </span>",
"      (100",
"      <span class=\"nowrap\">",
"       mcg/L",
"      </span>",
"      SI units) is typically associated with overt hypogonadism, subnormal estradiol secretion and its consequences, including amenorrhea, hot flashes, and vaginal dryness.",
"     </li>",
"     <li>",
"      Moderate degrees of hyperprolactinemia, eg, serum prolactin values of 50 to 100",
"      <span class=\"nowrap\">",
"       ng/mL",
"      </span>",
"      (50 to 100",
"      <span class=\"nowrap\">",
"       mcg/L",
"      </span>",
"      SI units), cause either amenorrhea or oligomenorrhea.",
"     </li>",
"     <li>",
"      Mild degrees of hyperprolactinemia, eg, serum prolactin values of 20 to 50",
"      <span class=\"nowrap\">",
"       ng/mL",
"      </span>",
"      (20 to 50",
"      <span class=\"nowrap\">",
"       mcg/L",
"      </span>",
"      SI units), may cause only insufficient progesterone secretion and, therefore, a short luteal phase of the menstrual cycle [",
"      <a class=\"abstract\" href=\"UTD.htm?18/51/19254/abstract/3,4\">",
"       3,4",
"      </a>",
"      ]. Mild hyperprolactinemia can cause infertility even when there is no abnormality of the menstrual cycle; these women account for about 20 percent of those evaluated for infertility.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Women with amenorrhea secondary to hyperprolactinemia have a lower spine and forearm bone mineral density compared with normal women or women with hyperprolactinemia and normal menses [",
"    <a class=\"abstract\" href=\"UTD.htm?18/51/19254/abstract/5,6\">",
"     5,6",
"    </a>",
"    ]. Restoration of menses following therapy results in an increase in bone density, although it may not return to normal [",
"    <a class=\"abstract\" href=\"UTD.htm?18/51/19254/abstract/5,6\">",
"     5,6",
"    </a>",
"    ]. Adolescents, when compared to adults with prolactinomas, have lower bone density at the time of diagnosis and less improvement after two years of dopamine agonist therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?18/51/19254/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Galactorrhea",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hyperprolactinemia in premenopausal women can also cause galactorrhea [",
"    <a class=\"abstract\" href=\"UTD.htm?18/51/19254/abstract/8\">",
"     8",
"    </a>",
"    ], but most premenopausal women who have hyperprolactinemia do not have galactorrhea. On the other hand, many women who have galactorrhea have normal serum prolactin concentrations [",
"    <a class=\"abstract\" href=\"UTD.htm?18/51/19254/abstract/8\">",
"     8",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/23/3449?source=see_link\">",
"     \"Nipple discharge\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Postmenopausal women",
"    </span>",
"    &nbsp;&mdash;&nbsp;Postmenopausal women, by definition, are already hypogonadal, and hyperprolactinemia does not change that situation. Because postmenopausal women are also markedly hypoestrogenemic, galactorrhea is rare. Hyperprolactinemia in these women is recognized only in the relatively unusual situation when a lactotroph adenoma becomes so large as to cause headaches or impair vision, or is detected as an incidental finding when an MRI is performed for an unrelated reason.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Men",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hyperprolactinemia also causes hypogonadotropic hypogonadism in men, which is manifested by decreased libido, impotence, infertility, gynecomastia, or rarely galactorrhea [",
"    <a class=\"abstract\" href=\"UTD.htm?18/51/19254/abstract/9,10\">",
"     9,10",
"    </a>",
"    ]. As in women, there is a rough correlation between the presence of any of these symptoms and the degree of hyperprolactinemia.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Hypogonadotropic hypogonadism &mdash; Hyperprolactinemia causes decreased testosterone secretion and low serum testosterone concentrations that are not associated with an increase in LH secretion [",
"      <a class=\"abstract\" href=\"UTD.htm?18/51/19254/abstract/9\">",
"       9",
"      </a>",
"      ]. As in women, the effect of prolactin must be on the pituitary or hypothalamus. The consequences of the hypogonadism are similar to those of hypogonadism due to other causes and include, in the short-term, decreased energy and libido, and in the long-term, decreased muscle mass, body hair, and osteoporosis. In one study of 20 men, for example, 16 had osteopenia in the spine and six in the hip [",
"      <a class=\"abstract\" href=\"UTD.htm?18/51/19254/abstract/11\">",
"       11",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Erectile dysfunction &mdash; Hyperprolactinemia appears to cause erectile dysfunction by a mechanism unrelated to hypogonadism because correcting the hyperprolactinemia with a dopamine agonist drug corrects the impotence, while correcting the hypogonadism by the administration of testosterone does not [",
"      <a class=\"abstract\" href=\"UTD.htm?18/51/19254/abstract/9\">",
"       9",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Infertility &mdash; Although hyperprolactinemia can cause infertility in men, probably by decreasing LH and perhaps FSH secretion, it is not a common finding among men who present for evaluation of infertility. In a study of 171 infertile men, as an example, only seven (4 percent) had hyperprolactinemia [",
"      <a class=\"abstract\" href=\"UTD.htm?18/51/19254/abstract/10\">",
"       10",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?8/18/8488?source=see_link\">",
"       \"Causes of secondary hypogonadism in males\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?31/49/32533?source=see_link\">",
"       \"Evaluation of male sexual dysfunction\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Galactorrhea &mdash; Men with hyperprolactinemia may develop galactorrhea. This occurs less often than in women, presumably because the glandular breast tissue in men has not been made sensitive to prolactin by preceding stimulation by estrogen and progesterone.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     EVALUATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Women with oligomenorrhea, amenorrhea, or galactorrhea, and men with symptoms of hypogonadism or impotence or infertility should have a serum prolactin determination [",
"    <a class=\"abstract\" href=\"UTD.htm?18/51/19254/abstract/12\">",
"     12",
"    </a>",
"    ]. If the value is elevated, the next step is to determine the cause. The evaluation is aimed at exclusion of pharmacologic or extrapituitary causes of hyperprolactinemia and neuroradiologic evaluation of the hypothalamic-pituitary region [",
"    <a class=\"abstract\" href=\"UTD.htm?18/51/19254/abstract/13\">",
"     13",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/41/22167?source=see_link\">",
"     \"Causes of hyperprolactinemia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Serum prolactin concentration",
"    </span>",
"    &nbsp;&mdash;&nbsp;The usual normal range for serum prolactin is 5 to 20",
"    <span class=\"nowrap\">",
"     ng/mL",
"    </span>",
"    (5 to 20",
"    <span class=\"nowrap\">",
"     mcg/L).",
"    </span>",
"    The measurement can be performed at any time, since usual daily activities have little effect on prolactin secretion. Serum prolactin concentrations may increase slightly during sleep, strenuous exercise, and occasionally emotional or physical stress, intense breast stimulation, and high-protein meals. Therefore, a slightly high value (21 to 40",
"    <span class=\"nowrap\">",
"     ng/mL",
"    </span>",
"    [21 to 40",
"    <span class=\"nowrap\">",
"     mcg/L",
"    </span>",
"    SI units]) should be confirmed before the patient is considered to have hyperprolactinemia. A persistently elevated serum prolactin value of any magnitude should prompt a search for its cause.",
"   </p>",
"   <p>",
"    Serum prolactin values between 20 and 200",
"    <span class=\"nowrap\">",
"     ng/mL",
"    </span>",
"    (20 to 200",
"    <span class=\"nowrap\">",
"     mcg/L",
"    </span>",
"    SI units) can be found in patients with any cause of hyperprolactinemia. On the other hand, serum prolactin values above 200",
"    <span class=\"nowrap\">",
"     ng/mL",
"    </span>",
"    usually indicate the presence of a lactotroph adenoma (",
"    <a class=\"graphic graphic_figure graphicRef72540 \" href=\"UTD.htm?23/28/24014\">",
"     figure 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Hook effect",
"    </span>",
"    &nbsp;&mdash;&nbsp;Caution should be exercised in interpreting serum prolactin concentrations between 20 and 200",
"    <span class=\"nowrap\">",
"     ng/mL",
"    </span>",
"    (20 to 200",
"    <span class=\"nowrap\">",
"     mcg/L",
"    </span>",
"    SI units) in the presence of a macroadenoma, because of possible artifactually low values due to the \"hook effect\" [",
"    <a class=\"abstract\" href=\"UTD.htm?18/51/19254/abstract/14-16\">",
"     14-16",
"    </a>",
"    ]. This effect occurs when a very high serum prolactin, eg, 5000",
"    <span class=\"nowrap\">",
"     ng/mL",
"    </span>",
"    (5000",
"    <span class=\"nowrap\">",
"     mcg/L",
"    </span>",
"    SI units), saturates both the capture and signal antibodies used in immunoradiometric and chemiluminescent assays, preventing the binding of the two in a \"sandwich.\" The result is an apparent prolactin concentration that is only modestly elevated, suggesting that the macroadenoma is clinically nonfunctioning. The artifact can be avoided by repeating the assay using a 1:100 dilution of serum [",
"    <a class=\"abstract\" href=\"UTD.htm?18/51/19254/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     History",
"    </span>",
"    &nbsp;&mdash;&nbsp;A search for the cause of the hyperprolactinemia should begin with the history. One should inquire about pregnancy (nonpathologic hyperprolactinemia) and medications that can cause hyperprolactinemia (such as estrogen, neuroleptic drugs,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/13/216?source=see_link\">",
"     metoclopramide",
"    </a>",
"    , antidepressant drugs,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/54/2921?source=see_link\">",
"     cimetidine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/15/28918?source=see_link\">",
"     methyldopa",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/35/16950?source=see_link\">",
"     reserpine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/18/9514?source=see_link\">",
"     verapamil",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/33/11802?source=see_link\">",
"     risperidone",
"    </a>",
"    ). One should also inquire about headache, visual symptoms, symptoms of hypothyroidism, and a history of renal disease.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Physical examination",
"    </span>",
"    &nbsp;&mdash;&nbsp;The physical examination should be directed toward testing for a chiasmal syndrome (eg, bitemporal field loss), and looking for chest wall injury and signs of hypothyroidism or hypogonadism.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Laboratory/imaging tests",
"    </span>",
"    &nbsp;&mdash;&nbsp;Studies should be performed to test for hypothyroidism and renal insufficiency. Magnetic resonance imaging (MRI) of the head should be performed in a patient with any degree of hyperprolactinemia to look for a mass lesion in the hypothalamic-pituitary region, except if the patient is taking a medication known to cause hyperprolactinemia. The degree of elevation that can be attributed to a drug depends on the drug. Most drugs do not cause an elevation to over 100",
"    <span class=\"nowrap\">",
"     ng/mL,",
"    </span>",
"    but the antipsychotic drug risperdal can cause an elevation up to 300 or even 400",
"    <span class=\"nowrap\">",
"     ng/dL",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?18/51/19254/abstract/17\">",
"     17",
"    </a>",
"    ]. Therefore, we recommend ordering an MRI if the serum prolactin concentration is greater than 100",
"    <span class=\"nowrap\">",
"     ng/mL",
"    </span>",
"    in patients taking a drug known to elevate the prolactin concentration but greater than 300",
"    <span class=\"nowrap\">",
"     ng/mL",
"    </span>",
"    in those taking",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/33/11802?source=see_link\">",
"     risperidone",
"    </a>",
"    . (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/41/22167?source=see_link\">",
"     \"Causes of hyperprolactinemia\"",
"    </a>",
"    .) There are no stimulatory or suppressive endocrine tests that distinguish among the causes of hyperprolactinemia.",
"   </p>",
"   <p>",
"    If a mass lesion is found in the region of the sella turcica, secretion of other pituitary hormones should also be evaluated. Only a pituitary adenoma can cause hypersecretion of other pituitary hormones, but any mass lesion in the area of the sella can cause hyposecretion of one or more pituitary hormones. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/39/31348?source=see_link\">",
"     \"Clinical manifestations of hypopituitarism\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    If the MRI shows normal hypothalamic-pituitary anatomy and there is no identifiable secondary cause of hyperprolactinemia, the diagnosis of idiopathic hyperprolactinemia is made. This syndrome may, in some patients, be due to microadenomas that are too small to be seen on imaging. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/41/22167?source=see_link\">",
"     \"Causes of hyperprolactinemia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     GALACTORRHEA WITHOUT HYPERPROLACTINEMIA",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Incidence",
"    </span>",
"    &nbsp;&mdash;&nbsp;The serum prolactin concentration is often normal in women who present with galactorrhea. In the largest series of patients presenting with galactorrhea, prolactin was normal in 46 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?18/51/19254/abstract/8\">",
"     8",
"    </a>",
"    ]. The likelihood that the prolactin is normal is even higher if menses are normal. No cause of this phenomenon has been documented, but often it represents persistent milk secretion following correction of elevated prolactin, most commonly after nursing or drug-induced hyperprolactinemia. Galactorrhea in the absence of hyperprolactinemia is not the result of any ongoing disease.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The first step in diagnosis is to be sure the breast secretion is clear or milky. Green or black fluid also usually represents milk, which can be confirmed by staining the fluid for fat. Blood in the fluid is a reason for referral for evaluation of a breast tumor. If the fluid is milk, the next step is to measure the serum prolactin concentration. If the prolactin is elevated, the cause should be sought, as described above. If the prolactin is not elevated, there is no ongoing disease, and no further tests are needed. Other causes of nipple discharge are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/23/3449?source=see_link\">",
"     \"Nipple discharge\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Galactorrhea in the absence of hyperprolactinemia usually does not need to be treated because it is not associated with ongoing disease and it is usually not bothersome. For the unusual patient whose galactorrhea occurs spontaneously and to a degree that causes staining of the clothes, treatment with a low dose of dopamine agonist, such as 0.25 mg of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?7/2/7206?source=see_link\">",
"     cabergoline",
"    </a>",
"    twice a week, will reduce the prolactin concentration to below normal and reduce or eliminate the galactorrhea.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?25/6/25698?source=see_link\">",
"       \"Patient information: Prolactinoma (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?25/0/25603?source=see_link\">",
"       \"Patient information: High prolactin levels and prolactinomas (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H504478654\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <strong>",
"     Premenopausal women",
"    </strong>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The clinical manifestations of hyperprolactinemia in premenopausal women are mainly those of hypogonadism and include menstrual cycle dysfunction (oligomenorrhea or amenorrhea) and infertility (luteal phase abnormalities or anovulation). Less often, galactorrhea occurs. Hyperprolactinemia accounts for approximately 10 to 20 percent of cases of amenorrhea. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Premenopausal women'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The symptoms of hypogonadism due to hyperprolactinemia in premenopausal women correlate with the magnitude of the hyperprolactinemia. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Hypogonadism'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Most premenopausal women with hyperprolactinemia do",
"      <strong>",
"       not",
"      </strong>",
"      have galactorrhea; among women who present with galactorrhea as an isolated finding, nearly 50 percent have normal serum prolactin concentrations. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Galactorrhea without hyperprolactinemia'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <strong>",
"     Postmenopausal women",
"    </strong>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Postmenopausal women are already hypogonadal, so hyperprolactinemia in them is recognized only when a lactotroph adenoma becomes large enough to cause headaches or impair vision, or is detected as an incidental sellar mass by MRI. In the setting of estrogen deficiency, hyperprolactinemia rarely causes galactorrhea. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Postmenopausal women'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <strong>",
"     Men",
"    </strong>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Hyperprolactinemia also causes hypogonadotropic hypogonadism in men, resulting in decreased libido and infertility. Other manifestations of hyperprolactinemia are erectile dysfunction, gynecomastia, and rarely, galactorrhea. As in women, there is a rough correlation between the presence of any of these symptoms and the degree of hyperprolactinemia. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Men'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <strong>",
"     Evaluation",
"    </strong>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Women with oligomenorrhea, amenorrhea, or galactorrhea, and men with symptoms of hypogonadism, impotence or gynecomastia should have a serum prolactin determination. The usual normal range for serum prolactin is 5 to 20",
"      <span class=\"nowrap\">",
"       ng/mL",
"      </span>",
"      (5 to 20",
"      <span class=\"nowrap\">",
"       mcg/L).",
"      </span>",
"     </li>",
"     <li>",
"      If the prolactin concentration is only slightly high (21 to 40",
"      <span class=\"nowrap\">",
"       ng/mL",
"      </span>",
"      [21 to 40",
"      <span class=\"nowrap\">",
"       mcg/L",
"      </span>",
"      SI units]), it should be repeated before the patient is considered to have hyperprolactinemia. If the repeat value is still elevated, the next step is to determine the cause. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?21/41/22167?source=see_link\">",
"       \"Causes of hyperprolactinemia\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Serum prolactin values above 200",
"      <span class=\"nowrap\">",
"       ng/mL",
"      </span>",
"      usually indicate the presence of a lactotroph adenoma (",
"      <a class=\"graphic graphic_figure graphicRef72540 \" href=\"UTD.htm?23/28/24014\">",
"       figure 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Serum prolactin concentration'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We recommend ordering an MRI if the serum prolactin concentration is greater than 100",
"      <span class=\"nowrap\">",
"       ng/mL",
"      </span>",
"      in patients taking a drug known to elevate the prolactin concentration but greater than 300",
"      <span class=\"nowrap\">",
"       ng/mL",
"      </span>",
"      in those taking",
"      <a class=\"drug drug_general\" href=\"UTD.htm?11/33/11802?source=see_link\">",
"       risperidone",
"      </a>",
"      . (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Laboratory/imaging tests'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/51/19254/abstract/1\">",
"      G&oacute;mez F, Reyes FI, Faiman C. Nonpuerperal galactorrhea and hyperprolactinemia. Clinical findings, endocrine features and therapeutic responses in 56 cases. Am J Med 1977; 62:648.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/51/19254/abstract/2\">",
"      Schlechte J, Sherman B, Halmi N, et al. Prolactin-secreting pituitary tumors in amenorrheic women: a comprehensive study. Endocr Rev 1980; 1:295.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/51/19254/abstract/3\">",
"      Sepp&auml;l&auml; M, Ranta T, Hirvonen E. Hyperprolactinaemia and luteal insufficiency. Lancet 1976; 1:229.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/51/19254/abstract/4\">",
"      Corenblum B, Pairaudeau N, Shewchuk AB. Prolactin hypersecretion and short luteal phase defects. Obstet Gynecol 1976; 47:486.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/51/19254/abstract/5\">",
"      Biller BM, Baum HB, Rosenthal DI, et al. Progressive trabecular osteopenia in women with hyperprolactinemic amenorrhea. J Clin Endocrinol Metab 1992; 75:692.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/51/19254/abstract/6\">",
"      Schlechte J, Walkner L, Kathol M. A longitudinal analysis of premenopausal bone loss in healthy women and women with hyperprolactinemia. J Clin Endocrinol Metab 1992; 75:698.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/51/19254/abstract/7\">",
"      Colao A, Di Somma C, Loche S, et al. Prolactinomas in adolescents: persistent bone loss after 2 years of prolactin normalization. Clin Endocrinol (Oxf) 2000; 52:319.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/51/19254/abstract/8\">",
"      Kleinberg DL, Noel GL, Frantz AG. Galactorrhea: a study of 235 cases, including 48 with pituitary tumors. N Engl J Med 1977; 296:589.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/51/19254/abstract/9\">",
"      Carter JN, Tyson JE, Tolis G, et al. Prolactin-screening tumors and hypogonadism in 22 men. N Engl J Med 1978; 299:847.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/51/19254/abstract/10\">",
"      Segal S, Yaffe H, Laufer N, Ben-David M. Male hyperprolactinemia:effects on fertility. Fertil Steril 1979; 32:556.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/51/19254/abstract/11\">",
"      Di Somma C, Colao A, Di Sarno A, et al. Bone marker and bone density responses to dopamine agonist therapy in hyperprolactinemic males. J Clin Endocrinol Metab 1998; 83:807.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/51/19254/abstract/12\">",
"      Melmed S, Casanueva FF, Hoffman AR, et al. Diagnosis and treatment of hyperprolactinemia: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 2011; 96:273.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/51/19254/abstract/13\">",
"      Casanueva FF, Molitch ME, Schlechte JA, et al. Guidelines of the Pituitary Society for the diagnosis and management of prolactinomas. Clin Endocrinol (Oxf) 2006; 65:265.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/51/19254/abstract/14\">",
"      St-Jean E, Blain F, Comtois R. High prolactin levels may be missed by immunoradiometric assay in patients with macroprolactinomas. Clin Endocrinol (Oxf) 1996; 44:305.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/51/19254/abstract/15\">",
"      Petakov MS, Damjanovi�� SS, Nikoli��-Durovi�� MM, et al. Pituitary adenomas secreting large amounts of prolactin may give false low values in immunoradiometric assays. The hook effect. J Endocrinol Invest 1998; 21:184.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/51/19254/abstract/16\">",
"      Barkan AL, Chandler WF. Giant pituitary prolactinoma with falsely low serum prolactin: the pitfall of the \"high-dose hook effect\": case report. Neurosurgery 1998; 42:913.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/51/19254/abstract/17\">",
"      David SR, Taylor CC, Kinon BJ, Breier A. The effects of olanzapine, risperidone, and haloperidol on plasma prolactin levels in patients with schizophrenia. Clin Ther 2000; 22:1085.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6638 Version 8.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1005-83.177.194.223-A277839E2F-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_51_19254=[""].join("\n");
var outline_f18_51_19254=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H504478654\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      CLINICAL PRESENTATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Premenopausal women",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      - Hypogonadism",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Galactorrhea",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Postmenopausal women",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Men",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      EVALUATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Serum prolactin concentration",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Hook effect",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      History",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Physical examination",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Laboratory/imaging tests",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      GALACTORRHEA WITHOUT HYPERPROLACTINEMIA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Incidence",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Diagnosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H504478654\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ENDO/6638\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ENDO/6638|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?23/28/24014\" title=\"figure 1\">",
"      Serum prolactin by dx",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/41/22167?source=related_link\">",
"      Causes of hyperprolactinemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/18/8488?source=related_link\">",
"      Causes of secondary hypogonadism in males",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/39/31348?source=related_link\">",
"      Clinical manifestations of hypopituitarism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/49/32533?source=related_link\">",
"      Evaluation of male sexual dysfunction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/23/3449?source=related_link\">",
"      Nipple discharge",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?25/0/25603?source=related_link\">",
"      Patient information: High prolactin levels and prolactinomas (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?25/6/25698?source=related_link\">",
"      Patient information: Prolactinoma (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/52/31561?source=related_link\">",
"      Treatment of hyperprolactinemia due to lactotroph adenoma and other causes",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f18_51_19255="Fever in human immunodeficiency virus-infected infants and children";
var content_f18_51_19255=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Fever in human immunodeficiency virus-infected infants and children",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?18/51/19255/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?18/51/19255/contributors\">",
"     Heidi Schwarzwald, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?18/51/19255/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?18/51/19255/contributors\">",
"     Mary E Paul, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?18/51/19255/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?18/51/19255/contributors\">",
"     Mary M Torchia, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?18/51/19255/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Sep 5, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;An approach to the evaluation of fever in HIV-infected infants and children is reviewed here. The natural history, classification, and epidemiology of pediatric HIV are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/3/3130?source=see_link\">",
"     \"Natural history and classification of pediatric HIV infection\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/0/31749?source=see_link\">",
"     \"Epidemiology of pediatric HIV infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     OVERVIEW",
"    </span>",
"    &nbsp;&mdash;&nbsp;Fever is a common reason for unscheduled outpatient clinic visits and hospital admission of HIV-infected children. Febrile children with human immunodeficiency virus (HIV) infection are diverse in their clinical presentations, necessitating a thoughtful and varied diagnostic approach. Febrile episodes may be acute (arbitrarily defined here as lasting for five or fewer consecutive days) or prolonged.",
"   </p>",
"   <p>",
"    Some acutely febrile HIV-infected children have fever alone (fever without a source (FWS)); others have focal infections, such as otitis media, pneumonia, or herpes simplex virus (HSV) stomatitis. Similarly, prolonged fever may be associated with a discernible cause, or a cause may not be evident after careful physical examination and initial laboratory testing (fever of unknown origin (FUO)). Such fevers can be caused by HIV-associated opportunistic infections or malignancy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/14/22762?source=see_link\">",
"     \"Fever without a source in children 3 to 36 months of age\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/63/38905?source=see_link\">",
"     \"Etiologies of fever of unknown origin in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/30/9706?source=see_link\">",
"     \"Approach to the child with fever of unknown origin\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Acutely febrile children with HIV infection often have illness that is mild and self-limited. Not all of these patients require diagnostic testing or antibiotic therapy. However, a few of these children have more serious infectious diseases. Differentiating these seriously ill patients from the larger group of mildly ill children can be difficult. HIV-infected children with prolonged fever often have complicating medical conditions, and the diagnostic evaluation can be complex.",
"   </p>",
"   <p>",
"    Several studies have elucidated more common infections in HIV-infected children since the introduction of highly active antiretroviral therapy (HAART) [",
"    <a class=\"abstract\" href=\"UTD.htm?18/51/19255/abstract/1-6\">",
"     1-6",
"    </a>",
"    ]. These findings can guide therapeutic decisions in the febrile HIV-infected child.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     ETIOLOGY OF FEVER",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acutely febrile HIV-infected children may have focal infection, fever without a source, FUO, HIV-associated opportunistic infection, or malignancy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Serious bacterial and opportunistic infections",
"    </span>",
"    &nbsp;&mdash;&nbsp;Fevers in HIV-infected children frequently are caused by infection. Multiple serious bacterial infections are acquired immunodeficiency syndrome (AIDS)-defining conditions in children along with the opportunistic infections and malignancies that define this disease in adults. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/3/3130?source=see_link\">",
"     \"Natural history and classification of pediatric HIV infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Before the widespread use of antiretroviral therapy, serious bacterial infections occurred commonly in HIV-infected children [",
"    <a class=\"abstract\" href=\"UTD.htm?18/51/19255/abstract/7-11\">",
"     7-11",
"    </a>",
"    ]. Even after single- and double-agent antiretroviral therapy became widely available in the United States for the treatment of HIV-infected children, serious bacterial infections remained common. In an analysis of the records of 3331 HIV-infected children enrolled in 13 separate trials of antiretroviral therapy (not including highly active antiretroviral therapy (HAART)), serious bacterial infections occurred at a rate of 15.1 per 100 patient-years, far exceeding the rates observed for herpes zoster,",
"    <em>",
"     Pneumocystis carinii",
"    </em>",
"    pneumonia (PCP, officially renamed",
"    <em>",
"     Pneumocystis jirovecii",
"    </em>",
"    pneumonia), esophageal candidiasis, cytomegalovirus (CMV) disease, tuberculosis (TB), toxoplasmosis, and other opportunistic infections [",
"    <a class=\"abstract\" href=\"UTD.htm?18/51/19255/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The rate of serious bacterial infections in HIV-infected children in the era of HAART has decreased when compared with previous studies. Patients maintained on antiretroviral therapy had an incidence of 3.66 serious bacterial infections per 100 person-years [",
"    <a class=\"abstract\" href=\"UTD.htm?18/51/19255/abstract/1\">",
"     1",
"    </a>",
"    ]. The rates of other opportunistic infections, including",
"    <em>",
"     Pneumocystis jirovecii",
"    </em>",
"    and",
"    <em>",
"     Mycobacterium avium",
"    </em>",
"    have significantly decreased in the era of HAART [",
"    <a class=\"abstract\" href=\"UTD.htm?18/51/19255/abstract/2-4\">",
"     2-4",
"    </a>",
"    ]. Immune status remains the most predictive factor in an HIV-infected child&rsquo;s development of opportunistic infections [",
"    <a class=\"abstract\" href=\"UTD.htm?18/51/19255/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Bacterial pneumonia remains the most common serious infection in HIV-infected patients, followed by herpes zoster and dermatophyte infections [",
"    <a class=\"abstract\" href=\"UTD.htm?18/51/19255/abstract/2,4\">",
"     2,4",
"    </a>",
"    ].",
"    <em>",
"     Streptococcus pneumoniae",
"    </em>",
"    and",
"    <em>",
"     Staphylococcus aureus",
"    </em>",
"    were the most commonly isolated organisms in a retrospective cohort study [",
"    <a class=\"abstract\" href=\"UTD.htm?18/51/19255/abstract/5\">",
"     5",
"    </a>",
"    ]. Rates of invasive pneumococcal disease have declined in HIV-infected children by 84 percent since the introduction of HAART [",
"    <a class=\"abstract\" href=\"UTD.htm?18/51/19255/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     FWS and FUO",
"    </span>",
"    &nbsp;&mdash;&nbsp;The etiology of febrile illness among HIV-infected children is poorly defined. In a review of 68 inpatient admissions among HIV-infected children at Texas Children's Hospital, we found that 14 (21 percent) were attributable to fever without a source (FWS) or fever of unknown origin FUO (unpublished data).",
"   </p>",
"   <p>",
"    In the Texas Children's Hospital experience, most HIV-infected children with FWS have illness that is mild and self-limited; many appear to be caused by viruses. However, like immunologically normal children, some HIV-infected children with FWS have bacteremia or other serious complicating illnesses. The incidence of these complicating conditions probably is higher among HIV-infected children than among otherwise normal children with FWS [",
"    <a class=\"abstract\" href=\"UTD.htm?18/51/19255/abstract/13\">",
"     13",
"    </a>",
"    ]. The clinical or laboratory features, if any, that can be used to differentiate these few children with serious febrile illness from the larger group of febrile children with mild and self-limited illness are unknown. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/14/22762?source=see_link\">",
"     \"Fever without a source in children 3 to 36 months of age\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Like FWS, FUO is common among HIV-infected children. The term FUO is reserved for prolonged fevers, just as in immunocompetent hosts. Before the availability of highly active antiretroviral therapy (HAART), at least 35 of 118 known HIV-infected children treated at Baylor College of Medicine had one or more episodes of unexplained fever lasting one month or longer (unpublished data). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/30/9706?source=see_link\">",
"     \"Approach to the child with fever of unknown origin\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/63/38905?source=see_link\">",
"     \"Etiologies of fever of unknown origin in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     DIAGNOSTIC EVALUATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Febrile HIV-infected children should be evaluated initially with a thorough medical history and physical examination. The character and duration of symptoms, HIV disease status, adherence to antiretroviral therapy, and history of recent exposures to ill contacts are of particular relevance. The physical examination should include a careful search for signs of focal infection or inflammation, and the patient should be assessed generally for illness severity or \"toxicity.\"",
"   </p>",
"   <p>",
"    A broad array of possible etiologies must be considered in the febrile child with advanced HIV disease, whereas the child with HIV disease well controlled by HAART often can be approached diagnostically much like a child without underlying illness.",
"   </p>",
"   <p>",
"    One approach to the diagnostic evaluation of acutely febrile HIV-infected children is shown in the figure (",
"    <a class=\"graphic graphic_algorithm graphicRef54787 \" href=\"UTD.htm?12/55/13183\">",
"     algorithm 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Focal infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;The clinical features of focal infection in HIV-infected children are similar to the features observed in immunologically normal children. Fever and local signs of inflammation often are present. It is desirable, but not always feasible, to obtain cultures from the site of infection for accurate bacteriologic diagnosis and exclusion of other etiologic agents (eg, fungi).",
"   </p>",
"   <p>",
"    Bacteremia should be suspected when certain serious focal infections (eg, pneumonia, cellulitis, or osteomyelitis) are present. Bacteremia also should be suspected in the child who appears toxic or septic. Routine bacterial blood cultures should be obtained from all such children.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Children with FWS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The HIV-infected child with FWS and no evidence of toxicity poses more diagnostic dilemmas. A substantial percentage of these children are bacteremic despite appearing well. An individualized approach is necessary to determine who warrants diagnostic laboratory studies. The extensive literature on identifying occult bacteremia in immunologically normal children with FWS may not be applicable to HIV-infected children.",
"   </p>",
"   <p>",
"    For background purposes, a number of studies in immunocompetent children from 2 to 36 months of age after the introduction of",
"    <em>",
"     Haemophilus influenza",
"    </em>",
"    type b and pneumococcal conjugate vaccines document a frequency of occult bacteremia of less than 1 percent. Decision and cost-effectiveness analyses suggest that observation alone or screening with a complete blood count (CBC) followed by obtaining blood cultures and treating selected patients are the most reasonable approaches. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/14/22762?source=see_link&amp;anchor=H14#H14\">",
"     \"Fever without a source in children 3 to 36 months of age\", section on 'Impact of vaccines'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Features to identify immunocompetent children at increased risk for occult bacteremia include: age between 6 and 24 months, body temperature greater than 39.4&ordm;C (103&ordm;F), and white blood cell count (WBC) of",
"    <span class=\"nowrap\">",
"     15,000/microL",
"    </span>",
"    or greater [",
"    <a class=\"abstract\" href=\"UTD.htm?18/51/19255/abstract/14\">",
"     14",
"    </a>",
"    ]. Conflicting data exist on the utility of C-reactive protein for this purpose. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/14/22762?source=see_link&amp;anchor=H13#H13\">",
"     \"Fever without a source in children 3 to 36 months of age\", section on 'Predictors'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The predictive value of the above features in identifying febrile HIV-infected children who are at high risk for bacteremia has not been evaluated extensively. However, a retrospective study of HIV-infected children younger than 18 years identified 54 episodes of pneumococcal bacteremia, 26 of which were occult [",
"    <a class=\"abstract\" href=\"UTD.htm?18/51/19255/abstract/13\">",
"     13",
"    </a>",
"    ]. The sensitivity of elevated WBC in predicting bacteremia was low (40 percent for WBC",
"    <span class=\"nowrap\">",
"     &gt;15,000/microL",
"    </span>",
"    and 75 percent for",
"    <span class=\"nowrap\">",
"     WBC&gt;10,000/microL).",
"    </span>",
"    Thus, we recommend interpreting WBC in HIV-infected febrile children in relation to the patient's baseline values, rather than adhering to a fixed arbitrary threshold.",
"   </p>",
"   <p>",
"    Several other diagnostic studies may be warranted in children with HIV infection and FWS:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      We obtain a blood culture if the rectal temperature is greater than 39.4&ordm;C or if there are other findings, such as an elevated WBC, suggestive of bacteremia. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?22/14/22762?source=see_link&amp;anchor=H13#H13\">",
"       \"Fever without a source in children 3 to 36 months of age\", section on 'Predictors'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Young infants with bacterial meningitis may fail to manifest obvious signs of meningeal irritation (eg, nuchal rigidity), and a lumbar puncture (LP) may be necessary in some cases to exclude the diagnosis. Clinicians should apply clinical judgment in deciding when to perform an LP using the same considerations that apply in HIV-negative children. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?28/8/28810?source=see_link&amp;anchor=H18#H18\">",
"       \"Clinical features and diagnosis of acute bacterial meningitis in children older than one month of age\", section on 'CSF examination'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?25/1/25625?source=see_link\">",
"       \"Lumbar puncture: Indications, contraindications, technique, and complications in children\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Because febrile infants frequently are tachypneic even without pulmonary disease and because pneumonia does not always produce obvious auscultatory physical findings, a chest radiograph may be necessary to exclude a diagnosis of pneumonia. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?38/3/38970?source=see_link&amp;anchor=H16#H16\">",
"       \"Clinical features and diagnosis of community-acquired pneumonia in children\", section on 'Radiologic evaluation'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Urinalysis and urine culture may be indicated in some febrile infants to exclude occult urinary tract infection. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?20/40/21129?source=see_link&amp;anchor=H2#H2\">",
"       \"Clinical features and diagnosis of urinary tract infections in infants and children older than one month\", section on 'Clinical presentation'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Children with FUO",
"    </span>",
"    &nbsp;&mdash;&nbsp;Fever of unknown origin (FUO) in HIV-infected children, particularly those with CD4 cell percentages below 15 percent, is associated with a broad spectrum of potential infectious and noninfectious causes. Some of the more important causes of FUO in HIV-infected children are listed in the table (",
"    <a class=\"graphic graphic_table graphicRef81833 \" href=\"UTD.htm?39/33/40475\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    The broad spectrum of potential infectious and noninfectious causes for FUO necessitates meticulous physical examination and often extensive diagnostic testing. Such studies may include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Chest and sinus radiographs",
"     </li>",
"     <li>",
"      Blood cultures for routine bacteria, mycobacteria, and fungi",
"     </li>",
"     <li>",
"      Cultures of throat and nasopharynx, urine, and blood for viruses (especially CMV)",
"     </li>",
"     <li>",
"      Cryptococcal and other fungal antigen tests",
"     </li>",
"     <li>",
"      Epstein-Barr virus (EBV) antibody tests",
"     </li>",
"     <li>",
"      Liver enzyme measurements",
"     </li>",
"     <li>",
"      Ophthalmologic examination for chorioretinitis",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Cerebrospinal fluid (CSF) can be obtained by LP for routine cell counts; protein and glucose concentrations; bacterial, mycobacterial, fungal, and viral studies; cryptococcal antigen tests and cytology.",
"   </p>",
"   <p>",
"    Bone marrow aspiration and biopsy sometimes are useful diagnostically. Specimens should be obtained for Gram stain and bacterial culture, fungal stains and culture, stains for acid-fast bacteria, mycobacterial culture, viral culture, histopathology, and cytology.",
"   </p>",
"   <p>",
"    High-resolution abdominal ultrasonography also may be warranted. FUO has been associated with microabscesses in the liver or spleen of HIV-infected patients in some studies. Etiologies include tuberculosis, visceral leishmaniasis, disseminated",
"    <em>",
"     Mycobacterium avium",
"    </em>",
"    ,",
"    <em>",
"     Pneumocystis carinii (jirovecii)",
"    </em>",
"    ,",
"    <em>",
"     Bartonella henselae",
"    </em>",
"    , and others [",
"    <a class=\"abstract\" href=\"UTD.htm?18/51/19255/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The breadth and pace of the diagnostic evaluation for FUO generally is determined by the pace of the illness. In the case of a child who appears only mildly ill, diagnostic studies are prioritized and conducted in a stepwise manner with common causes of disease excluded first. A patient with more fulminant illness may require immediate and extensive testing to address the full range of diagnostic possibilities. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/63/38905?source=see_link\">",
"     \"Etiologies of fever of unknown origin in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/30/9706?source=see_link&amp;anchor=H4#H4\">",
"     \"Approach to the child with fever of unknown origin\", section on 'Diagnostic approach'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     EMPIRIC AND EXPECTANT ANTIBIOTIC THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;As with the diagnostic evaluation, an individualized approach to the therapy of HIV-infected children with fever is necessary (",
"    <a class=\"graphic graphic_algorithm graphicRef54787 \" href=\"UTD.htm?12/55/13183\">",
"     algorithm 1",
"    </a>",
"    ). The selection of antibiotics for empiric or expectant therapy is influenced by several factors, including the nature of the infection (eg, presumed bacterial meningitis, pneumonia), the clinical scenario (eg, community-acquired versus hospital-acquired infection), the child's HIV disease status, and how ill the child appears.",
"   </p>",
"   <p>",
"    The goal of",
"    <span class=\"nowrap\">",
"     empiric/expectant",
"    </span>",
"    antibiotic therapy is to provide coverage against likely pathogens (ie,",
"    <em>",
"     S. pneumoniae",
"    </em>",
"    ,",
"    <em>",
"     S. aureus",
"    </em>",
"    ); it is not feasible to include coverage for every conceivable pathogen. Empiric therapy usually is directed only against potential bacterial pathogens. Unless there is convincing clinical or laboratory evidence of serious opportunistic fungal or viral infection, expectant or empiric therapy for these organisms is not indicated. Similarly, if PCP is suspected, laboratory confirmation of the diagnosis should be pursued before therapy is instituted.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Asymptomatic/mildly symptomatic HIV disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;In general, empiric antibiotic therapy for asymptomatic or mildly symptomatic HIV-infected children with fever should be similar to the routine coverage provided to immunologically normal children with comparable clinical presentations or focal infection.",
"   </p>",
"   <p>",
"    We typically choose",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?0/19/312?source=see_link\">",
"     ceftriaxone",
"    </a>",
"    (50",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    IM or IV every 24 hours; maximum 2 g per day) or an oral antibiotic, such as",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?33/26/34214?source=see_link\">",
"     amoxicillin-clavulanate",
"    </a>",
"    (45",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day of the",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?33/49/34583?source=see_link\">",
"     amoxicillin",
"    </a>",
"    component divided into two doses per day; maximum 3 g per day) or",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?30/61/31701?source=see_link\">",
"     cefuroxime",
"    </a>",
"    (30",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day in two divided doses; maximum 2 g per day), for children who are less ill and can be managed as outpatients. Oral antibiotic therapy is possible for many well-appearing children with HIV infection and focal infection.",
"   </p>",
"   <p>",
"    Other children, because of ill appearance or the nature of the focal infection, will require hospitalization and parenteral antibiotic therapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Advanced HIV disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Children with more advanced HIV disease and debilitation may require broader initial antibiotic coverage. We generally include coverage for penicillin-resistant pneumococci in such patients. Because these organisms also may be resistant to cephalosporins, we usually add",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?22/58/23465?source=see_link\">",
"     vancomycin",
"    </a>",
"    (10",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per dose given every six hours; maximum 4 g per day) to",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?39/23/40310?source=see_link\">",
"     cefotaxime",
"    </a>",
"    (50",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    IV every eight hours; maximum 12 g per day) or",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?0/19/312?source=see_link\">",
"     ceftriaxone",
"    </a>",
"    (50",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    IV every 24 hours; maximum 2 g per day).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Neutropenia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Children with neutropenia resulting from either HIV infection or various medications (eg,",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?26/55/27512?source=see_link\">",
"     zidovudine",
"    </a>",
"    ) should be given antibiotics similar to those prescribed for other immunocompromised neutropenic children. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/20/30022?source=see_link\">",
"     \"Risk of infection in children with fever and non-chemotherapy-induced neutropenia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/33/15898?source=see_link&amp;anchor=H8#H8\">",
"     \"Fever in children with chemotherapy-induced neutropenia\", section on 'Empiric antimicrobial therapy'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/3/20537?source=see_link&amp;anchor=H736498253#H736498253\">",
"     \"Evaluation and management of fever in children with non-chemotherapy-induced neutropenia\", section on 'Treatment'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Nosocomial infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nosocomial infection often requires very broad initial antibiotic therapy because of the wide variety of bacterial pathogens observed in that setting. Such treatment should be chosen with knowledge of prevailing pathogens and antimicrobial susceptibility patterns in the institution.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Fever without a source",
"    </span>",
"    &nbsp;&mdash;&nbsp;Therapeutic decisions regarding the expectant therapy for HIV-infected children with fever without a source (FWS) are influenced by the degree of elevation of the body temperature, the observed clinical appearance of the patient, and the white blood cell count (WBC).",
"   </p>",
"   <p>",
"    Because of the high incidence of bacteremia among febrile HIV-infected children, it probably is reasonable to administer expectant therapy more liberally to this group of patients than to a comparable group of otherwise healthy children with FWS. This was illustrated in a retrospective series of 54 HIV-infected children with pneumococcal bacteremia in which 0 of 19 patients who were treated with expectant antibiotics had persistent bacteremia on a follow-up visit within 72 hours compared to two of five patients who were released without antibiotics [",
"    <a class=\"abstract\" href=\"UTD.htm?18/51/19255/abstract/13\">",
"     13",
"    </a>",
"    ]. None of the 26 patients with occult bacteremia in this series died or developed meningitis or other complicating sequelae of pneumococcal infection.",
"   </p>",
"   <p>",
"    Specific antibiotic options are similar to those used for immunocompetent children. Expectant therapy generally should be administered for 48 hours while awaiting the results of blood cultures. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/14/22762?source=see_link&amp;anchor=H24#H24\">",
"     \"Fever without a source in children 3 to 36 months of age\", section on 'Initial approach'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Fever of unknown origin",
"    </span>",
"    &nbsp;&mdash;&nbsp;As in immunologically normal children, expectant antibiotic therapy rarely is indicated in HIV-infected children with fever of unknown origin (FUO), and such therapy often confounds the diagnostic evaluation. Therefore, all relevant diagnostic studies ideally should be obtained before the institution of specific therapeutic options.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     SPECIFIC THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;If a bacterial pathogen is isolated and other etiologic agents are excluded, antibiotic therapy can be targeted more narrowly.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     DURATION OF TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The duration of antibiotic therapy generally is similar to that for comparable infections in immunologically normal children.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Overview",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In the era of highly active antiretroviral therapy (HAART), HIV-infected children who have successfully reconstituted their immune system develop serious infections at rates similar to HIV-uninfected children. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Overview'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Acutely febrile HIV-infected children may have focal infection, fever without a source (FWS), fever of unknown origin (FUO), HIV-associated opportunistic infection, or malignancy. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Etiology of fever'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The incidence of focal bacterial infection and bacteremia is increased among HIV-infected children.",
"      <em>",
"       Streptococcus pneumoniae",
"      </em>",
"      and",
"      <em>",
"       Staphylococcus aureus",
"      </em>",
"      are the bacterial organisms isolated most frequently from children with HIV infection. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Serious bacterial and opportunistic infections'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Evaluation",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The diagnostic evaluation begins with a thorough medical history and physical examination. The character and duration of symptoms, HIV disease status, history of recent exposures to ill contacts, signs of focal",
"      <span class=\"nowrap\">",
"       infection/inflammation,",
"      </span>",
"      and assessment of illness severity are of particular relevance (",
"      <a class=\"graphic graphic_algorithm graphicRef54787 \" href=\"UTD.htm?12/55/13183\">",
"       algorithm 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Diagnostic evaluation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Among children with focal infection, bacteriologic diagnosis by culture is desirable whenever it is possible. Blood cultures should be obtained in children with serious focal infections (eg, pneumonia, cellulitis, or osteomyelitis), and those who appear toxic or septic. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Focal infection'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Among HIV-infected children with FWS, we obtain a blood culture if the rectal temperature is &gt;39.4&ordm;C or the WBC is elevated (compared to the patient's baseline). In addition, lumbar puncture, chest radiograph, urinalysis, and urine culture may be warranted to exclude serious bacterial infection. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Children with FWS'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      FUO in HIV-infected children is associated with a broad spectrum of potential infectious and noninfectious causes (",
"      <a class=\"graphic graphic_table graphicRef81833 \" href=\"UTD.htm?39/33/40475\">",
"       table 1",
"      </a>",
"      ). Meticulous physical examination and diagnostic testing are necessary for specific diagnosis. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Children with FUO'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Treatment",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For most febrile children with or without HIV infection, empiric and expectant antibiotic therapy considerations are similar. However, children with advanced HIV disease, neutropenia, or nosocomial infection usually require broader initial antibiotic coverage. If a bacterial pathogen is isolated and other etiologic agents are excluded,",
"      <span class=\"nowrap\">",
"       empiric/expectant",
"      </span>",
"      antibiotic therapy can be targeted more narrowly. The duration of antibiotic therapy generally is similar to that for comparable infections in immunologically normal children. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Empiric and expectant antibiotic therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Expectant antibiotic therapy rarely is indicated in HIV-infected children with FUO; if expectant antibiotic therapy is planned, relevant diagnostic studies ideally should be obtained before its institution. (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Fever of unknown origin'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/51/19255/abstract/1\">",
"      Nachman S, Gona P, Dankner W, et al. The rate of serious bacterial infections among HIV-infected children with immune reconstitution who have discontinued opportunistic infection prophylaxis. Pediatrics 2005; 115:e488.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/51/19255/abstract/2\">",
"      Gona P, Van Dyke RB, Williams PL, et al. Incidence of opportunistic and other infections in HIV-infected children in the HAART era. JAMA 2006; 296:292.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/51/19255/abstract/3\">",
"      Ylitalo N, Brogly S, Hughes MD, et al. Risk factors for opportunistic illnesses in children with human immunodeficiency virus in the era of highly active antiretroviral therapy. Arch Pediatr Adolesc Med 2006; 160:778.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/51/19255/abstract/4\">",
"      Guill&eacute;n S, Garc&iacute;a San Miguel L, Resino S, et al. Opportunistic infections and organ-specific diseases in HIV-1-infected children: a cohort study (1990-2006). HIV Med 2010; 11:245.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/51/19255/abstract/5\">",
"      Jaspan HB, Huang LC, Cotton MF, et al. Bacterial disease and antimicrobial susceptibility patterns in HIV-infected, hospitalized children: a retrospective cohort study. PLoS One 2008; 3:e3260.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/51/19255/abstract/6\">",
"      Steenhoff AP, Wood SM, Rutstein RM, et al. Invasive pneumococcal disease among human immunodeficiency virus-infected children, 1989-2006. Pediatr Infect Dis J 2008; 27:886.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/51/19255/abstract/7\">",
"      Andiman WA, Mezger J, Shapiro E. Invasive bacterial infections in children born to women infected with human immunodeficiency virus type 1. J Pediatr 1994; 124:846.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/51/19255/abstract/8\">",
"      Bernstein LJ, Krieger BZ, Novick B, et al. Bacterial infection in the acquired immunodeficiency syndrome of children. Pediatr Infect Dis 1985; 4:472.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/51/19255/abstract/9\">",
"      Krasinski K, Borkowsky W, Bonk S, et al. Bacterial infections in human immunodeficiency virus-infected children. Pediatr Infect Dis J 1988; 7:323.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/51/19255/abstract/10\">",
"      Intravenous immune globulin for the prevention of bacterial infections in children with symptomatic human immunodeficiency virus infection. The National Institute of Child Health and Human Developments Intravenous Immunoglobulin Study Group. N Engl J Med 1991; 325:73.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/51/19255/abstract/11\">",
"      Kline, MW. Management of occult bacteremia in children. Semin Pediatr Infect Dis 1990; 1:333.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/51/19255/abstract/12\">",
"      Dankner WM, Lindsey JC, Levin MJ, Pediatric AIDS Clinical Trials Group Protocol Teams 051, 128, 138, 144, 152, 179, 190, 220, 240, 245, 254, 300 and 327. Correlates of opportunistic infections in children infected with the human immunodeficiency virus managed before highly active antiretroviral therapy. Pediatr Infect Dis J 2001; 20:40.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/51/19255/abstract/13\">",
"      Dayan PS, Chamberlain JM, Arpadi SM, et al. Streptococcus pneumoniae bacteremia in children infected with HIV: presentation, course, and outcome. Pediatr Emerg Care 1998; 14:194.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/51/19255/abstract/14\">",
"      Baraff LJ. Management of fever without source in infants and children. Ann Emerg Med 2000; 36:602.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/51/19255/abstract/15\">",
"      Bernabeu-Wittel M, Villanueva JL, Pach&oacute;n J, et al. Etiology, clinical features and outcome of splenic microabscesses in HIV-infected patients with prolonged fever. Eur J Clin Microbiol Infect Dis 1999; 18:324.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5964 Version 3.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0605-61.234.146.186-F35B292492-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_51_19255=[""].join("\n");
var outline_f18_51_19255=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H19\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      OVERVIEW",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      ETIOLOGY OF FEVER",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Serious bacterial and opportunistic infections",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      FWS and FUO",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      DIAGNOSTIC EVALUATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Focal infection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Children with FWS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Children with FUO",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      EMPIRIC AND EXPECTANT ANTIBIOTIC THERAPY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Asymptomatic/mildly symptomatic HIV disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Advanced HIV disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Neutropenia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Nosocomial infection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Fever without a source",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Fever of unknown origin",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      SPECIFIC THERAPY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      DURATION OF TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Overview",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Evaluation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PEDS/5964\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/5964|ALG\">",
"      <a href=\"#\" title=\"ALGORITHMS\">",
"       ALGORITHMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"UTD.htm?12/55/13183\" title=\"algorithm 1\">",
"      Evaluation of febrile HIV child",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/5964|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?39/33/40475\" title=\"table 1\">",
"      Causes of FUO in pediatric HIV",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/30/9706?source=related_link\">",
"      Approach to the child with fever of unknown origin",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/8/28810?source=related_link\">",
"      Clinical features and diagnosis of acute bacterial meningitis in children older than one month of age",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/3/38970?source=related_link\">",
"      Clinical features and diagnosis of community-acquired pneumonia in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/40/21129?source=related_link\">",
"      Clinical features and diagnosis of urinary tract infections in infants and children older than one month",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/0/31749?source=related_link\">",
"      Epidemiology of pediatric HIV infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/63/38905?source=related_link\">",
"      Etiologies of fever of unknown origin in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/3/20537?source=related_link\">",
"      Evaluation and management of fever in children with non-chemotherapy-induced neutropenia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/33/15898?source=related_link\">",
"      Fever in children with chemotherapy-induced neutropenia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/14/22762?source=related_link\">",
"      Fever without a source in children 3 to 36 months of age",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/1/25625?source=related_link\">",
"      Lumbar puncture: Indications, contraindications, technique, and complications in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/3/3130?source=related_link\">",
"      Natural history and classification of pediatric HIV infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/20/30022?source=related_link\">",
"      Risk of infection in children with fever and non-chemotherapy-induced neutropenia",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f18_51_19256="Clinical features and diagnosis of autoimmune hemolytic anemia: Warm agglutinins";
var content_f18_51_19256=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Clinical features and diagnosis of autoimmune hemolytic anemia: Warm agglutinins",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?18/51/19256/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?18/51/19256/contributors\">",
"     Wendell F Rosse, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?18/51/19256/contributors\">",
"     Stanley L Schrier, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?18/51/19256/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?18/51/19256/contributors\">",
"     William C Mentzer, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?18/51/19256/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?18/51/19256/contributors\">",
"     Stephen A Landaw, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?18/51/19256/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 5, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Autoimmune hemolytic anemia (AIHA) due to the presence of warm agglutinins is almost always due to IgG antibodies that react with protein antigens on the red blood cell (RBC) surface at body temperature. For this reason, they are called \"warm agglutinins\" even though they seldom directly agglutinate the RBCs.",
"   </p>",
"   <p>",
"    This topic review will discuss the clinical manifestations and diagnosis of AIHA due to warm agglutinins [",
"    <a class=\"abstract\" href=\"UTD.htm?18/51/19256/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. Treatment of this disorder is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/62/14313?source=see_link\">",
"     \"Treatment of autoimmune hemolytic anemia: Warm agglutinins\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    AIHA is also a frequent problem in patients with systemic lupus erythematosus (SLE), occurring in up to 10 percent of patients. This subject is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/49/14106?source=see_link&amp;anchor=H8#H8\">",
"     \"Hematologic manifestations of systemic lupus erythematosus in adults\", section on 'Autoimmune hemolytic anemia'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     ETIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;A variety of factors may initiate the antibody production in warm agglutinin AIHA. This issue is discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/2/20521?source=see_link&amp;anchor=H11#H11\">",
"     \"Pathogenesis of autoimmune hemolytic anemia: Warm agglutinins and drugs\", section on 'Genesis of antibody production'",
"    </a>",
"    .) Reviewed briefly, most cases are idiopathic, in that no underlying disorder or direct cause can be found.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Underlying causes",
"    </span>",
"    &nbsp;&mdash;&nbsp;Underlying causes or conditions that may be associated with AIHA include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Viral infections (usually in children)",
"     </li>",
"     <li>",
"      Autoimmune and connective tissue diseases (particularly systemic lupus erythematosus). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?13/49/14106?source=see_link&amp;anchor=H8#H8\">",
"       \"Hematologic manifestations of systemic lupus erythematosus in adults\", section on 'Autoimmune hemolytic anemia'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Immune deficiency diseases, such as common variable immunodeficiency [",
"      <a class=\"abstract\" href=\"UTD.htm?18/51/19256/abstract/3\">",
"       3",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?17/28/17866?source=see_link&amp;anchor=H1193493#H1193493\">",
"       \"Clinical manifestations, epidemiology, and diagnosis of common variable immunodeficiency in adults\", section on 'Autoimmune disease'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Malignancies of the immune system (eg, non-Hodgkin lymphoma, chronic lymphocytic leukemia (CLL), with a higher incidence in those treated with purine analogs). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?34/12/35017?source=see_link&amp;anchor=H13#H13\">",
"       \"Overview of the complications of chronic lymphocytic leukemia\", section on 'Autoimmune hemolytic anemia'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?8/29/8665?source=see_link&amp;anchor=H3#H3\">",
"       \"Autoimmune complications following purine analog therapy\", section on 'Autoimmune hemolytic anemia'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Prior allogeneic blood transfusion, hematopoietic cell transplantation, or solid organ transplantation [",
"      <a class=\"abstract\" href=\"UTD.htm?18/51/19256/abstract/4,5\">",
"       4,5",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?25/38/26218?source=see_link&amp;anchor=H12#H12\">",
"       \"Donor selection for hematopoietic cell transplantation\", section on 'ABO and Rh status'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    CLL may be a particular problem. It has been estimated that as many as 11 percent of patients with this disorder develop AIHA. The incidence is even higher in patients with CLL who are treated with purine analogs such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9545?source=see_link\">",
"     fludarabine",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?18/51/19256/abstract/6,7\">",
"     6,7",
"    </a>",
"    ],",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/9/40086?source=see_link\">",
"     pentostatin",
"    </a>",
"    (2-deoxycoformycin) [",
"    <a class=\"abstract\" href=\"UTD.htm?18/51/19256/abstract/8\">",
"     8",
"    </a>",
"    ], or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/22/19815?source=see_link\">",
"     cladribine",
"    </a>",
"    (2-chlorodeoxyadenosine) [",
"    <a class=\"abstract\" href=\"UTD.htm?18/51/19256/abstract/9\">",
"     9",
"    </a>",
"    ]. Anemia has been severe in some cases, resulting in death [",
"    <a class=\"abstract\" href=\"UTD.htm?18/51/19256/abstract/8,10\">",
"     8,10",
"    </a>",
"    ]. Why purine analogs appear to predispose to AIHA in patients with CLL is not clear. One possibility is immune deregulation, which is a common complication when purine analogs are used in this setting [",
"    <a class=\"abstract\" href=\"UTD.htm?18/51/19256/abstract/11,12\">",
"     11,12",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/25/410?source=see_link&amp;anchor=H5#H5\">",
"     \"Overview of infectious complications following purine analog therapy\", section on 'Other immune defects'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Drugs",
"    </span>",
"    &nbsp;&mdash;&nbsp;A large number of drugs have been implicated as the cause of immune hemolytic anemia. This subject is discussed in depth separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/2/20521?source=see_link&amp;anchor=H15#H15\">",
"     \"Pathogenesis of autoimmune hemolytic anemia: Warm agglutinins and drugs\", section on 'Drug-related immune hemolysis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Evans syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;Evans syndrome (ES), the occurrence of two or more hematologic immune cytopenias, most often hemolytic anemia and thrombocytopenia, is recognized as a special variant of AIHA [",
"    <a class=\"abstract\" href=\"UTD.htm?18/51/19256/abstract/13\">",
"     13",
"    </a>",
"    ]. Although usually described in children, adults may also have ES. In about half of the patients, no other immune disorder is recognized, but in half it may be a manifestation of systemic lupus erythematosus, common variable immune deficiency [",
"    <a class=\"abstract\" href=\"UTD.htm?18/51/19256/abstract/14\">",
"     14",
"    </a>",
"    ], autoimmune lymphoproliferative disorder [",
"    <a class=\"abstract\" href=\"UTD.htm?18/51/19256/abstract/15,16\">",
"     15,16",
"    </a>",
"    ], or other immune disorder. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/36/30279?source=see_link&amp;anchor=H1699873#H1699873\">",
"     \"Autoimmune lymphoproliferative syndrome (ALPS): Clinical features and diagnosis\", section on 'Diagnosis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    It is important to recognize ES and to test for these various underlying immune disorders [",
"    <a class=\"abstract\" href=\"UTD.htm?18/51/19256/abstract/16\">",
"     16",
"    </a>",
"    ], as ES is more difficult to treat and has a higher mortality than AIHA presenting alone. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/38/5735?source=see_link&amp;anchor=H9#H9\">",
"     \"Apoptosis and autoimmune disease\", section on 'Autoimmune lymphoproliferative syndrome'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/62/14313?source=see_link&amp;anchor=H19#H19\">",
"     \"Treatment of autoimmune hemolytic anemia: Warm agglutinins\", section on 'Evans syndrome'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/15/246?source=see_link\">",
"     \"Autoimmune lymphoproliferative syndrome (ALPS): Management and prognosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The signs and symptoms of AIHA are nonspecific and common to all types of anemia. The clinical syndrome seen with AIHA of the warm-antibody type varies greatly with the amount and effectiveness of the causative antibody. When the amount is small or the antibody is inefficient at effecting hemolysis, the patient may be asymptomatic even if slightly anemic. More commonly, the patient is moderately to severely anemic.",
"   </p>",
"   <p>",
"    The likelihood of a patient with AIHA developing symptoms due to anemia is determined by the severity of the disease, whether the patient is at rest or during exertion, the rapidity with which the anemia develops, and whether there is concurrent illness (eg, underlying cardiac disease). In healthy resting humans, normal oxygen delivery can be maintained by enhanced extraction alone down to a hemoglobin concentration of 8 to 9",
"    <span class=\"nowrap\">",
"     g/dL",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?18/51/19256/abstract/17\">",
"     17",
"    </a>",
"    ]; when the added compensation of increases in stroke volume and heart rate (and therefore cardiac output) are included, oxygen delivery can be maintained at a hemoglobin concentration as low as 5",
"    <span class=\"nowrap\">",
"     g/dL",
"    </span>",
"    (equivalent to a hematocrit of 15 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?18/51/19256/abstract/18\">",
"     18",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/52/5961?source=see_link&amp;anchor=H2#H2\">",
"     \"Indications for red cell transfusion in the adult\", section on 'Physiology of anemia'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Symptoms will occur when the hemoglobin concentration falls below this level at rest, at higher hemoglobin concentrations during exertion, or when the cardiac compensation does not occur due to underlying heart disease. The primary symptoms include exertional dyspnea, dyspnea at rest, varying degrees of fatigue, and signs and symptoms of the hyperdynamic state, such as bounding pulses, palpitations, and \"roaring in the ears\". (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/46/29418?source=see_link&amp;anchor=H11#H11\">",
"     \"Approach to the adult patient with anemia\", section on 'Clinical consequences'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The clinical syndrome of AIHA may become life-threatening with more severe anemia. If the hemoglobin falls below a level able to sustain sufficient oxygenation, the patient may become lethargic, confused, and dyspneic with tachycardia. In such patients, corrective measures must be taken at once (eg, corticosteroids, intravenous immunoglobulin, transfusion). It is important to remember that wholly compatible blood for transfusion will not be available, but that transfusion with the most compatible, quickly found unit(s), may be life-saving. If not corrected, death from pulmonary edema, myocardial infarction, or terminal cardiac arrhythmia is inevitable.",
"   </p>",
"   <p>",
"    Physical examination may show varying degrees of pallor and jaundice. The spleen is commonly enlarged to a moderate degree. Signs and symptoms of cardiac decompensation may be present in those with severe anemia",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    underlying cardiac disease.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Laboratory findings",
"    </span>",
"    &nbsp;&mdash;&nbsp;The laboratory findings in patients with warm agglutinin AIHA are those of hemolytic anemia, with a hemoglobin usually in the range of 7 to 10",
"    <span class=\"nowrap\">",
"     g/dL",
"    </span>",
"    (equivalent to a hematocrit of 21 to 30 percent). In one series of 109 patients, for example, the mean hematocrit at presentation was 24 percent, with 30 percent of patients having values below this level [",
"    <a class=\"abstract\" href=\"UTD.htm?18/51/19256/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The reticulocyte count is elevated, as are serum levels of lactate dehydrogenase and indirect bilirubin, and the serum haptoglobin concentration is markedly reduced. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/3/18489?source=see_link&amp;anchor=H16#H16\">",
"     \"Approach to the diagnosis of hemolytic anemia in the adult\", section on 'Diagnostic approach'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The combination of an increased serum LDH and reduced haptoglobin is 90 percent specific for diagnosing hemolysis, while the combination of a normal serum LDH and a serum haptoglobin greater than 25",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      is 92 percent sensitive for ruling out hemolysis [",
"      <a class=\"abstract\" href=\"UTD.htm?18/51/19256/abstract/20,21\">",
"       20,21",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The increase in erythropoietin production induced by anemia should raise the reticulocyte percentage above 4 to 5 percent; in one series of patients with AIHA, the median reticulocyte percentage at diagnosis was 9 percent [",
"      <a class=\"abstract\" href=\"UTD.htm?18/51/19256/abstract/19\">",
"       19",
"      </a>",
"      ]. The absolute reticulocyte count or the reticulocyte production index are preferred methods to measure the reticulocyte response. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?18/3/18489?source=see_link&amp;anchor=H6#H6\">",
"       \"Approach to the diagnosis of hemolytic anemia in the adult\", section on 'Reticulocyte response'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Some patients (20 to 37 percent in one series) with acute hemolysis do not have the expected degree of reticulocytosis [",
"    <a class=\"abstract\" href=\"UTD.htm?18/51/19256/abstract/19\">",
"     19",
"    </a>",
"    ], and a few may actually have reticulocytopenia [",
"    <a class=\"abstract\" href=\"UTD.htm?18/51/19256/abstract/22\">",
"     22",
"    </a>",
"    ]. This is most often due to a lag in marrow responsiveness to hemolytic stress [",
"    <a class=\"abstract\" href=\"UTD.htm?18/51/19256/abstract/19\">",
"     19",
"    </a>",
"    ]. Alternatively, the antibody may also be directed against Rh receptors that appear on late orthochromic normoblasts and lead to their recognition and removal by bone marrow macrophages, thus preventing reticulocytes from being formed. Other patients may have direct or indirect bone marrow suppression (eg, parvovirus B19 or other infection). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/3/18489?source=see_link&amp;anchor=H25#H25\">",
"     \"Approach to the diagnosis of hemolytic anemia in the adult\", section on 'Hemolysis without reticulocytosis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The peripheral blood smear usually shows the presence of spherocytosis (",
"    <a class=\"graphic graphic_picture graphicRef53523 \" href=\"UTD.htm?32/10/32935\">",
"     picture 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_picture graphicRef50601 \" href=\"UTD.htm?9/21/9552\">",
"     picture 2",
"    </a>",
"    ), although this may not be obvious in milder cases. RBC indices may show an elevated mean corpuscular hemoglobin concentration (MCHC), consistent with the presence of spherocytes",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    an increase in the mean corpuscular volume (MCV) indicative of an increase in the percent of reticulocytes. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/46/29418?source=see_link&amp;anchor=H37#H37\">",
"     \"Approach to the adult patient with anemia\", section on 'Mean corpuscular hemoglobin concentration'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/16/21767?source=see_link&amp;anchor=H3#H3\">",
"     \"Macrocytosis\", section on 'Reticulocytosis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Thrombocytopenia due to immune destruction of the platelets is occasionally seen, especially in children (Evans-Duane syndrome). Signs of intravascular hemolysis (elevated plasma hemoglobin, hemoglobinuria, and hemosiderinuria) are not typical of warm AIHA, but may be present in severe cases.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Direct Coombs' test",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of warm agglutinin AIHA is based upon detection of antibody",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    complement components on the surface of the RBC, usually by the direct antiglobulin (Coombs') test. In this test, the RBCs of the patient are washed free of adherent proteins and reacted with antiserum or monoclonal antibodies prepared against the various immunoglobulins, particularly IgG and a fragment of the third component of complement, C3d. When these tests are accurately and specifically performed, 97 to 99 percent of patients with warm agglutinin AIHA will exhibit a positive result with anti-IgG, anti-C3, or both, compared with less than 1 percent of the normal population (",
"    <a class=\"graphic graphic_table graphicRef69817 \" href=\"UTD.htm?38/6/39020\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?18/51/19256/abstract/23-25\">",
"     23-25",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The Coombs test can be quantitated by an estimate of the degree of agglutination, or by more quantitative methods such as ELISA, immunoassay techniques, or flow cytometry [",
"    <a class=\"abstract\" href=\"UTD.htm?18/51/19256/abstract/26-29\">",
"     26-29",
"    </a>",
"    ]. The specificity of the antibody can be identified by eluting it from the red cells and testing it against a panel of red cells of known antigenic composition. In most cases, the antigen with which the antibody reacts is not polymorphic and occurs on the cells of almost all donors.",
"   </p>",
"   <p>",
"    The indirect antiglobulin (Coombs') test, in which the patient's serum is incubated with normal red cells in order to test for circulating antibodies, is generally of little value except in two circumstances:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      When testing blood for compatibility for transfusion. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?26/53/27480?source=see_link&amp;anchor=H15#H15\">",
"       \"The incompatible crossmatch\", section on 'Autoantibodies'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?13/62/14313?source=see_link&amp;anchor=H15#H15\">",
"       \"Treatment of autoimmune hemolytic anemia: Warm agglutinins\", section on 'Red blood cell transfusion'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Antibodies of low affinity may sometimes be detected by enzymatically digesting the normal red cells used in an indirect antiglobulin test; this procedure increases the affinity between antigen and antibody. Sometimes the specificity of the antibody may be identified by the indirect Coombs alone.",
"     </li>",
"     <li>",
"      In some instances, the antibody may have specificity for a known blood group antigen. This may be tested using serum in an indirect antiglobulin test or, preferably, using an eluate of the patient&rsquo;s red cells. Often, test cells of rare phenotype (eg, Rh",
"      <sub>",
"       null",
"      </sub>",
"      ) are necessary to establish a specificity.",
"     </li>",
"     <li>",
"      Antibodies of IgA or IgM isotype are rare causes of warm AIHA and can be detected with specific anti-IgA or anti-IgM antisera, respectively [",
"      <a class=\"abstract\" href=\"UTD.htm?18/51/19256/abstract/30-35\">",
"       30-35",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Cold-reacting IgG antibodies (the Donath-Landsteiner antibodies of paroxysmal cold hemoglobinuria) may be demonstrated by specific tests of the serum. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?16/2/16422?source=see_link&amp;anchor=H6#H6\">",
"       \"Paroxysmal cold hemoglobinuria\", section on 'Diagnosis'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10556119\">",
"    <span class=\"h3\">",
"     Coombs' negative AIHA",
"    </span>",
"    &nbsp;&mdash;&nbsp;In 1 to 10 percent of patients with warm agglutinin AIHA, the direct Coombs' test (the customary agglutination test used to diagnose AIHA) is negative. Tests more sensitive and quantitative than this agglutination test may be needed in order to demonstrate the presence of increased numbers of bound immunoglobulin",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    complement molecules on the red cell surface [",
"    <a class=\"abstract\" href=\"UTD.htm?18/51/19256/abstract/26,27\">",
"     26,27",
"    </a>",
"    ]. As an example, in one specialized laboratory employing a radioimmunoassay, the following observations were made concerning the number of IgG molecules per red blood cell in these various scenarios [",
"    <a class=\"abstract\" href=\"UTD.htm?18/51/19256/abstract/36,37\">",
"     36,37",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Normal subjects &mdash; 33 &plusmn; 13",
"     </li>",
"     <li>",
"      Average level in patients with Coombs&rsquo; negative AIHA &mdash; 179 &plusmn; 288",
"     </li>",
"     <li>",
"      Minimal level required for direct Coombs&rsquo; test positivity &mdash; 335 &plusmn; 72",
"     </li>",
"     <li>",
"      Average level in patients with Coombs&rsquo; positive AIHA &mdash; 1397 &plusmn; 1934",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     DIFFERENTIAL DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The major differential diagnosis of warm AIHA includes hemolytic anemia due to drugs and AIHA due to the presence of cold agglutinins. Accordingly, a complete drug history is required as well as a history of the relationship, if any, between the onset of hemolysis and exposure to cold. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/2/20521?source=see_link&amp;anchor=H15#H15\">",
"     \"Pathogenesis of autoimmune hemolytic anemia: Warm agglutinins and drugs\", section on 'Drug-related immune hemolysis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The immunosuppressive modalities used in warm agglutinin AIHA are generally not effective in cold agglutinin AIHA, which is generally due to the presence of IgM autoantibodies. Thus, distinction between warm and cold agglutinin AIHA is important for the selection of the proper treatment. The two most common conditions causing cold agglutinin AIHA are listed below:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Symptoms of acral cyanosis upon exposure to cold temperatures and a direct Coombs' test that is positive for C3 but not IgG are suggestive features; the diagnosis is confirmed by documenting the presence of high titers of cold agglutinins in the serum. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?32/56/33672?source=see_link\">",
"       \"Clinical features and treatment of autoimmune hemolytic anemia: Cold agglutinins\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Patients with paroxysmal cold hemoglobinuria (PCH) typically present with hemolysis and darkly colored urine (hemoglobinuria), beginning a few minutes to several hours after exposure to cold. Many patients with PCH have an antibody titer that is too low to produce these findings and present with simple hemolytic anemia. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?16/2/16422?source=see_link\">",
"       \"Paroxysmal cold hemoglobinuria\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     DISEASE COMPLICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Two potential complications of warm AIHA are the development of a lymphoproliferative disorder and venous thromboembolic disease.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Lymphoproliferative disorder",
"    </span>",
"    &nbsp;&mdash;&nbsp;The onset of AIHA may either precede or follow the diagnosis of a lymphoproliferative disorder [",
"    <a class=\"abstract\" href=\"UTD.htm?18/51/19256/abstract/38\">",
"     38",
"    </a>",
"    ]. In one series of 107 patients with idiopathic AIHA, 18 percent developed a malignant lymphoproliferative disorder (LPD) after a median time of approximately two years (range: 9 to 76 months) [",
"    <a class=\"abstract\" href=\"UTD.htm?18/51/19256/abstract/39\">",
"     39",
"    </a>",
"    ]. The following were risk factors for development of LPD in this group of patients:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Advanced age",
"     </li>",
"     <li>",
"      Underlying autoimmune disease",
"     </li>",
"     <li>",
"      The presence of a monoclonal IgM gammopathy",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    AIHA may also follow the use of purine analog therapy in patients with chronic lymphocytic leukemia or other indolent non-Hodgkin lymphoma variants. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/29/8665?source=see_link\">",
"     \"Autoimmune complications following purine analog therapy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Venous thromboembolism",
"    </span>",
"    &nbsp;&mdash;&nbsp;Venous thromboembolism (VTE), occasionally fatal, has been described in adults with idiopathic AIHA [",
"    <a class=\"abstract\" href=\"UTD.htm?18/51/19256/abstract/40,41\">",
"     40,41",
"    </a>",
"    ] as well as in those with AIHA and underlying HIV infection [",
"    <a class=\"abstract\" href=\"UTD.htm?18/51/19256/abstract/42\">",
"     42",
"    </a>",
"    ]. In one prospective study of 30 patients with AIHA, 19 were antiphospholipid antibody positive and 8 had a documented VTE [",
"    <a class=\"abstract\" href=\"UTD.htm?18/51/19256/abstract/43\">",
"     43",
"    </a>",
"    ]. The relative risk for VTE in subjects positive for the \"lupus anticoagulant\" by a variant of the kaolin plasma clotting time was 7.5 (95 percent confidence interval: 1.2 to 45), suggesting that such studies might help to identify patients at highest risk of developing VTE. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/31/23034?source=see_link&amp;anchor=H11#H11\">",
"     \"Clinical manifestations of the antiphospholipid syndrome\", section on 'Thrombosis'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/31/23034?source=see_link&amp;anchor=H160817409#H160817409\">",
"     \"Clinical manifestations of the antiphospholipid syndrome\", section on 'Lupus anticoagulant'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Additional studies are required to confirm these observations.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topic (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?11/51/12081?source=see_link\">",
"       \"Patient information: Autoimmune hemolytic anemia (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14054385\">",
"    <span class=\"h2\">",
"     Etiology",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most cases of warm agglutinin autoimmune hemolytic anemia (AIHA) are idiopathic. Associated disorders may include (see",
"    <a class=\"local\" href=\"#H2\">",
"     'Etiology'",
"    </a>",
"    above):",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Preceding viral infection, usually in children",
"     </li>",
"     <li>",
"      Autoimmune disorders, especially systemic lupus erythematosus",
"     </li>",
"     <li>",
"      Lymphoproliferative diseases (eg, chronic lymphocytic leukemia)",
"     </li>",
"     <li>",
"      Disorders of immune",
"      <span class=\"nowrap\">",
"       deficiency/regulation",
"      </span>",
"     </li>",
"     <li>",
"      Drugs (eg, penicillin,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?28/15/28918?source=see_link\">",
"       methyldopa",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Allogeneic blood transfusion or hematopoietic cell transplantation",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Clinical manifestations",
"    </span>",
"    &nbsp;&mdash;&nbsp;The clinical syndrome seen with AIHA of the warm-antibody type varies greatly with the amount and effectiveness of the causative antibody (see",
"    <a class=\"local\" href=\"#H6\">",
"     'Clinical manifestations'",
"    </a>",
"    above).",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      When the amount is small or the antibody is inefficient at effecting hemolysis, the patient may be asymptomatic even if slightly anemic.",
"     </li>",
"     <li>",
"      More commonly, the patient may complain of shortness of breath and dyspnea on exertion. If the hemolysis is severe and of sudden onset, symptoms may be those of severe degrees of cardiac decompensation, including heart failure, arrhythmia,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      chest pain, constituting a medical emergency.",
"     </li>",
"     <li>",
"      Physical examination usually reveals the presence of pallor and jaundice. The spleen is usually enlarged to a moderate degree.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14054411\">",
"    <span class=\"h2\">",
"     Laboratory testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;Recommended laboratory tests to document the presence and extent of AIHA include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Complete blood count with red blood cell indices (eg, MCV, MCH, MCHC) and reticulocyte percentage",
"     </li>",
"     <li>",
"      Tests for hemolysis, including indirect bilirubin, lactate dehydrogenase, and haptoglobin",
"     </li>",
"     <li>",
"      Direct and indirect Coombs testing, including testing for both IgG and C3 on the red cell surface",
"     </li>",
"     <li>",
"      Testing for specificity of the antibody for antigens identified on red blood cells",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Accurate diagnosis requires the documentation of the presence of hemolysis along with demonstration of the presence of a warm-reacting autoantibody",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    complement components on the surface of the patient's red cells (see",
"    <a class=\"local\" href=\"#H7\">",
"     'Diagnosis'",
"    </a>",
"    above).",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Anemia is usually present and may be severe. The mean corpuscular hemoglobin concentrations (MCHC) is increased, reflecting the presence of spherocytes. If anemia has been present long enough, the absolute reticulocyte count and the mean corpuscular volume (MCV) will be elevated, reflecting the bone marrow's response to anemia.",
"     </li>",
"     <li>",
"      Laboratory findings indicating the presence of hemolysis include elevated levels of indirect bilirubin and lactate dehydrogenase, along with reduced levels of haptoglobin. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?18/3/18489?source=see_link&amp;anchor=H16#H16\">",
"       \"Approach to the diagnosis of hemolytic anemia in the adult\", section on 'Diagnostic approach'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The peripheral blood smear shows the presence of spherocytes, usually with an increased number of polychromatophilic red cells (reticulocytes) (",
"      <a class=\"graphic graphic_picture graphicRef53523 \" href=\"UTD.htm?32/10/32935\">",
"       picture 1",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      The diagnosis of warm agglutinin AIHA is based upon detection of antibody",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      complement components on the surface of the RBC, usually by the direct antiglobulin (Coombs') test. Over 99 percent of patients with warm agglutinin AIHA will exhibit a positive result with anti-IgG, anti-C3, or both. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Direct Coombs' test'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/51/19256/abstract/1\">",
"      Gehrs BC, Friedberg RC. Autoimmune hemolytic anemia. Am J Hematol 2002; 69:258.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/51/19256/abstract/2\">",
"      Petz LD. Treatment of autoimmune hemolytic anemias. Curr Opin Hematol 2001; 8:411.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/51/19256/abstract/3\">",
"      S&egrave;ve P, Bourdillon L, Sarrot-Reynauld F, et al. Autoimmune hemolytic anemia and common variable immunodeficiency: a case-control study of 18 patients. Medicine (Baltimore) 2008; 87:177.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/51/19256/abstract/4\">",
"      Young PP, Uzieblo A, Trulock E, et al. Autoantibody formation after alloimmunization: are blood transfusions a risk factor for autoimmune hemolytic anemia? Transfusion 2004; 44:67.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/51/19256/abstract/5\">",
"      Hoffman PC. Immune hemolytic anemia--selected topics. Hematology Am Soc Hematol Educ Program 2009; :80.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/51/19256/abstract/6\">",
"      Gonzalez H, Leblond V, Azar N, et al. Severe autoimmune hemolytic anemia in eight patients treated with fludarabine. Hematol Cell Ther 1998; 40:113.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/51/19256/abstract/7\">",
"      Myint H, Copplestone JA, Orchard J, et al. Fludarabine-related autoimmune haemolytic anaemia in patients with chronic lymphocytic leukaemia. Br J Haematol 1995; 91:341.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/51/19256/abstract/8\">",
"      Byrd JC, Hertler AA, Weiss RB, et al. Fatal recurrence of autoimmune hemolytic anemia following pentostatin therapy in a patient with a history of fludarabine-associated hemolytic anemia. Ann Oncol 1995; 6:300.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/51/19256/abstract/9\">",
"      Fleischman RA, Croy D. Acute onset of severe autoimmune hemolytic anemia after treatment with 2-chlorodeoxyadenosine for chronic lymphocytic leukemia. Am J Hematol 1995; 48:293.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/51/19256/abstract/10\">",
"      Tertian G, Cartron J, Bayle C, et al. Fatal intravascular autoimmune hemolytic anemia after fludarabine treatment for chronic lymphocytic leukemia. Hematol Cell Ther 1996; 38:359.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/51/19256/abstract/11\">",
"      Juliusson G. Complications in the treatment of CLL with purine analogues. Hematol Cell Ther 1997; 39 Suppl 1:S41.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/51/19256/abstract/12\">",
"      Beyer M, Kochanek M, Darabi K, et al. Reduced frequencies and suppressive function of CD4+CD25hi regulatory T cells in patients with chronic lymphocytic leukemia after therapy with fludarabine. Blood 2005; 106:2018.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/51/19256/abstract/13\">",
"      Michel M, Chanet V, Dechartres A, et al. The spectrum of Evans syndrome in adults: new insight into the disease based on the analysis of 68 cases. Blood 2009; 114:3167.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/51/19256/abstract/14\">",
"      Sava��an S, Warrier I, Buck S, et al. Increased lymphocyte Fas expression and high incidence of common variable immunodeficiency disorder in childhood Evans' syndrome. Clin Immunol 2007; 125:224.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/51/19256/abstract/15\">",
"      Teachey DT, Manno CS, Axsom KM, et al. Unmasking Evans syndrome: T-cell phenotype and apoptotic response reveal autoimmune lymphoproliferative syndrome (ALPS). Blood 2005; 105:2443.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/51/19256/abstract/16\">",
"      Seif AE, Manno CS, Sheen C, et al. Identifying autoimmune lymphoproliferative syndrome in children with Evans syndrome: a multi-institutional study. Blood 2010; 115:2142.",
"     </a>",
"    </li>",
"    <li>",
"     Jones J. Transfusion in oligemia. In: Blood Transfusion in Clinical Medicine, 8th ed, Mollison PL, Engelfriet CP, Contreras M (Eds), Blackwell, Oxford 1987. p.41.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/51/19256/abstract/18\">",
"      Weiskopf RB, Viele MK, Feiner J, et al. Human cardiovascular and metabolic response to acute, severe isovolemic anemia. JAMA 1998; 279:217.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/51/19256/abstract/19\">",
"      Liesveld JL, Rowe JM, Lichtman MA. Variability of the erythropoietic response in autoimmune hemolytic anemia: analysis of 109 cases. Blood 1987; 69:820.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/51/19256/abstract/20\">",
"      Marchand A, Galen RS, Van Lente F. The predictive value of serum haptoglobin in hemolytic disease. JAMA 1980; 243:1909.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/51/19256/abstract/21\">",
"      Galen RS. Application of the predictive value model in the analysis of test effectiveness. Clin Lab Med 1982; 2:685.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/51/19256/abstract/22\">",
"      Conley CL, Lippman SM, Ness P. Autoimmune hemolytic anemia with reticulocytopenia. A medical emergency. JAMA 1980; 244:1688.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/51/19256/abstract/23\">",
"      Chaplin H Jr. Clinical usefulness of specific antiglobulin reagents in autoimmune hemolytic anemias. Prog Hematol 1973; 8:25.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/51/19256/abstract/24\">",
"      Wheeler CA, Calhoun L, Blackall DP. Warm reactive autoantibodies: clinical and serologic correlations. Am J Clin Pathol 2004; 122:680.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/51/19256/abstract/25\">",
"      Sachs UJ, R&ouml;der L, Santoso S, Bein G. Does a negative direct antiglobulin test exclude warm autoimmune haemolytic anaemia? A prospective study of 504 cases. Br J Haematol 2006; 132:655.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/51/19256/abstract/26\">",
"      Podberezin M, Levina A, Romanova L, et al. Quantitation of red cell-bound immunoglobulins and complement in lymphoma patients. Immunohematology 2000; 16:147.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/51/19256/abstract/27\">",
"      Bencomo AA, Diaz M, Alfonso Y, et al. Quantitation of red cell-bound IgG, IgA, and IgM in patients with autoimmune hemolytic anemia and blood donors by enzyme-linked immunosorbent assay. Immunohematology 2003; 19:47.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/51/19256/abstract/28\">",
"      Nathalang O, Chuansumrit A, Prayoonwiwat W, et al. Comparison between the conventional tube technique and the gel technique in direct antiglobulin tests. Vox Sang 1997; 72:169.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/51/19256/abstract/29\">",
"      Lin JS, Hao TC, Lyou JY, et al. Clinical application of a flow cytometric direct antiglobulin test. Transfusion 2009; 49:1335.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/51/19256/abstract/30\">",
"      Garratty G, Arndt P, Domen R, et al. Severe autoimmune hemolytic anemia associated with IgM warm autoantibodies directed against determinants on or associated with glycophorin A. Vox Sang 1997; 72:124.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/51/19256/abstract/31\">",
"      Reusser P, Osterwalder B, Burri H, Speck B. Autoimmune hemolytic anemia associated with IgA--diagnostic and therapeutic aspects in a case with long-term follow-up. Acta Haematol 1987; 77:53.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/51/19256/abstract/32\">",
"      Janvier D, Sellami F, Missud F, et al. Severe autoimmune hemolytic anemia caused by a warm IgA autoantibody directed against the third loop of band 3 (RBC anion-exchange protein 1). Transfusion 2002; 42:1547.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/51/19256/abstract/33\">",
"      Bardill B, Mengis C, Tschopp M, Wuillemin WA. Severe IgA-mediated auto-immune haemolytic anaemia in a 48-yr-old woman. Eur J Haematol 2003; 70:60.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/51/19256/abstract/34\">",
"      Arndt PA, Leger RM, Garratty G. Serologic findings in autoimmune hemolytic anemia associated with immunoglobulin M warm autoantibodies. Transfusion 2009; 49:235.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/51/19256/abstract/35\">",
"      Bartolm&auml;s T, Salama A. A dual antiglobulin test for the detection of weak or nonagglutinating immunoglobulin M warm autoantibodies. Transfusion 2010; 50:1131.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/51/19256/abstract/36\">",
"      Kamesaki T, Oyamada T, Omine M, et al. Cut-off value of red-blood-cell-bound IgG for the diagnosis of Coombs-negative autoimmune hemolytic anemia. Am J Hematol 2009; 84:98.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/51/19256/abstract/37\">",
"      Kamesaki T, Toyotsuji T, Kajii E. Characterization of direct antiglobulin test-negative autoimmune hemolytic anemia: a study of 154 cases. Am J Hematol 2013; 88:93.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/51/19256/abstract/38\">",
"      Genty I, Michel M, Hermine O, et al. [Characteristics of autoimmune hemolytic anemia in adults: retrospective analysis of 83 cases]. Rev Med Interne 2002; 23:901.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/51/19256/abstract/39\">",
"      Sallah S, Wan JY, Hanrahan LR. Future development of lymphoproliferative disorders in patients with autoimmune hemolytic anemia. Clin Cancer Res 2001; 7:791.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/51/19256/abstract/40\">",
"      Allgood JW, Chaplin H Jr. Idiopathic acquired autoimmune hemolytic anemia. A review of forty-seven cases treated from 1955 through 1965. Am J Med 1967; 43:254.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/51/19256/abstract/41\">",
"      Hendrick AM. Auto-immune haemolytic anaemia--a high-risk disorder for thromboembolism? Hematology 2003; 8:53.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/51/19256/abstract/42\">",
"      Saif MW, Bona R, Greenberg B. AIDS and thrombosis: retrospective study of 131 HIV-infected patients. AIDS Patient Care STDS 2001; 15:311.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/51/19256/abstract/43\">",
"      Pullarkat V, Ngo M, Iqbal S, et al. Detection of lupus anticoagulant identifies patients with autoimmune haemolytic anaemia at increased risk for venous thromboembolism. Br J Haematol 2002; 118:1166.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7078 Version 13.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-200.131.240.2-FE77A46CF4-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_51_19256=[""].join("\n");
var outline_f18_51_19256=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H14\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      ETIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Underlying causes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Drugs",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Evans syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      CLINICAL MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Laboratory findings",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Direct Coombs' test",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10556119\">",
"      - Coombs' negative AIHA",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      DIFFERENTIAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      DISEASE COMPLICATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Lymphoproliferative disorder",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Venous thromboembolism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14054385\">",
"      Etiology",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Clinical manifestations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14054411\">",
"      Laboratory testing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"HEME/7078\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"HEME/7078|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?32/10/32935\" title=\"picture 1\">",
"      Warm reactive AIHA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?9/21/9552\" title=\"picture 2\">",
"      Nucleated RBC in AIHA",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"HEME/7078|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?38/6/39020\" title=\"table 1\">",
"      Coombs test in AIHA",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/38/5735?source=related_link\">",
"      Apoptosis and autoimmune disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/46/29418?source=related_link\">",
"      Approach to the adult patient with anemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/3/18489?source=related_link\">",
"      Approach to the diagnosis of hemolytic anemia in the adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/29/8665?source=related_link\">",
"      Autoimmune complications following purine analog therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/36/30279?source=related_link\">",
"      Autoimmune lymphoproliferative syndrome (ALPS): Clinical features and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/15/246?source=related_link\">",
"      Autoimmune lymphoproliferative syndrome (ALPS): Management and prognosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/56/33672?source=related_link\">",
"      Clinical features and treatment of autoimmune hemolytic anemia: Cold agglutinins",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/31/23034?source=related_link\">",
"      Clinical manifestations of the antiphospholipid syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/28/17866?source=related_link\">",
"      Clinical manifestations, epidemiology, and diagnosis of common variable immunodeficiency in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/38/26218?source=related_link\">",
"      Donor selection for hematopoietic cell transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/49/14106?source=related_link\">",
"      Hematologic manifestations of systemic lupus erythematosus in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/52/5961?source=related_link\">",
"      Indications for red cell transfusion in the adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/16/21767?source=related_link\">",
"      Macrocytosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/25/410?source=related_link\">",
"      Overview of infectious complications following purine analog therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/12/35017?source=related_link\">",
"      Overview of the complications of chronic lymphocytic leukemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/2/16422?source=related_link\">",
"      Paroxysmal cold hemoglobinuria",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/2/20521?source=related_link\">",
"      Pathogenesis of autoimmune hemolytic anemia: Warm agglutinins and drugs",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?11/51/12081?source=related_link\">",
"      Patient information: Autoimmune hemolytic anemia (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/53/27480?source=related_link\">",
"      The incompatible crossmatch",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/62/14313?source=related_link\">",
"      Treatment of autoimmune hemolytic anemia: Warm agglutinins",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f18_51_19257="DeLancey levels pelvic support";
var content_f18_51_19257=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F60888%7EOBGYN%2F61643&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F60888%7EOBGYN%2F61643&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    DeLancey levels of female pelvic floor support: Level 1 (apical suspension) and level 2 (lateral attachment)",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 439px; height: 345px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Level 1: paracolpium suspends the vaginal apex from the lateral pelvic sidewall via the uterosacral-cardinal complex.",
"    <br>",
"     Level 2: the anterior vaginal wall is attached laterally to arcus tendinous fascia pelvis and the posterior vaginal wall is attached laterally to the facia overlying the levator ani muscle.",
"     <div class=\"footnotes\">",
"     </div>",
"     <div class=\"reference\">",
"      Reproduced with permission from: DeLancey, JO. Anatomic aspects of vaginal eversion after hysterectomy. Am J Obstet Gynecol 1992; 166(6 Pt 1):1717. Copyright &copy; 1992 Elsevier Inc.",
"     </div>",
"    </br>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 554px\">",
"   <div class=\"ttl\">",
"    DeLancey levels of vaginal support",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 534px; height: 393px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Level I consists of the cardinal and uterosacral ligaments, and suspends the vaginal apex. Level II consists of the endopelvic fascia connections to the arcus tendineus fascia pelvis, which attaches the vagina to the aponeurosis of the levator ani. Level III consists of the perineal body and includes interlacing muscle fibers of the bulbospongiosus, transverse perinei, and external anal sphincter.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Walters, MD, Karram, MM. Urogynecology and reconstructive pelvic surgery, 3rd ed, Mosby-Elsevier, 2007. Copyright &copy; 2007 Elsevier.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_51_19257=[""].join("\n");
var outline_f18_51_19257=null;
var title_f18_51_19258="Disorders of the calcium-sensing receptor: Familial hypocalciuric hypercalcemia and autosomal dominant hypocalcemia";
var content_f18_51_19258=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Disorders of the calcium-sensing receptor: Familial hypocalciuric hypercalcemia and autosomal dominant hypocalcemia",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?18/51/19258/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?18/51/19258/contributors\">",
"     Edward M Brown, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?18/51/19258/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?18/51/19258/contributors\">",
"     Clifford J Rosen, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?18/51/19258/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?18/51/19258/contributors\">",
"     Jean E Mulder, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?18/51/19258/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 25, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The demonstration that the rare disorder, familial hypocalciuric hypercalcemia, was caused by inactivating mutations in the gene for the calcium-sensing receptor (CaSR, sometimes referred to as CaR) had two major consequences: it explained the phenotypic expression of the disease, and it initiated an ongoing effort to explain the normal physiologic functions of the receptor. This topic will briefly review our understanding of the function of the CaSR in the parathyroid glands and kidneys and then describe conditions caused by mutations in this gene, particularly familial hypocalciuric hypercalcemia and autosomal dominant hypocalcemia (",
"    <a class=\"graphic graphic_table graphicRef58108 \" href=\"UTD.htm?28/40/29323\">",
"     table 1",
"    </a>",
"    ). There is also increasing evidence that abnormalities of the CaSR can be an acquired defect in hyperparathyroidism and hypoparathyroidism.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     FUNCTIONS OF THE CALCIUM-SENSING RECEPTOR",
"    </span>",
"    &nbsp;&mdash;&nbsp;The CaSR is expressed in multiple tissues, including the parathyroid glands, kidneys, bone marrow, osteoclasts and osteoblasts, breast, thyroid C-cells, gastrin-secreting cells in the stomach, intestine, some areas of the brain, and others [",
"    <a class=\"abstract\" href=\"UTD.htm?18/51/19258/abstract/1-7\">",
"     1-7",
"    </a>",
"    ]. One of its main functions is to regulate calcium balance [",
"    <a class=\"abstract\" href=\"UTD.htm?18/51/19258/abstract/1,2,8\">",
"     1,2,8",
"    </a>",
"    ]. The CaSR senses small changes in the serum ionized calcium concentration. In response to these changes, the CaSR brings about changes in the function of parathyroid glands and kidneys, which are directed at normalizing serum calcium concentration. This receptor is also activated by magnesium and by certain amino acids and therefore may have a role in the cellular response to changes in other constituents of the extracellular environment [",
"    <a class=\"abstract\" href=\"UTD.htm?18/51/19258/abstract/9,10\">",
"     9,10",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Parathyroid gland",
"    </span>",
"    &nbsp;&mdash;&nbsp;The CaSR is highly expressed on the surface of the chief cells of the parathyroid glands [",
"    <a class=\"abstract\" href=\"UTD.htm?18/51/19258/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. It permits the parathyroid gland to sense variations in the serum calcium concentration, leading to the desired changes in parathyroid hormone (PTH) secretion. A fall in serum calcium concentration is a potent stimulus to the release of PTH (",
"    <a class=\"graphic graphic_figure graphicRef63814 \" href=\"UTD.htm?32/10/32942\">",
"     figure 1",
"    </a>",
"    ). This is an appropriate physiologic response since, via its effects to increase bone resorption, to increase the formation of calcitriol in the kidney and to reduce renal calcium excretion, PTH acts to raise the serum calcium concentration toward normal. Chronic hypocalcemia, acting via the CaSR, has other homeostatically appropriate effects on parathyroid function, including increasing PTH gene expression and stimulating parathyroid cellular proliferation. Conversely, when serum calcium concentration is high, synthesis and secretion of PTH are inhibited. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/56/36744?source=see_link&amp;anchor=H16#H16\">",
"     \"Parathyroid hormone secretion and action\", section on 'Actions of PTH'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    There are clearly PTH-independent roles for the CaSR in maintaining the normally exquisitely tight regulation of serum calcium concentration. Mice lacking both the PTH and CaSR genes develop marked hypercalcemia in response to oral calcium loads, while those lacking only PTH can mount an effective defense against hypercalcemia via the CaSR by upregulating renal calcium excretion and calcitonin secretion [",
"    <a class=\"abstract\" href=\"UTD.htm?18/51/19258/abstract/11\">",
"     11",
"    </a>",
"    ]. In addition, polymorphisms of the CaSR may underlie some of the variability observed in the serum calcium concentrations in normal subjects [",
"    <a class=\"abstract\" href=\"UTD.htm?18/51/19258/abstract/12-14\">",
"     12-14",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Kidney",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Urine calcium excretion",
"    </span>",
"    &nbsp;&mdash;&nbsp;The CaSR is an important regulator of urinary calcium excretion [",
"    <a class=\"abstract\" href=\"UTD.htm?18/51/19258/abstract/15-19\">",
"     15-19",
"    </a>",
"    ]. It explains why hypercalcemia reduces calcium and sodium transport in the loop of Henle, with an associated decrease in urinary concentrating ability. Receptors expressed on the basolateral membrane on the cells of the thick ascending limb of the loop of Henle appear to be the major site where this occurs [",
"    <a class=\"abstract\" href=\"UTD.htm?18/51/19258/abstract/8,20,21\">",
"     8,20,21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A brief review of normal function in this segment is required to understand the mechanism by which the CaSR acts. Filtered sodium chloride enters the cells in the thick ascending limb of the loop of Henle via Na-K-2Cl cotransporters in the luminal (or apical) membrane (",
"    <a class=\"graphic graphic_figure graphicRef75301 \" href=\"UTD.htm?30/62/31725\">",
"     figure 2",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?18/51/19258/abstract/22\">",
"     22",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/49/36630?source=see_link\">",
"     \"Chapter 4A: Cell model for loop of Henle transport\"",
"    </a>",
"    .) Although this process is electrically neutral, most of the potassium reabsorbed by the cotransporter leaks back into the lumen to drive further inward sodium chloride transport. This movement of cationic potassium into the lumen plus the movement of reabsorbed chloride (via a chloride channel) out of the basolateral surface of the cells generates a net transepithelial potential difference. That is, the tubular lumen is positive with respect to the interstitial fluid and capillaries at the basolateral cell surface. The resulting lumen electropositivity drives the passive reabsorption of cations (sodium and, to a lesser degree, calcium and magnesium) via the paracellular pathway between the cells [",
"    <a class=\"abstract\" href=\"UTD.htm?18/51/19258/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    When calcium intake is increased, some of the excess calcium is absorbed, enters the systemic circulation, and slightly raises the serum calcium concentration. Suppression of PTH release with subsequent reduction in distal tubular calcium reabsorption increases calcium excretion. This appropriate change may be augmented by direct effects of hypercalcemia on the CaSR in the ascending limb of Henle's loop via the following sequence [",
"    <a class=\"abstract\" href=\"UTD.htm?18/51/19258/abstract/8\">",
"     8",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Calcium binding to the receptor leads to the generation of an arachidonic acid metabolite (which may be 20-hydroxyeicosatetraenoic acid [20-HETE] [",
"      <a class=\"abstract\" href=\"UTD.htm?18/51/19258/abstract/24\">",
"       24",
"      </a>",
"      ]) that then inhibits the potassium channel in the luminal membrane [",
"      <a class=\"abstract\" href=\"UTD.htm?18/51/19258/abstract/25\">",
"       25",
"      </a>",
"      ] and the sodium-potassium ATPase pump in the basolateral membrane [",
"      <a class=\"abstract\" href=\"UTD.htm?18/51/19258/abstract/26\">",
"       26",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Inhibition of potassium recycling via the potassium channel reduces sodium chloride reabsorption via the Na-K-2Cl transporter, diminishing the generation of the lumen-positive electrical gradient and therefore passive reabsorption of calcium and magnesium.",
"     </li>",
"     <li>",
"      Inhibition of the sodium pump reduces the driving force for sodium and chloride entry from the tubular fluid by the Na-K 2Cl cotransporter.",
"     </li>",
"     <li>",
"      An additional action of the CaSR reduces cellular cAMP levels, thereby diminishing the increase in lumen positive potential that is stimulated by PTH through activation of adenylate cyclase [",
"      <a class=\"abstract\" href=\"UTD.htm?18/51/19258/abstract/27\">",
"       27",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Urinary concentration",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is increasing evidence that calcium-induced activation of the CaSR impairs concentrating ability. Two sites appear to be involved: first, interference with sodium chloride reabsorption in the thick ascending limb directly impairs generation of the medullary osmotic gradient that is essential for urinary concentration; second, activation of calcium-sensing receptors expressed on the luminal membrane of the cells of the inner medullary collecting duct reduces antidiuretic hormone-induced increases in water permeability [",
"    <a class=\"abstract\" href=\"UTD.htm?18/51/19258/abstract/28\">",
"     28",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Acutely, the CaSR-mediated reduction in concentrating ability allows calcium excretion to increase while minimizing the risk of crystallization of calcium salts and the resultant possibility of stone formation owing to dilution of the calcium in a larger volume of urine. Chronically, it may be responsible for the nephrogenic diabetes insipidus associated with chronic hypercalcemia. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/2/21545?source=see_link\">",
"     \"Clinical manifestations and causes of nephrogenic diabetes insipidus\"",
"    </a>",
"    .) This action of the CaSR on urinary concentrating ability may be augmented by CaSR-mediated activation of proton secretion in the intercalated cells of the outer medullary collecting duct, which further increases the solubility of calcium salts, particularly the calcium-phosphate in mouse models [",
"    <a class=\"abstract\" href=\"UTD.htm?18/51/19258/abstract/29\">",
"     29",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Bone",
"    </span>",
"    &nbsp;&mdash;&nbsp;The CaSR is expressed in chondrocytes, osteoblasts, osteoclast precursors, and some osteoclasts. Experiments in CaSR knockout mice suggest that the CaSR plays a role in the embryonic development of the skeleton, postnatal bone formation, and osteoblast differentiation [",
"    <a class=\"abstract\" href=\"UTD.htm?18/51/19258/abstract/30-32\">",
"     30-32",
"    </a>",
"    ]. Additional studies are required to clarify further the role of the CaSR in skeletal homeostasis, including how it relates to mineral ion homeostasis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     INACTIVATING MUTATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Activating or inactivating mutations in the CaSR gene result in altered calcium sensing and therefore inappropriate PTH release with respect to the serum calcium concentration (",
"    <a class=\"graphic graphic_table graphicRef58108 \" href=\"UTD.htm?28/40/29323\">",
"     table 1",
"    </a>",
"    ). An inactivating (or loss-of-function) mutation shifts the calcium-PTH curve to the right and produces hypercalcemia, since higher concentrations of calcium are required to suppress PTH release, in effect \"resetting\" the serum calcium concentration to a higher level (",
"    <a class=\"graphic graphic_figure graphicRef63814 \" href=\"UTD.htm?32/10/32942\">",
"     figure 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Inactivating mutations of the CaSR gene have been reported in inherited hypercalcemic disorders, eg, familial hypocalciuric hypercalcemia (FHH; also called familial benign hypercalcemia) and neonatal severe primary hyperparathyroidism (NSHPT) [",
"    <a class=\"abstract\" href=\"UTD.htm?18/51/19258/abstract/33-37\">",
"     33-37",
"    </a>",
"    ]. The degree of hypercalcemia in these two disorders reflects a gene dose effect [",
"    <a class=\"abstract\" href=\"UTD.htm?18/51/19258/abstract/34-36\">",
"     34-36",
"    </a>",
"    ]. FHH heterozygotes have mild hypercalcemia because of partial loss of CaSR function. In contrast, patients who are homozygous for the CaSR gene defect have more marked disease, presenting with NSHPT [",
"    <a class=\"abstract\" href=\"UTD.htm?18/51/19258/abstract/33,34,36,37\">",
"     33,34,36,37",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    These differences have been confirmed in mice lacking the CaSR gene [",
"    <a class=\"abstract\" href=\"UTD.htm?18/51/19258/abstract/38\">",
"     38",
"    </a>",
"    ]. Heterozygotes have a syndrome similar to FHH, while homozygotes have the murine equivalent of NSHPT. The number of CaSR molecules on the surface of the parathyroid glands may be a major determinant of the serum calcium concentration in normal subjects. However, some mutations exert a dominant negative action, thereby producing hypercalcemia in heterozygotes higher than is typically seen [",
"    <a class=\"abstract\" href=\"UTD.htm?18/51/19258/abstract/39\">",
"     39",
"    </a>",
"    ]. Conversely, other mutations are so mild that heterozygotes are normocalcemic, and the diagnosis is only made following the birth of a homozygous infant [",
"    <a class=\"abstract\" href=\"UTD.htm?18/51/19258/abstract/40\">",
"     40",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Familial hypocalciuric hypercalcemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;FHH is a benign cause of hypercalcemia that is characterized by autosomal dominant inheritance with high penetrance. Affected heterozygous patients typically present in childhood with the incidental discovery of mild hypercalcemia, hypocalciuria, a normal PTH level, and high-normal to frankly elevated serum magnesium levels [",
"    <a class=\"abstract\" href=\"UTD.htm?18/51/19258/abstract/41-44\">",
"     41-44",
"    </a>",
"    ]. In most cases, FHH results from an inactivating mutation in the CaSR, whose gene resides on the long arm of chromosome 3 [",
"    <a class=\"abstract\" href=\"UTD.htm?18/51/19258/abstract/33-37\">",
"     33-37",
"    </a>",
"    ]. In addition, two families have been described in whom the condition is linked to the short arm of chromosome 19 in one [",
"    <a class=\"abstract\" href=\"UTD.htm?18/51/19258/abstract/45\">",
"     45",
"    </a>",
"    ] and the long arm of the same chromosome in the other [",
"    <a class=\"abstract\" href=\"UTD.htm?18/51/19258/abstract/46\">",
"     46",
"    </a>",
"    ]. The forms of FHH arising from these two loci result from missense mutations of adaptor-related protein complex 2, sigma 1 subunit (AP2S1) [",
"    <a class=\"abstract\" href=\"UTD.htm?18/51/19258/abstract/47\">",
"     47",
"    </a>",
"    ], which participates in clathrin-mediated endocytosis of G protein-coupled receptors. Mutations in AP2S1 decrease the sensitivity of the CaSR-expressing cells to extracellular calcium and modify the receptor&rsquo;s endocytosis.",
"   </p>",
"   <p>",
"    About 200 different mutations of the CaSR have been identified [",
"    <a class=\"abstract\" href=\"UTD.htm?18/51/19258/abstract/44\">",
"     44",
"    </a>",
"    ]. (A summary of CaSR mutations is maintained at the calcium-sensing receptor database [CASRdb] at McGill University [",
"    <a class=\"abstract\" href=\"UTD.htm?18/51/19258/abstract/48\">",
"     48",
"    </a>",
"    ].) Most result in receptors that have a change in a single amino acid (missense mutation) that reduces the receptor's function or, less commonly, that produce a truncated, inactive CaSR; in both cases, the result is fewer normally functioning receptors on the parathyroid or renal cell surface [",
"    <a class=\"abstract\" href=\"UTD.htm?18/51/19258/abstract/34,37,44\">",
"     34,37,44",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The inactivating mutations of the CaSR in FHH make the parathyroid glands less sensitive to calcium. This defect means that a higher than normal serum calcium concentration is required to reduce PTH release [",
"    <a class=\"abstract\" href=\"UTD.htm?18/51/19258/abstract/39,44,49\">",
"     39,44,49",
"    </a>",
"    ]. In the kidney, this defect leads to an increase in tubular calcium and magnesium reabsorption [",
"    <a class=\"abstract\" href=\"UTD.htm?18/51/19258/abstract/41,42\">",
"     41,42",
"    </a>",
"    ]. The net effect is hypercalcemia, hypocalciuria, and frequently high normal levels of serum magnesium or frank hypermagnesemia. Thus, the relative insensitivity of the CaSR to calcium effectively \"resets\" not only parathyroid but also kidney to maintain mild to moderate hypercalcemia.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Clinical findings",
"    </span>",
"    &nbsp;&mdash;&nbsp;In FHH, serum PTH concentrations are typically inappropriately normal or high (in about 20 percent of cases) in the presence of mild hypercalcemia. One cause of a high serum PTH level in FHH is the presence of coexistent vitamin D deficiency [",
"    <a class=\"abstract\" href=\"UTD.htm?18/51/19258/abstract/50\">",
"     50",
"    </a>",
"    ]. Patients with FHH have few (if any) symptoms or signs of hypercalcemia (eg, constipation, polyuria, renal insufficiency, or neuropsychiatric disease), although occasional cases have exhibited pancreatitis or chondrocalcinosis [",
"    <a class=\"abstract\" href=\"UTD.htm?18/51/19258/abstract/41,42,51,52\">",
"     41,42,51,52",
"    </a>",
"    ]. The CaSR gene is one of several genes that, when mutated, can confer increased susceptibility to pancreatitis [",
"    <a class=\"abstract\" href=\"UTD.htm?18/51/19258/abstract/53\">",
"     53",
"    </a>",
"    ]. The usual lack of high serum PTH concentrations may contribute to the benign clinical course of FHH, as compared with primary hyperparathyroidism [",
"    <a class=\"abstract\" href=\"UTD.htm?18/51/19258/abstract/41,42,51\">",
"     41,42,51",
"    </a>",
"    ]. In the latter disorder, excess PTH is directly responsible for the bone disease that occurs in some patients.",
"   </p>",
"   <p>",
"    Urinary calcium excretion is low in patients with FHH. The 24-hour urinary calcium excretion is typically below 200",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    (5",
"    <span class=\"nowrap\">",
"     mmol/day)",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?18/51/19258/abstract/41,42\">",
"     41,42",
"    </a>",
"    ]. In contrast, approximately 40 percent of patients with primary hyperparathyroidism have hypercalciuria (24-hour calcium excretion above 250 mg [6.2 mmol] in women and 300 mg [7.5 mmol] in men) [",
"    <a class=\"abstract\" href=\"UTD.htm?18/51/19258/abstract/54\">",
"     54",
"    </a>",
"    ]. When evaluating patients suspected of having FHH, it is important to exclude other factors causing hypocalciuria in the setting of PTH-dependent, hypocalciuric hypercalcemia. These include vitamin D deficiency",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    very low calcium intake, mild renal insufficiency, and treatment with thiazides or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/11/23736?source=see_link\">",
"     lithium",
"    </a>",
"    (both of which are hypocalciuric). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/26/5545?source=see_link&amp;anchor=H5#H5\">",
"     \"Diagnosis and differential diagnosis of primary hyperparathyroidism\", section on 'Differential diagnosis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Calculation of the",
"    <span class=\"nowrap\">",
"     Ca/Cr",
"    </span>",
"    clearance ratio, which is equivalent to the fractional excretion of calcium, is felt by most authorities to be preferable to simply measuring 24-hour excretion of calcium for diagnosing FHH [",
"    <a class=\"abstract\" href=\"UTD.htm?18/51/19258/abstract/41,42,44\">",
"     41,42,44",
"    </a>",
"    ]. This ratio is calculated from the results of a 24-hour urine collection and simultaneously measured total serum calcium and creatinine concentrations, using the following formula:",
"   </p>",
"   <p>",
"    &nbsp;",
"    <span class=\"nowrap\">",
"     Ca/Cr",
"    </span>",
"    clearance ratio &nbsp;= &nbsp;[24-hour Urine Ca &nbsp;x &nbsp;serum Cr] &nbsp;&divide; &nbsp;[Serum Ca &nbsp;x &nbsp;24-hour Urine Cr]",
"   </p>",
"   <p>",
"    The data establishing the value of the calcium to creatinine clearance ratio in differentiating FHH from primary hyperparathyroidism are based primarily on 24-hour urine collections [",
"    <a class=\"abstract\" href=\"UTD.htm?18/51/19258/abstract/41,42\">",
"     41,42",
"    </a>",
"    ]. While there are insufficient data available to prove that",
"    <span class=\"nowrap\">",
"     Ca/Cr",
"    </span>",
"    ratios calculated from spot urines are equivalent to those determined from 24-hour urines, in principle the two should reflect renal calcium handling similarly.",
"   </p>",
"   <p>",
"    The",
"    <span class=\"nowrap\">",
"     Ca/Cr",
"    </span>",
"    clearance ratio is less than 0.01 in approximately 80 percent of patients with FHH, indicating that more than 99 percent of the filtered calcium has been reabsorbed despite the presence of hypercalcemia. In patients with primary hyperparathyroidism, however, the",
"    <span class=\"nowrap\">",
"     Ca/Cr",
"    </span>",
"    clearance ratio is most often &gt;0.02. In a study that reevaluated the discriminative power of the",
"    <span class=\"nowrap\">",
"     Ca/Cr",
"    </span>",
"    clearance ratio, a value of 0.0115, similar to that proposed earlier [",
"    <a class=\"abstract\" href=\"UTD.htm?18/51/19258/abstract/41,42\">",
"     41,42",
"    </a>",
"    ], provided optimal discrimination between FHH and primary hyperparathyroidism [",
"    <a class=\"abstract\" href=\"UTD.htm?18/51/19258/abstract/55\">",
"     55",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Distinction from primary hyperparathyroidism",
"    </span>",
"    &nbsp;&mdash;&nbsp;It is important to distinguish asymptomatic primary hyperparathyroidism from FHH because FHH is a benign inherited condition that typically does not require parathyroidectomy, nor will it be routinely cured by it. Although it is not difficult to differentiate patients with typical biochemical findings of either FHH or PHPT, it can be challenging to differentiate patients with atypical presentations of either disease.",
"   </p>",
"   <p>",
"    Hypercalcemia with \"normal\" serum PTH concentrations occurs in approximately 10 percent of patients with primary hyperparathyroidism, which is a much more common cause of hypercalcemia than FHH, and 15 to 20 percent of patients with FHH may have a mildly elevated PTH concentration.",
"   </p>",
"   <p>",
"    In addition, there may be overlap in urinary calcium excretion. In patients with primary hyperparathyroidism, the",
"    <span class=\"nowrap\">",
"     Ca/Cr",
"    </span>",
"    clearance ratio is usually between 0.01 and 0.05 and most often &gt;0.02. However, the",
"    <span class=\"nowrap\">",
"     Ca/Cr",
"    </span>",
"    clearance ratio may be less than 0.01 in approximately 20 percent of patients with primary hyperparathyroidism, particularly those with concomitant vitamin D deficiency. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/26/5545?source=see_link&amp;anchor=H13#H13\">",
"     \"Diagnosis and differential diagnosis of primary hyperparathyroidism\", section on 'Measurement of urinary calcium excretion'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/26/5545?source=see_link&amp;anchor=H14#H14\">",
"     \"Diagnosis and differential diagnosis of primary hyperparathyroidism\", section on 'Vitamin D metabolites'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In contrast, affected family members in occasional FHH families are hypercalciuric [",
"    <a class=\"abstract\" href=\"UTD.htm?18/51/19258/abstract/56\">",
"     56",
"    </a>",
"    ]. As an example, in some families with what was thought by experienced clinicians to be familial isolated hyperparathyroidism, inactivating mutations of the CaSR have been identified [",
"    <a class=\"abstract\" href=\"UTD.htm?18/51/19258/abstract/57,58\">",
"     57,58",
"    </a>",
"    ]. In these patients, the clinical presentation is similar to that of primary hyperparathyroidism (hypercalcemia and hypercalciuria). Furthermore, in one family with an atypical presentation of FHH (including hypercalciuria and even renal stone disease), which was confirmed by mutational analysis to be due to an inactivating mutation in the CaSR, subtotal parathyroidectomy was effective in reversing the biochemical abnormalities [",
"    <a class=\"abstract\" href=\"UTD.htm?18/51/19258/abstract/59\">",
"     59",
"    </a>",
"    ]. It should be emphasized, however, that parathyroidectomy is neither desirable nor curative in most typical cases of FHH. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/41/30361?source=see_link&amp;anchor=H21#H21\">",
"     \"Pathogenesis and etiology of primary hyperparathyroidism\", section on 'Familial hyperparathyroidism'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Establishing the diagnosis of FHH biochemically is more difficult in these atypical patients. CaSR mutational analysis, although available, is not routinely performed. However, mutational analysis may be of benefit in distinguishing FHH from primary hyperparathyroidism in the following clinical settings [",
"    <a class=\"abstract\" href=\"UTD.htm?18/51/19258/abstract/55\">",
"     55",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Families with familial isolated hyperparathyroidism",
"     </li>",
"     <li>",
"      Patients with overlap in the",
"      <span class=\"nowrap\">",
"       Ca/Cr",
"      </span>",
"      clearance ratio, namely between 0.01 and 0.02",
"     </li>",
"     <li>",
"      Patients with the phenotype of FHH whose parents are both normocalcemic (ie, FHH possibly caused by a de novo CaSR mutation)",
"     </li>",
"     <li>",
"      Atypical cases where no family members are available for testing",
"     </li>",
"     <li>",
"      Infants or children under 10 years of age in whom NSHPT, neonatal hyperparathyroidism (NHPT, a milder condition described below), and FHH are the most common causes of PTH-dependent hypercalcemia",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The genetic test is by no means infallible. As many as one-third of families with FHH linked to chromosome 3 do not have a detectable mutation within the coding region of the gene or its intron-exon boundaries. It is thought that these cases harbor mutations in regulatory regions of the gene affecting its level of expression.",
"   </p>",
"   <p>",
"    In most circumstances, the diagnosis of FHH, particularly its distinction from primary hyperparathyroidism, is primarily based upon the absence of symptoms, as well as laboratory findings typical of FHH in the proband (PTH-dependent, hypocalciuric hypercalcemia). A history of familial hypercalcemia with hypocalciuria, sometimes with previously unsuccessful parathyroid surgery, in other affected family members, including young children, is helpful in diagnosing FHH. Even if the family history is negative, this does not rule out familial involvement in this typically asymptomatic condition, and serum and urinary calcium determination should be performed in several first degree relatives, if possible. Penetrance is high, and typical findings in the proband, combined with family screening that yields biochemical findings characteristic of FHH, is often the most reliable method of confirming the diagnosis, thereby obviating the need for mutational analysis.",
"   </p>",
"   <p>",
"    The laboratory findings that help to distinguish FHH from primary hyperparathyroidism are discussed in more detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/26/5545?source=see_link&amp;anchor=H7#H7\">",
"     \"Diagnosis and differential diagnosis of primary hyperparathyroidism\", section on 'Familial hypocalciuric hypercalcemia'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/26/5545?source=see_link&amp;anchor=H13#H13\">",
"     \"Diagnosis and differential diagnosis of primary hyperparathyroidism\", section on 'Measurement of urinary calcium excretion'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Course and management",
"    </span>",
"    &nbsp;&mdash;&nbsp;Because of the usually benign natural history of FHH and because subtotal parathyroidectomy does not cure the disorder, the great majority of these patients should not undergo neck exploration or any other aggressive intervention [",
"    <a class=\"abstract\" href=\"UTD.htm?18/51/19258/abstract/41-44,52\">",
"     41-44,52",
"    </a>",
"    ]. Affected family members should be identified and counseled on the benign nature of this condition and, consequently, the importance of avoiding parathyroid surgery, sometimes undertaken because of a mistaken diagnosis of primary hyperparathyroidism. In one family with an atypical presentation of FHH (including hypercalciuria and even renal stone disease), which was confirmed by mutational analysis to be due to an inactivating mutation in the CaSR, subtotal parathyroidectomy was effective in reversing the biochemical abnormalities [",
"    <a class=\"abstract\" href=\"UTD.htm?18/51/19258/abstract/59\">",
"     59",
"    </a>",
"    ]. Thus, while typically ineffective in curing hypercalcemia in FHH, subtotal parathyroidectomy may be appropriate in occasional kindreds with atypical features (pancreatitis, hypercalciuria,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    overt hyperparathyroidism) [",
"    <a class=\"abstract\" href=\"UTD.htm?18/51/19258/abstract/60\">",
"     60",
"    </a>",
"    ]. Further experience with cases of familial isolated hyperparathyroidism caused by mutations in the CaSR gene is needed to define the role of parathyroidectomy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Neonatal severe hyperparathyroidism",
"    </span>",
"    &nbsp;&mdash;&nbsp;NSHPT is usually caused by a homozygous inactivating mutation in the CaSR gene [",
"    <a class=\"abstract\" href=\"UTD.htm?18/51/19258/abstract/33,34,36,37\">",
"     33,34,36,37",
"    </a>",
"    ], although a compound heterozygote harboring a different mutation from each parent has been described [",
"    <a class=\"abstract\" href=\"UTD.htm?18/51/19258/abstract/61\">",
"     61",
"    </a>",
"    ]. It is most commonly an autosomal recessive condition. A milder condition has also been described, termed neonatal hyperparathyroidism (NHPT), that is usually caused by inherited or de novo heterozygous inactivating mutations of the CaSR [",
"    <a class=\"abstract\" href=\"UTD.htm?18/51/19258/abstract/37,39,62\">",
"     37,39,62",
"    </a>",
"    ]. In some cases NHPT may be the result of the mutant receptor exerting a dominant negative action on its wild type partner, thereby leading to a greater elevation in set-point for PTH secretion and, as a consequence, more severe hypercalcemia [",
"    <a class=\"abstract\" href=\"UTD.htm?18/51/19258/abstract/39\">",
"     39",
"    </a>",
"    ]. Such cases may revert to the clinical and biochemical picture of FHH if managed medically with careful monitoring.",
"   </p>",
"   <p>",
"    Infants who are homozygous for the CaSR defect present with severe neonatal hyperparathyroidism (serum PTH concentrations as much as 10-fold higher than normal), usually severe hypercalcemia (serum calcium concentration often above 15",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    [3.75",
"    <span class=\"nowrap\">",
"     mmol/L]),",
"    </span>",
"    and relative hypocalciuria [",
"    <a class=\"abstract\" href=\"UTD.htm?18/51/19258/abstract/33-36,44,63,64\">",
"     33-36,44,63,64",
"    </a>",
"    ]. Rachitic changes often occur and bone x-rays may reveal marked demineralization and subperiosteal resorption with multiple fractures. This disorder can be fatal without immediate parathyroidectomy, although case reports have described the use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/62/3048?source=see_link\">",
"     pamidronate",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/23/26998?source=see_link\">",
"     cinacalcet",
"    </a>",
"    as a \"rescue\" therapy to stabilize infants with NSHPT prior to surgery or after failed surgery [",
"    <a class=\"abstract\" href=\"UTD.htm?18/51/19258/abstract/65,66\">",
"     65,66",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     ACTIVATING MUTATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;An activating (or gain-of-function) mutation of the CaSR gene shifts the calcium-PTH curve to the left and decreases the set point of the CaSR, so that PTH is not released at serum calcium concentrations that normally trigger PTH release, thereby causing hypocalcemia (",
"    <a class=\"graphic graphic_figure graphicRef63814 \" href=\"UTD.htm?32/10/32942\">",
"     figure 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef58108 \" href=\"UTD.htm?28/40/29323\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    One form of autosomal dominant hypocalcemia (ADH, sometimes called autosomal dominant hypoparathyroidism) is caused by an activating mutation in the CaSR [",
"    <a class=\"abstract\" href=\"UTD.htm?18/51/19258/abstract/44,67,68\">",
"     44,67,68",
"    </a>",
"    ]; as a result, a low serum calcium concentration is perceived as normal, leading to a downward resetting of the PTH-calcium relationship [",
"    <a class=\"abstract\" href=\"UTD.htm?18/51/19258/abstract/49\">",
"     49",
"    </a>",
"    ]. In patients with ADH, serum PTH concentrations are low or inappropriately normal despite the presence of mild to moderate and occasionally severe hypocalcemia. In contrast to other causes of hypocalcemia, urinary calcium excretion is normal or frankly high in the untreated state, presumably due to increased activation of the CaSR in the kidney (see",
"    <a class=\"local\" href=\"#H4\">",
"     'Kidney'",
"    </a>",
"    above).",
"   </p>",
"   <p>",
"    Some patients also have potassium wasting, hypokalemia, and metabolic alkalosis, creating a phenotype similar to Bartter syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?18/51/19258/abstract/69,70\">",
"     69,70",
"    </a>",
"    ]. These patients appear to have a more marked gain-of-function in the CaSR than those without hypokalemia. The presumed mechanism, as described above, is that activation of the CaSR inhibits the outer medullary luminal potassium channel, thereby diminishing potassium reabsorption [",
"    <a class=\"abstract\" href=\"UTD.htm?18/51/19258/abstract/8,25\">",
"     8,25",
"    </a>",
"    ]. Bartter syndrome is reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/43/23226?source=see_link\">",
"     \"Bartter and Gitelman syndromes\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Autosomal dominant hypocalcemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Autosomal dominant hypocalcemia is commonly caused by an activating mutation of the CaSR gene [",
"    <a class=\"abstract\" href=\"UTD.htm?18/51/19258/abstract/44,48,67,68,71-77\">",
"     44,48,67,68,71-77",
"    </a>",
"    ]. Most reported mutations occur in the extracellular domain of the CaSR, although some occur in the transmembrane domain [",
"    <a class=\"abstract\" href=\"UTD.htm?18/51/19258/abstract/44,48,64,71\">",
"     44,48,64,71",
"    </a>",
"    ]. In addition to point mutations, a large 181 amino acid deletion from the carboxyl terminal tail of the CaSR has been reported in a French family [",
"    <a class=\"abstract\" href=\"UTD.htm?18/51/19258/abstract/74\">",
"     74",
"    </a>",
"    ]. Interestingly, a homozygous member of the family had a similar phenotype to heterozygous individuals, implying that one mutated allele is enough to cause a maximal shift of calcium sensitivity [",
"    <a class=\"abstract\" href=\"UTD.htm?18/51/19258/abstract/74\">",
"     74",
"    </a>",
"    ]. Sporadic de novo mutations in the CaSR have also been identified [",
"    <a class=\"abstract\" href=\"UTD.htm?18/51/19258/abstract/75,76\">",
"     75,76",
"    </a>",
"    ]. Such patients are often labeled as having idiopathic hypoparathyroidism, unless their CaSR gene is subjected to mutational analysis.",
"   </p>",
"   <p>",
"    These findings have been confirmed in a mouse model of an activating mutation in the CaSR. Affected mice displayed features similar to those in ADH [",
"    <a class=\"abstract\" href=\"UTD.htm?18/51/19258/abstract/78\">",
"     78",
"    </a>",
"    ]. In addition, they were noted to have ectopic calcifications and cataracts.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Clinical manifestations",
"    </span>",
"    &nbsp;&mdash;&nbsp;The majority of patients with ADH are asymptomatic and therefore are not diagnosed until adulthood, when hypocalcemia is incidentally noted. A few patients, however, have symptomatic hypocalcemia [",
"    <a class=\"abstract\" href=\"UTD.htm?18/51/19258/abstract/44\">",
"     44",
"    </a>",
"    ]. Children in particular may become symptomatic with seizures and neuromuscular irritability during periods of stress, such as a febrile illness, and may be mislabeled as having febrile seizures.",
"   </p>",
"   <p>",
"    The biochemical features are as follows:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Serum calcium concentration usually in the range of 6 to 8",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (1.5 to 2.0",
"      <span class=\"nowrap\">",
"       mmol/L),",
"      </span>",
"      but as low as 5",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      in occasional families",
"     </li>",
"     <li>",
"      Normal (or only slightly low) serum PTH concentrations",
"     </li>",
"     <li>",
"      High or high normal urinary calcium excretion rather than the expected low excretion",
"     </li>",
"     <li>",
"      Recurrent nephrolithiasis and nephrocalcinosis, particularly during treatment with vitamin D and calcium supplementation",
"     </li>",
"     <li>",
"      No previous normal serum calcium values",
"     </li>",
"     <li>",
"      Low serum magnesium concentration (in some)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The usual biochemical tests do not reliably discriminate this disorder from other forms of PTH-deficient hypoparathyroidism [",
"    <a class=\"abstract\" href=\"UTD.htm?18/51/19258/abstract/44,79,80\">",
"     44,79,80",
"    </a>",
"    ]. In addition to the features listed above, the major clinical clue to this syndrome is its familial nature and the tendency of patients to develop renal complications during treatment with calcium and vitamin D supplementation [",
"    <a class=\"abstract\" href=\"UTD.htm?18/51/19258/abstract/60,79\">",
"     60,79",
"    </a>",
"    ]. The diagnosis can be confirmed by analysis for mutations in the CaSR gene [",
"    <a class=\"abstract\" href=\"UTD.htm?18/51/19258/abstract/60,64\">",
"     60,64",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Once the diagnosis is established, attempts to raise the serum calcium concentration should be considered only in patients who are symptomatic, and they should only be treated to the point where symptoms disappear [",
"    <a class=\"abstract\" href=\"UTD.htm?18/51/19258/abstract/60,74,79,80\">",
"     60,74,79,80",
"    </a>",
"    ]. In addition to the lack of need for therapy in asymptomatic patients, there is a high potential for adverse effects from raising the serum calcium with vitamin D supplementation. As the serum calcium concentration increases, the activating mutation in the CaSR in the loop of Henle will lead to a marked increase in urinary calcium excretion, which can cause renal stones, nephrocalcinosis, and renal insufficiency [",
"    <a class=\"abstract\" href=\"UTD.htm?18/51/19258/abstract/60,79\">",
"     60,79",
"    </a>",
"    ]. A similar phenomenon occurs in hypoparathyroidism (although usually to a lesser degree), in which lack of the calcium-conserving effect of PTH results in hypercalciuria well before normocalcemia is achieved. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/37/44632?source=see_link&amp;anchor=H13#H13\">",
"     \"Treatment of hypocalcemia\", section on 'Preventing hypercalciuria'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Fortunately, most patients with ADH are asymptomatic and do not require therapy. The goal of treatment in symptomatic patients with autosomal dominant (or sporadic) hypocalcemia with hypercalciuria is to maintain a serum calcium concentration just sufficient to alleviate the symptoms. This can be achieved with cautious calcium and vitamin D supplementation with monitoring of urinary calcium excretion [",
"    <a class=\"abstract\" href=\"UTD.htm?18/51/19258/abstract/60,74,79,80\">",
"     60,74,79,80",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/37/44632?source=see_link&amp;anchor=H12#H12\">",
"     \"Treatment of hypocalcemia\", section on 'Hypoparathyroidism'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/37/44632?source=see_link&amp;anchor=H17#H17\">",
"     \"Treatment of hypocalcemia\", section on 'Autosomal dominant hypocalcemia'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A possible adjunct in patients who remain symptomatic despite hypercalciuria is to give a thiazide diuretic to reduce urinary calcium excretion and raise the serum calcium concentration. This approach, which has been effective in patients with hypoparathyroidism, has been successfully used in rare cases of hypocalcemic hypocalciuria due to sporadic mutations [",
"    <a class=\"abstract\" href=\"UTD.htm?18/51/19258/abstract/81\">",
"     81",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/39/19061?source=see_link\">",
"     \"Diuretics and calcium balance\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Although it is not currently approved for use in hypoparathyroidism, the administration of recombinant parathyroid hormone (PTH), which is available for the treatment of osteoporosis, holds promise as a treatment for hypoparathyroidism, particularly in patients with ADH and refractory hypercalciuria. In clinical trials, recombinant PTH increased serum calcium while maintaining a normal level of urinary calcium excretion [",
"    <a class=\"abstract\" href=\"UTD.htm?18/51/19258/abstract/82\">",
"     82",
"    </a>",
"    ]. This topic is reviewed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/37/44632?source=see_link&amp;anchor=H14#H14\">",
"     \"Treatment of hypocalcemia\", section on 'Recombinant human PTH'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Alternatively, calcilytics, a class of drugs in development that inhibit the CaSR, may provide a useful therapeutic approach in the future by blocking the calciuric action of elevating serum calcium on the distal tubule. (See",
"    <a class=\"local\" href=\"#H21\">",
"     'Calcimimetics and calcilytics'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     ACQUIRED DISORDERS OF THE CALCIUM-SENSING RECEPTOR",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is increasing recognition of acquired changes in the CaSR in patients with hyperparathyroidism and hypoparathyroidism. The following observations illustrate the range of findings:",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Hyperparathyroidism",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Expression of the CaSR protein is commonly reduced in adenomas from patients with primary hyperparathyroidism [",
"      <a class=\"abstract\" href=\"UTD.htm?18/51/19258/abstract/83,84\">",
"       83,84",
"      </a>",
"      ]",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      severe secondary or so-called \"tertiary\" (eg, hypercalcemic) hyperparathyroidism due to chronic kidney disease [",
"      <a class=\"abstract\" href=\"UTD.htm?18/51/19258/abstract/84\">",
"       84",
"      </a>",
"      ]. Although the pathogenetic importance of this change is uncertain, it would make PTH secretion less responsive to suppression by calcium, as occurs in FHH.",
"     </li>",
"     <li>",
"      Some patients have antibodies that inactivate the CaSR, resulting in acquired hypocalciuric hypercalcemia [",
"      <a class=\"abstract\" href=\"UTD.htm?18/51/19258/abstract/85-87\">",
"       85-87",
"      </a>",
"      ]. Some of them have a history of multiple autoimmune disorders. Hypercalcemia and elevated parathyroid hormone levels may respond to corticosteroids in occasional patients with this condition. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Familial hypocalciuric hypercalcemia'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Hypoparathyroidism",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Occasional patients with apparently sporadic idiopathic hypoparathyroidism have an activating mutation of the CaSR [",
"      <a class=\"abstract\" href=\"UTD.htm?18/51/19258/abstract/60,75,76\">",
"       60,75,76",
"      </a>",
"      ]. The hypocalcemia in these cases ranges from mild to severe. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Autosomal dominant hypocalcemia'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Autoimmune hypoparathyroidism is a common feature of polyglandular autoimmune syndrome type I, which is a familial disorder. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?40/0/40969?source=see_link&amp;anchor=H3#H3\">",
"       \"Causes of primary adrenal insufficiency (Addison's disease)\", section on 'Polyglandular autoimmune syndrome type I'",
"      </a>",
"      .) In several studies of patients with hypoparathyroidism, autoantibodies directed at the CaSR's extracellular domain have been identified [",
"      <a class=\"abstract\" href=\"UTD.htm?18/51/19258/abstract/88-92\">",
"       88-92",
"      </a>",
"      ]. In two such studies, the anti-CaSR antibodies in patients with autoimmune hypoparathyroidism activated the CaSR in vitro, presumably inhibiting PTH secretion and producing hypoparathyroidism in vivo by this mechanism [",
"      <a class=\"abstract\" href=\"UTD.htm?18/51/19258/abstract/88,93\">",
"       88,93",
"      </a>",
"      ]. In one of these studies, the anti-CaSR antibodies were apparently not cytotoxic to parathyroid cells in vivo, since the hypoparathyroidism remitted spontaneously in one patient, while a histologically normal parathyroid gland was identified in the other at the time of thyroidectomy long after the onset of the hypoparathyroidism [",
"      <a class=\"abstract\" href=\"UTD.htm?18/51/19258/abstract/88\">",
"       88",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h1\">",
"     CALCIMIMETICS AND CALCILYTICS",
"    </span>",
"    &nbsp;&mdash;&nbsp;CaSR modulators that function as agonists (calcimimetics) or antagonists (calcilytics) are in development for the treatment of select disorders of calcium and parathyroid hormone regulation [",
"    <a class=\"abstract\" href=\"UTD.htm?18/51/19258/abstract/94,95\">",
"     94,95",
"    </a>",
"    ]. One calcimimetic agent (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/23/26998?source=see_link\">",
"     cinacalcet",
"    </a>",
"    ) is approved in the United States for the treatment of secondary hyperparathyroidism in patients with chronic kidney disease receiving dialysis and for the treatment of hypercalcemia in patients with parathyroid carcinoma. It has also been approved for use in other forms of primary hyperparathyroidism in Europe. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/36/38474?source=see_link&amp;anchor=H25#H25\">",
"     \"Management of secondary hyperparathyroidism and mineral metabolism abnormalities in dialysis patients\", section on 'Calcimimetics'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/23/13688?source=see_link&amp;anchor=H12#H12\">",
"     \"Parathyroid carcinoma\", section on 'Calcimimetics'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A calcimimetic agent modulates the CaSR by sensitizing it to activation by calcium, such that PTH secretion is reduced, thereby effectively lowering serum calcium concentration. Although not approved for other indications, calcimimetics may prove useful in the treatment of neonatal severe primary hyperparathyroidism, FHH [",
"    <a class=\"abstract\" href=\"UTD.htm?18/51/19258/abstract/96\">",
"     96",
"    </a>",
"    ], and forms of primary hyperparathyroidism other than primary hyperparathyroidism. In mild primary hyperparathyroidism, it has been shown to normalize the serum calcium concentration in about three quarters of the patients receiving it. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/47/8954?source=see_link&amp;anchor=H20#H20\">",
"     \"Management of primary hyperparathyroidism\", section on 'Calcimimetics'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Oral CaSR antagonists (calcilytics) are in development for the treatment of osteoporosis [",
"    <a class=\"abstract\" href=\"UTD.htm?18/51/19258/abstract/97\">",
"     97",
"    </a>",
"    ]. Administration leads to a transient rise in endogenous parathyroid hormone, similar to intermittently administered exogenous parathyroid hormone [",
"    <a class=\"abstract\" href=\"UTD.htm?18/51/19258/abstract/98\">",
"     98",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Calcilytics may also eventually have a role in the treatment of autosomal dominant hypoparathyroidism and in some patients with autoimmune hypoparathyroidism caused by activating CaSR antibodies.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The calcium-sensing receptor (CaSR) senses small changes in the serum ionized calcium concentration. In response to these changes, the CaSR allows functional changes in the parathyroid glands and kidneys, which are directed at normalizing serum calcium concentrations. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Functions of the calcium-sensing receptor'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Inactivating mutations of the CaSR cause familial hypocalciuric hypercalcemia (FHH), neonatal severe hyperparathyroidism, a milder form of neonatal hyperparathyroidism (NHPT), and occasionally familial isolated hyperparathyroidism. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Inactivating mutations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In most cases of FHH, parathyroid surgery is neither curative nor appropriate, although in the uncommon cases with atypical features, such as pancreatitis, hypercalciuria,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      overt hyperparathyroidism, subtotal parathyroidectomy has in some cases corrected these clinical and biochemical abnormalities. In NSHPT due to homozygous inactivating CaSR mutations, total parathyroidectomy is usually the therapy of choice. Treatment of these patients prior to surgery with a bisphosphonate or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?26/23/26998?source=see_link\">",
"       cinacalcet",
"      </a>",
"      may be helpful in stabilizing them medically. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Course and management'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H13\">",
"       'Neonatal severe hyperparathyroidism'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Activating mutations of the CaSR cause autosomal dominant hypocalcemia and a form of autosomal dominant hypocalcemia (ADH) with features of Bartter syndrome. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Activating mutations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Autoimmune activation of the CaSR can cause autoimmune hypoparathyroidism, whereas blocking antibodies can cause autoimmune hypocalciuric hypercalcemia. (See",
"      <a class=\"local\" href=\"#H18\">",
"       'Acquired disorders of the calcium-sensing receptor'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      CaSR activators (calcimimetics) and antagonists (calcilytics) are already in clinical use (eg,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?26/23/26998?source=see_link\">",
"       cinacalcet",
"      </a>",
"      ) or hold promise for pharmacologically improving defective calcium sensing in inherited or acquired disorders of the CaSR.",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/51/19258/abstract/1\">",
"      Brown EM, Hebert SC. Calcium-receptor-regulated parathyroid and renal function. Bone 1997; 20:303.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/51/19258/abstract/2\">",
"      Brown EM, Hebert SC. A cloned extracellular Ca(2+)-sensing receptor: molecular mediator of the actions of extracellular Ca2+ on parathyroid and kidney cells? Kidney Int 1996; 49:1042.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/51/19258/abstract/3\">",
"      Cheng I, Klingensmith ME, Chattopadhyay N, et al. Identification and localization of the extracellular calcium-sensing receptor in human breast. J Clin Endocrinol Metab 1998; 83:703.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/51/19258/abstract/4\">",
"      Ray JM, Squires PE, Curtis SB, et al. Expression of the calcium-sensing receptor on human antral gastrin cells in culture. J Clin Invest 1997; 99:2328.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/51/19258/abstract/5\">",
"      Kameda T, Mano H, Yamada Y, et al. Calcium-sensing receptor in mature osteoclasts, which are bone resorbing cells. Biochem Biophys Res Commun 1998; 245:419.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/51/19258/abstract/6\">",
"      Hebert SC, Cheng S, Geibel J. Functions and roles of the extracellular Ca2+-sensing receptor in the gastrointestinal tract. Cell Calcium 2004; 35:239.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/51/19258/abstract/7\">",
"      Geibel J, Sritharan K, Geibel R, et al. Calcium-sensing receptor abrogates secretagogue- induced increases in intestinal net fluid secretion by enhancing cyclic nucleotide destruction. Proc Natl Acad Sci U S A 2006; 103:9390.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/51/19258/abstract/8\">",
"      Hebert SC. Extracellular calcium-sensing receptor: implications for calcium and magnesium handling in the kidney. Kidney Int 1996; 50:2129.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/51/19258/abstract/9\">",
"      Tfelt-Hansen J, Brown EM. The calcium-sensing receptor in normal physiology and pathophysiology: a review. Crit Rev Clin Lab Sci 2005; 42:35.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/51/19258/abstract/10\">",
"      Hofer AM, Curci S, Doble MA, et al. Intercellular communication mediated by the extracellular calcium-sensing receptor. Nat Cell Biol 2000; 2:392.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/51/19258/abstract/11\">",
"      Kantham L, Quinn SJ, Egbuna OI, et al. The calcium-sensing receptor (CaSR) defends against hypercalcemia independently of its regulation of parathyroid hormone secretion. Am J Physiol Endocrinol Metab 2009; 297:E915.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/51/19258/abstract/12\">",
"      Cole DE, Peltekova VD, Rubin LA, et al. A986S polymorphism of the calcium-sensing receptor and circulating calcium concentrations. Lancet 1999; 353:112.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/51/19258/abstract/13\">",
"      Cole DE, Vieth R, Trang HM, et al. Association between total serum calcium and the A986S polymorphism of the calcium-sensing receptor gene. Mol Genet Metab 2001; 72:168.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/51/19258/abstract/14\">",
"      Scillitani A, Guarnieri V, De Geronimo S, et al. Blood ionized calcium is associated with clustered polymorphisms in the carboxyl-terminal tail of the calcium-sensing receptor. J Clin Endocrinol Metab 2004; 89:5634.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/51/19258/abstract/15\">",
"      Kos CH, Karaplis AC, Peng JB, et al. The calcium-sensing receptor is required for normal calcium homeostasis independent of parathyroid hormone. J Clin Invest 2003; 111:1021.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/51/19258/abstract/16\">",
"      Tu Q, Pi M, Karsenty G, et al. Rescue of the skeletal phenotype in CasR-deficient mice by transfer onto the Gcm2 null background. J Clin Invest 2003; 111:1029.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/51/19258/abstract/17\">",
"      Houillier P, Paillard M. Calcium-sensing receptor and renal cation handling. Nephrol Dial Transplant 2003; 18:2467.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/51/19258/abstract/18\">",
"      Frick KK, Bushinsky DA. Molecular mechanisms of primary hypercalciuria. J Am Soc Nephrol 2003; 14:1082.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/51/19258/abstract/19\">",
"      Gambaro G, Vezzoli G, Casari G, et al. Genetics of hypercalciuria and calcium nephrolithiasis: from the rare monogenic to the common polygenic forms. Am J Kidney Dis 2004; 44:963.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/51/19258/abstract/20\">",
"      Riccardi D, Lee WS, Lee K, et al. Localization of the extracellular Ca(2+)-sensing receptor and PTH/PTHrP receptor in rat kidney. Am J Physiol 1996; 271:F951.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/51/19258/abstract/21\">",
"      Hebert SC. Calcium and salinity sensing by the thick ascending limb: a journey from mammals to fish and back again. Kidney Int Suppl 2004; :S28.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/51/19258/abstract/22\">",
"      Haas M. The Na-K-Cl cotransporters. Am J Physiol 1994; 267:C869.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/51/19258/abstract/23\">",
"      Friedman PA, Gesek FA. Calcium transport in renal epithelial cells. Am J Physiol 1993; 264:F181.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/51/19258/abstract/24\">",
"      Amlal H, Legoff C, Vernimmen C, et al. Na(+)-K+(NH4+)-2Cl- cotransport in medullary thick ascending limb: control by PKA, PKC, and 20-HETE. Am J Physiol 1996; 271:C455.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/51/19258/abstract/25\">",
"      Wang WH, Lu M, Hebert SC. Cytochrome P-450 metabolites mediate extracellular Ca(2+)-induced inhibition of apical K+ channels in the TAL. Am J Physiol 1996; 271:C103.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/51/19258/abstract/26\">",
"      Schwartzman M, Ferreri NR, Carroll MA, et al. Renal cytochrome P450-related arachidonate metabolite inhibits (Na+ + K+)ATPase. Nature 1985; 314:620.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/51/19258/abstract/27\">",
"      de Jesus Ferreira MC, H&eacute;li&egrave;s-Toussaint C, Imbert-Teboul M, et al. Co-expression of a Ca2+-inhibitable adenylyl cyclase and of a Ca2+-sensing receptor in the cortical thick ascending limb cell of the rat kidney. Inhibition of hormone-dependent cAMP accumulation by extracellular Ca2+. J Biol Chem 1998; 273:15192.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/51/19258/abstract/28\">",
"      Sands JM, Naruse M, Baum M, et al. Apical extracellular calcium/polyvalent cation-sensing receptor regulates vasopressin-elicited water permeability in rat kidney inner medullary collecting duct. J Clin Invest 1997; 99:1399.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/51/19258/abstract/29\">",
"      Renkema KY, Velic A, Dijkman HB, et al. The calcium-sensing receptor promotes urinary acidification to prevent nephrolithiasis. J Am Soc Nephrol 2009; 20:1705.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/51/19258/abstract/30\">",
"      Yamaguchi T, Sugimoto T. [Impaired bone mineralization in calcium-sensing receptor (CaSR) knockout mice : the physiological action of CaSR in bone microenvironments]. Clin Calcium 2007; 17:1567.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/51/19258/abstract/31\">",
"      Brown EM, Lian JB. New insights in bone biology: unmasking skeletal effects of the extracellular calcium-sensing receptor. Sci Signal 2008; 1:pe40.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/51/19258/abstract/32\">",
"      Chang W, Tu C, Chen TH, et al. The extracellular calcium-sensing receptor (CaSR) is a critical modulator of skeletal development. Sci Signal 2008; 1:ra1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/51/19258/abstract/33\">",
"      Pollak MR, Brown EM, Chou YH, et al. Mutations in the human Ca(2+)-sensing receptor gene cause familial hypocalciuric hypercalcemia and neonatal severe hyperparathyroidism. Cell 1993; 75:1297.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/51/19258/abstract/34\">",
"      Pollak MR, Chou YH, Marx SJ, et al. Familial hypocalciuric hypercalcemia and neonatal severe hyperparathyroidism. Effects of mutant gene dosage on phenotype. J Clin Invest 1994; 93:1108.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/51/19258/abstract/35\">",
"      Bai M, Janicic N, Trivedi S, et al. Markedly reduced activity of mutant calcium-sensing receptor with an inserted Alu element from a kindred with familial hypocalciuric hypercalcemia and neonatal severe hyperparathyroidism. J Clin Invest 1997; 99:1917.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/51/19258/abstract/36\">",
"      Cole DE, Janicic N, Salisbury SR, Hendy GN. Neonatal severe hyperparathyroidism, secondary hyperparathyroidism, and familial hypocalciuric hypercalcemia: multiple different phenotypes associated with an inactivating Alu insertion mutation of the calcium-sensing receptor gene. Am J Med Genet 1997; 71:202.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/51/19258/abstract/37\">",
"      Pearce SH, Trump D, Wooding C, et al. Calcium-sensing receptor mutations in familial benign hypercalcemia and neonatal hyperparathyroidism. J Clin Invest 1995; 96:2683.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/51/19258/abstract/38\">",
"      Ho C, Conner DA, Pollak MR, et al. A mouse model of human familial hypocalciuric hypercalcemia and neonatal severe hyperparathyroidism. Nat Genet 1995; 11:389.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/51/19258/abstract/39\">",
"      Bai M, Pearce SH, Kifor O, et al. In vivo and in vitro characterization of neonatal hyperparathyroidism resulting from a de novo, heterozygous mutation in the Ca2+-sensing receptor gene: normal maternal calcium homeostasis as a cause of secondary hyperparathyroidism in familial benign hypocalciuric hypercalcemia. J Clin Invest 1997; 99:88.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/51/19258/abstract/40\">",
"      Lietman SA, Tenenbaum-Rakover Y, Jap TS, et al. A novel loss-of-function mutation, Gln459Arg, of the calcium-sensing receptor gene associated with apparent autosomal recessive inheritance of familial hypocalciuric hypercalcemia. J Clin Endocrinol Metab 2009; 94:4372.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/51/19258/abstract/41\">",
"      Marx SJ, Attie MF, Levine MA, et al. The hypocalciuric or benign variant of familial hypercalcemia: clinical and biochemical features in fifteen kindreds. Medicine (Baltimore) 1981; 60:397.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/51/19258/abstract/42\">",
"      Law WM Jr, Heath H 3rd. Familial benign hypercalcemia (hypocalciuric hypercalcemia). Clinical and pathogenetic studies in 21 families. Ann Intern Med 1985; 102:511.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/51/19258/abstract/43\">",
"      Heath H 3rd. Familial benign (hypocalciuric) hypercalcemia. A troublesome mimic of mild primary hyperparathyroidism. Endocrinol Metab Clin North Am 1989; 18:723.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/51/19258/abstract/44\">",
"      Brown EM. Clinical lessons from the calcium-sensing receptor. Nat Clin Pract Endocrinol Metab 2007; 3:122.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/51/19258/abstract/45\">",
"      Heath H 3rd, Jackson CE, Otterud B, Leppert MF. Genetic linkage analysis in familial benign (hypocalciuric) hypercalcemia: evidence for locus heterogeneity. Am J Hum Genet 1993; 53:193.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/51/19258/abstract/46\">",
"      Lloyd SE, Pannett AA, Dixon PH, et al. Localization of familial benign hypercalcemia, Oklahoma variant (FBHOk), to chromosome 19q13. Am J Hum Genet 1999; 64:189.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/51/19258/abstract/47\">",
"      Nesbit MA, Hannan FM, Howles SA, et al. Mutations in AP2S1 cause familial hypocalciuric hypercalcemia type 3. Nat Genet 2013; 45:93.",
"     </a>",
"    </li>",
"    <li>",
"     CASRdb: Calcium-sensing receptor database. www.casrdb.mcgill.ca (Accessed on January 21, 2009).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/51/19258/abstract/49\">",
"      Pearce SH, Bai M, Quinn SJ, et al. Functional characterization of calcium-sensing receptor mutations expressed in human embryonic kidney cells. J Clin Invest 1996; 98:1860.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/51/19258/abstract/50\">",
"      Zajickova K, Vrbikova J, Canaff L, et al. Identification and functional characterization of a novel mutation in the calcium-sensing receptor gene in familial hypocalciuric hypercalcemia: modulation of clinical severity by vitamin D status. J Clin Endocrinol Metab 2007; 92:2616.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/51/19258/abstract/51\">",
"      Marx SJ, Stock JL, Attie MF, et al. Familial hypocalciuric hypercalcemia: recognition among patients referred after unsuccessful parathyroid exploration. Ann Intern Med 1980; 92:351.",
"     </a>",
"    </li>",
"    <li>",
"     Heath H III. The familial benign hypocalciuric hypercalcemia syndromes. In: Principles of Bone Biology, Bilezikian JP, Raisz LG, Rodan GA (Eds), Academic Press, San Diego, CA 1996. p.769.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/51/19258/abstract/53\">",
"      Whitcomb DC. Genetic aspects of pancreatitis. Annu Rev Med 2010; 61:413.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/51/19258/abstract/54\">",
"      Silverberg SJ, Shane E, Jacobs TP, et al. Nephrolithiasis and bone involvement in primary hyperparathyroidism. Am J Med 1990; 89:327.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/51/19258/abstract/55\">",
"      Christensen SE, Nissen PH, Vestergaard P, et al. Discriminative power of three indices of renal calcium excretion for the distinction between familial hypocalciuric hypercalcaemia and primary hyperparathyroidism: a follow-up study on methods. Clin Endocrinol (Oxf) 2008; 69:713.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/51/19258/abstract/56\">",
"      Pasieka JL, Andersen MA, Hanley DA. Familial benign hypercalcaemia: hypercalciuria and hypocalciuria in affected members of a small kindred. Clin Endocrinol (Oxf) 1990; 33:429.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/51/19258/abstract/57\">",
"      Warner J, Epstein M, Sweet A, et al. Genetic testing in familial isolated hyperparathyroidism: unexpected results and their implications. J Med Genet 2004; 41:155.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/51/19258/abstract/58\">",
"      Simonds WF, James-Newton LA, Agarwal SK, et al. Familial isolated hyperparathyroidism: clinical and genetic characteristics of 36 kindreds. Medicine (Baltimore) 2002; 81:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/51/19258/abstract/59\">",
"      Carling T, Szabo E, Bai M, et al. Familial hypercalcemia and hypercalciuria caused by a novel mutation in the cytoplasmic tail of the calcium receptor. J Clin Endocrinol Metab 2000; 85:2042.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/51/19258/abstract/60\">",
"      Egbuna OI, Brown EM. Hypercalcaemic and hypocalcaemic conditions due to calcium-sensing receptor mutations. Best Pract Res Clin Rheumatol 2008; 22:129.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/51/19258/abstract/61\">",
"      Kobayashi M, Tanaka H, Tsuzuki K, et al. Two novel missense mutations in calcium-sensing receptor gene associated with neonatal severe hyperparathyroidism. J Clin Endocrinol Metab 1997; 82:2716.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/51/19258/abstract/62\">",
"      Obermannova B, Banghova K, Sumn&iacute;k Z, et al. Unusually severe phenotype of neonatal primary hyperparathyroidism due to a heterozygous inactivating mutation in the CASR gene. Eur J Pediatr 2009; 168:569.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/51/19258/abstract/63\">",
"      Marx SJ, Lasker RD, Brown EM, et al. Secretory dysfunction in parathyroid cells from a neonate with severe primary hyperparathyroidism. J Clin Endocrinol Metab 1986; 62:445.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/51/19258/abstract/64\">",
"      Hendy GN, D'Souza-Li L, Yang B, et al. Mutations of the calcium-sensing receptor (CASR) in familial hypocalciuric hypercalcemia, neonatal severe hyperparathyroidism, and autosomal dominant hypocalcemia. Hum Mutat 2000; 16:281.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/51/19258/abstract/65\">",
"      Waller S, Kurzawinski T, Spitz L, et al. Neonatal severe hyperparathyroidism: genotype/phenotype correlation and the use of pamidronate as rescue therapy. Eur J Pediatr 2004; 163:589.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/51/19258/abstract/66\">",
"      Wilhelm-Bals A, Parvex P, Magdelaine C, Girardin E. Successful use of bisphosphonate and calcimimetic in neonatal severe primary hyperparathyroidism. Pediatrics 2012; 129:e812.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/51/19258/abstract/67\">",
"      Pollak MR, Brown EM, Estep HL, et al. Autosomal dominant hypocalcaemia caused by a Ca(2+)-sensing receptor gene mutation. Nat Genet 1994; 8:303.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/51/19258/abstract/68\">",
"      D'Souza-Li L, Yang B, Canaff L, et al. Identification and functional characterization of novel calcium-sensing receptor mutations in familial hypocalciuric hypercalcemia and autosomal dominant hypocalcemia. J Clin Endocrinol Metab 2002; 87:1309.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/51/19258/abstract/69\">",
"      Watanabe S, Fukumoto S, Chang H, et al. Association between activating mutations of calcium-sensing receptor and Bartter's syndrome. Lancet 2002; 360:692.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/51/19258/abstract/70\">",
"      Konrad M, Weber S. Recent advances in molecular genetics of hereditary magnesium-losing disorders. J Am Soc Nephrol 2003; 14:249.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/51/19258/abstract/71\">",
"      Watanabe T, Bai M, Lane CR, et al. Familial hypoparathyroidism: identification of a novel gain of function mutation in transmembrane domain 5 of the calcium-sensing receptor. J Clin Endocrinol Metab 1998; 83:2497.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/51/19258/abstract/72\">",
"      Conley YP, Finegold DN, Peters DG, et al. Three novel activating mutations in the calcium-sensing receptor responsible for autosomal dominant hypocalcemia. Mol Genet Metab 2000; 71:591.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/51/19258/abstract/73\">",
"      Tan YM, Cardinal J, Franks AH, et al. Autosomal dominant hypocalcemia: a novel activating mutation (E604K) in the cysteine-rich domain of the calcium-sensing receptor. J Clin Endocrinol Metab 2003; 88:605.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/51/19258/abstract/74\">",
"      Lienhardt A, Bai M, Lagarde JP, et al. Activating mutations of the calcium-sensing receptor: management of hypocalcemia. J Clin Endocrinol Metab 2001; 86:5313.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/51/19258/abstract/75\">",
"      Baron J, Winer KK, Yanovski JA, et al. Mutations in the Ca(2+)-sensing receptor gene cause autosomal dominant and sporadic hypoparathyroidism. Hum Mol Genet 1996; 5:601.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/51/19258/abstract/76\">",
"      De Luca F, Ray K, Mancilla EE, et al. Sporadic hypoparathyroidism caused by de Novo gain-of-function mutations of the Ca(2+)-sensing receptor. J Clin Endocrinol Metab 1997; 82:2710.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/51/19258/abstract/77\">",
"      Suzuki M, Aso T, Sato T, et al. A case of gain-of-function mutation in calcium-sensing receptor: supplemental hydration is required for renal protection. Clin Nephrol 2005; 63:481.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/51/19258/abstract/78\">",
"      Hough TA, Bogani D, Cheeseman MT, et al. Activating calcium-sensing receptor mutation in the mouse is associated with cataracts and ectopic calcification. Proc Natl Acad Sci U S A 2004; 101:13566.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/51/19258/abstract/79\">",
"      Pearce SH, Williamson C, Kifor O, et al. A familial syndrome of hypocalcemia with hypercalciuria due to mutations in the calcium-sensing receptor. N Engl J Med 1996; 335:1115.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/51/19258/abstract/80\">",
"      Burren CP, Curley A, Christie P, et al. A family with autosomal dominant hypocalcaemia with hypercalciuria (ADHH): mutational analysis, phenotypic variability and treatment challenges. J Pediatr Endocrinol Metab 2005; 18:689.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/51/19258/abstract/81\">",
"      Sato K, Hasegawa Y, Nakae J, et al. Hydrochlorothiazide effectively reduces urinary calcium excretion in two Japanese patients with gain-of-function mutations of the calcium-sensing receptor gene. J Clin Endocrinol Metab 2002; 87:3068.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/51/19258/abstract/82\">",
"      Winer KK, Ko CW, Reynolds JC, et al. Long-term treatment of hypoparathyroidism: a randomized controlled study comparing parathyroid hormone-(1-34) versus calcitriol and calcium. J Clin Endocrinol Metab 2003; 88:4214.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/51/19258/abstract/83\">",
"      Kifor O, Moore FD Jr, Wang P, et al. Reduced immunostaining for the extracellular Ca2+-sensing receptor in primary and uremic secondary hyperparathyroidism. J Clin Endocrinol Metab 1996; 81:1598.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/51/19258/abstract/84\">",
"      Gogusev J, Duchambon P, Hory B, et al. Depressed expression of calcium receptor in parathyroid gland tissue of patients with hyperparathyroidism. Kidney Int 1997; 51:328.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/51/19258/abstract/85\">",
"      Pallais JC, Kifor O, Chen YB, et al. Acquired hypocalciuric hypercalcemia due to autoantibodies against the calcium-sensing receptor. N Engl J Med 2004; 351:362.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/51/19258/abstract/86\">",
"      Kifor O, Moore FD Jr, Delaney M, et al. A syndrome of hypocalciuric hypercalcemia caused by autoantibodies directed at the calcium-sensing receptor. J Clin Endocrinol Metab 2003; 88:60.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/51/19258/abstract/87\">",
"      Makita N, Sato J, Manaka K, et al. An acquired hypocalciuric hypercalcemia autoantibody induces allosteric transition among active human Ca-sensing receptor conformations. Proc Natl Acad Sci U S A 2007; 104:5443.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/51/19258/abstract/88\">",
"      Kifor O, McElduff A, LeBoff MS, et al. Activating antibodies to the calcium-sensing receptor in two patients with autoimmune hypoparathyroidism. J Clin Endocrinol Metab 2004; 89:548.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/51/19258/abstract/89\">",
"      Li Y, Song YH, Rais N, et al. Autoantibodies to the extracellular domain of the calcium sensing receptor in patients with acquired hypoparathyroidism. J Clin Invest 1996; 97:910.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/51/19258/abstract/90\">",
"      Gavalas NG, Kemp EH, Krohn KJ, et al. The calcium-sensing receptor is a target of autoantibodies in patients with autoimmune polyendocrine syndrome type 1. J Clin Endocrinol Metab 2007; 92:2107.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/51/19258/abstract/91\">",
"      Mayer A, Ploix C, Orgiazzi J, et al. Calcium-sensing receptor autoantibodies are relevant markers of acquired hypoparathyroidism. J Clin Endocrinol Metab 2004; 89:4484.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/51/19258/abstract/92\">",
"      Brown EM. Anti-parathyroid and anti-calcium sensing receptor antibodies in autoimmune hypoparathyroidism. Endocrinol Metab Clin North Am 2009; 38:437.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/51/19258/abstract/93\">",
"      Kemp EH, Gavalas NG, Krohn KJ, et al. Activating autoantibodies against the calcium-sensing receptor detected in two patients with autoimmune polyendocrine syndrome type 1. J Clin Endocrinol Metab 2009; 94:4749.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/51/19258/abstract/94\">",
"      Hu J. Allosteric modulators of the human calcium-sensing receptor: structures, sites of action, and therapeutic potentials. Endocr Metab Immune Disord Drug Targets 2008; 8:192.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/51/19258/abstract/95\">",
"      Nemeth EF. Pharmacological regulation of parathyroid hormone secretion. Curr Pharm Des 2002; 8:2077.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/51/19258/abstract/96\">",
"      Timmers HJ, Karperien M, Hamdy NA, et al. Normalization of serum calcium by cinacalcet in a patient with hypercalcaemia due to a de novo inactivating mutation of the calcium-sensing receptor. J Intern Med 2006; 260:177.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/51/19258/abstract/97\">",
"      Fitzpatrick LA, Dabrowski CE, Cicconetti G, et al. The effects of ronacaleret, a calcium-sensing receptor antagonist, on bone mineral density and biochemical markers of bone turnover in postmenopausal women with low bone mineral density. J Clin Endocrinol Metab 2011; 96:2441.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/51/19258/abstract/98\">",
"      Kumar S, Matheny CJ, Hoffman SJ, et al. An orally active calcium-sensing receptor antagonist that transiently increases plasma concentrations of PTH and stimulates bone formation. Bone 2010; 46:534.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 838 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0605-61.234.146.186-73A94EB3C9-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_51_19258=[""].join("\n");
var outline_f18_51_19258=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H22\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      FUNCTIONS OF THE CALCIUM-SENSING RECEPTOR",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Parathyroid gland",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Kidney",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Urine calcium excretion",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Urinary concentration",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Bone",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      INACTIVATING MUTATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Familial hypocalciuric hypercalcemia",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Clinical findings",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Distinction from primary hyperparathyroidism",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Course and management",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Neonatal severe hyperparathyroidism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      ACTIVATING MUTATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Autosomal dominant hypocalcemia",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Clinical manifestations",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      ACQUIRED DISORDERS OF THE CALCIUM-SENSING RECEPTOR",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Hyperparathyroidism",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Hypoparathyroidism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      CALCIMIMETICS AND CALCILYTICS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ENDO/838\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ENDO/838|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?32/10/32942\" title=\"figure 1\">",
"      Ca PTH curve",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?30/62/31725\" title=\"figure 2\">",
"      Loop of Henle transport",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ENDO/838|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?28/40/29323\" title=\"table 1\">",
"      Disorders ca sensing CaSR",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/43/23226?source=related_link\">",
"      Bartter and Gitelman syndromes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/0/40969?source=related_link\">",
"      Causes of primary adrenal insufficiency (Addison's disease)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/49/36630?source=related_link\">",
"      Chapter 4A: Cell model for loop of Henle transport",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/2/21545?source=related_link\">",
"      Clinical manifestations and causes of nephrogenic diabetes insipidus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/26/5545?source=related_link\">",
"      Diagnosis and differential diagnosis of primary hyperparathyroidism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/39/19061?source=related_link\">",
"      Diuretics and calcium balance",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/47/8954?source=related_link\">",
"      Management of primary hyperparathyroidism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/36/38474?source=related_link\">",
"      Management of secondary hyperparathyroidism and mineral metabolism abnormalities in dialysis patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/23/13688?source=related_link\">",
"      Parathyroid carcinoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/56/36744?source=related_link\">",
"      Parathyroid hormone secretion and action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/41/30361?source=related_link\">",
"      Pathogenesis and etiology of primary hyperparathyroidism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/37/44632?source=related_link\">",
"      Treatment of hypocalcemia",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f18_51_19259="Pustules";
var content_f18_51_19259=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F56796&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F56796&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Differential diagnosis of pustules",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td>",
"        Acne rosacea/perioral dermatitis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Acne vulgaris",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Arthropod bite (fire ants)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Drug eruption",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Eosinophilic folliculitis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Erythema toxicum neonatorum",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Folliculitis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Fungal or yeast infections (especially tinea capitis and Majocchi's granuloma)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Furunculosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Gonorrhea (disseminated)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Herpes simplex/zoster",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Impetigo",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Keratosis pilaris",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Neonatal pustulosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Pseudofolliculitis barbae",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Pustular psoriasis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Pyoderma gangrenosum",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Syphilis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Varicella",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_51_19259=[""].join("\n");
var outline_f18_51_19259=null;
var title_f18_51_19260="Radiology for urolithiasis";
var content_f18_51_19260=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F65056&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F65056&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Radiologic procedures in evaluating renal stones",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        &nbsp;",
"       </td>",
"       <td class=\"subtitle1\">",
"        Advantages",
"       </td>",
"       <td class=\"subtitle1\">",
"        Disadvantages",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        KUB",
"       </td>",
"       <td>",
"        <p>",
"         Readily available",
"        </p>",
"        <p>",
"         Inexpensive",
"        </p>",
"        <p>",
"         Limited radiation",
"        </p>",
"        <p>",
"         Useful in acute setting",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         Requires skilled radiologist to interpret",
"        </p>",
"        <p>",
"         Limited sensitivity and specificity",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Ultrasound",
"       </td>",
"       <td>",
"        <p>",
"         Readily available",
"        </p>",
"        <p>",
"         Roughly equivalent to IVP as a diagnostic test",
"        </p>",
"        <p>",
"         Improved sensitivity with use of color Doppler",
"        </p>",
"        <p>",
"         No radiation exposure",
"        </p>",
"        <p>",
"         Good for hydronephrosis",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         Moderately expensive",
"        </p>",
"        <p>",
"         Poor performance with small stones",
"        </p>",
"        <p>",
"         Requires skilled technician and radiologist",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Excretory urography (IVP)",
"       </td>",
"       <td>",
"        <p>",
"         Useful in planning therapy and confirming diagnosis",
"        </p>",
"        <p>",
"         Long established history as gold standard",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         Moderately expensive",
"        </p>",
"        <p>",
"         Intravenous contrast required",
"        </p>",
"        <p>",
"         Moderate x-ray exposure",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        CT scan (including spiral CT)",
"       </td>",
"       <td>",
"        <p>",
"         Probably new gold standard",
"        </p>",
"        <p>",
"         Can distinguish radiolucent stones from blood or tumor",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         Expensive",
"        </p>",
"        <p>",
"         Moderate x-ray exposure",
"        </p>",
"        <p>",
"         Not uniformly available",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        MRI",
"       </td>",
"       <td>",
"        Great potential for localizing site of stone in ureter",
"       </td>",
"       <td>",
"        <p>",
"         Very expensive",
"        </p>",
"        <p>",
"         Largely investigational so far except in certain centers",
"        </p>",
"        <p>",
"         Poorly tolerated by many patients",
"        </p>",
"        <p>",
"         Stones are not affected by magnet and may be missed",
"        </p>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_51_19260=[""].join("\n");
var outline_f18_51_19260=null;
var title_f18_51_19261="Bethesda class cervix cytol";
var content_f18_51_19261=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F71416&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F71416&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Bethesda classification of cervical cytology",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Specimen type",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Conventional smear, liquid-based, or other technique",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Specimen adequacy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Satisfactory for evaluation (description includes quality indicators, including endocervical/transformation zone component and obscuring blood or inflammation)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Unsatisfactory due to... (specify reason)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        General categorization (optional)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Negative for intraepithelial lesion or malignancy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Epithelial cell abnormality (specify squamous or glandular)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Other: see interpretation/result (eg, endometrial cells in woman &ge;age 40)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Automated review",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        If examined by a device, specify device and result",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Ancillary testing",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Describe method and result (eg, molecular testing)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Interpretation/result",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Negative for intraepithelial lesion or malignancy (when there is absence of neoplasia this should be stated specifically, regardless of other findings)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2_start\">",
"        In addition describe, if present:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Infection (Trichomonas vaginalis, Candida spp, shift in flora consistent with bacterial vaginosis, Actinomyces spp, cellular changes)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2_start\">",
"        Other nonneoplastic findings, such as, but not limited to:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Reactive cellular changes associated with inflammation/cellular repair, radiation, or an intrauterine contraceptive device",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Glandular cells post hysterectomy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Atrophy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Other",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Endometrial cells (in a woman &ge;age 40) and specify whether negative for squamous intraepithelial lesion",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Epithelial cell abnormalities",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle3_single\">",
"        Squamous cell",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist3_start\">",
"        Atypical squamous cells (ASC)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist3\">",
"        of undetermined significance (ASC-US)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist3\">",
"        cannot exclude HSIL (ASC-H)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        Low grade squamous intraepithelial lesion (LSIL) cellular changes consistent with HPV, mild dysplasia, CIN 1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist3_start\">",
"        High grade squamous intraepithelial lesion (HSIL) moderate/severe dysplasia, CIN 2, CIN 3, CIS",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist3\">",
"        indicate if there are features suspicious for invasion (if invasion suspected)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        Squamous cell carcinoma",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle3_single\">",
"        Glandular cell",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist3_start\">",
"        Atypical",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist3\">",
"        Endocervical cells",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist3\">",
"        Endometrial cells",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist3\">",
"        Not otherwise specified",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist3_start\">",
"        Atypical, favor neoplastic",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist3\">",
"        Endocervical cells",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist3\">",
"        Not otherwise specified",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        Endocervical adenocarcinoma in situ (AIS)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        Adenocarcinoma",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Other malignant neoplasms (specify)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Educational notes and suggestions",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Suggestions should be concise and consistent with clinical follow-up guidelines published by professional organizations",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Solomon D, Davey D, Kurman R, et al. The 2001 Bethesda system: terminology for reporting results of cervical cytology. JAMA 2002; 287:2114.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_51_19261=[""].join("\n");
var outline_f18_51_19261=null;
var title_f18_51_19262="Disease specific guidelines for hospice";
var content_f18_51_19262=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F61282&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F61282&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Medical guidelines for determining appropriateness of hospice referral: Disease specific guidelines",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr class=\"divider_bottom\">",
"       <td>",
"        A patient will be considered to have a life expectancy of six months and be eligible for hospice services if he/she meets criteria for the following disease specific baseline guidelines as well as evidence of decline as outlined in non disease-specific baseline guidelines (shown on a separate table):",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Cancer diagnoses",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Disease with metastases at presentation, OR",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Progression from an earlier stage of disease to metastatic disease with either continued decline in spite of therapy or patient declines further disease-directed therapy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Dementia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Severity level beyond Stage 7-C of the Functional Assessment Staging (FAST): unable to walk/dress without assistance, urinary and fecal incontinence, no meaningful verbal communication: stereotypical phrases only or the ability to speak is limited to six words or less",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Medical complications such as aspiration pneumonia, urosepsis, multiple stage 3-4 decubitus ulcers",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Fever after a course of antibiotics",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Weight loss of &gt;10 percent over six months",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Heart disease",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Symptomatic at rest despite optimal treatment with diuretics and vasodilators (preferably ACE-inhibitors or ARBs)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Symptomatic supraventricular or ventricular arrhythmias resistant to antiarrhythmic medications",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Elderly patients with intractable angina despite appropriate medical therapy who are not candidates for coronary revascularization",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        HIV",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        CD4+ (T cell) count &lt;25",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Viral load &gt;100,000 copies/mL",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Decreased functional status with a Karnofsky performance score &lt;50",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        At least one AIDS related illness",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Central nervous system lymphoma",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Poorly responsive systemic lymphoma",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Weight loss of &gt;30 percent lean body mass",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Mycobacterium avium (MAC) bacteremia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Progressive multifocal leukoencephalopathy (PML)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Refractory visceral Kaposi's sarcoma (KS)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Refractory cryptosporidium infection",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Refractory toxoplasmosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Liver disease",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Prothrombin time more than five seconds over normal values or INR &gt;1.5",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Serum albumin &lt;2.5 gm/dL",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        One or more medical conditions associated with advanced liver failure",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Ascites despite optimal diuretic regimen",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Episodes of spontaneous bacterial peritonitis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Hepatorenal syndrome",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Hepatic encephalopathy despite optimal medical treatment",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Recurrent bleeding from esophageal varices after treatment",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Pulmonary disease",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Irreversible obstructive or restrictive disease",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Disabling dyspnea at rest or with minimal exertion (FEV1 &lt;30 percent predicted value is helpful but not required)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Progressive disease documented as increasing Emergency Room visits or hospitalizations",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hypoxemia as defined as PaO2 &le;55 mmHg or oxygen saturation &le;88 percent on room air",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hypercapnia as defined as PaCO2 &ge;50 mmHg",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cor pulmonale: right heart failure as a result of lung disease",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Unintentional progressive weight loss of greater than 10 percent of body weight over the preceding six months",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Resting tachycardia &gt;100 beats/min",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Renal disease (acute and chronic)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        No hemodialysis or renal transplant",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Signs of uremia (confusion, nausea, pruritus, restlessness, pericarditis)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Intractable fluid overload",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Oliguria",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Intractable hyperkalemia &gt;7.0 mg/dL",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Creatinine clearance &lt;10 cc/min (15 cc/min for diabetics)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Serum creatinine &gt;8.0 mg/dL",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Stroke or coma",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Coma for greater than three days after a cerebrovascular accident (CVA)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Severe dysphagia in patients not receiving a feeding tube or parenteral nutrition",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Chronic phase post-CVA with",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Dementia Stage 7-C of the FAST scale",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Karnofsky performance status &lt;40",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Weight loss of &gt;10 percent in six months",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Serum albumin &lt;2.5 gm/dL",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Coma with",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Abnormal brain stem reflexes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        No response to verbal stimuli",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        No withdrawal from painful stimuli",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Serum creatinine &gt;1.5 mg/dL",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Debility",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Multiple comorbidities with no primary diagnosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Multiple hospitalizations",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Physical decline",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Poor nutritional status (weight loss, albumin &lt;2.5)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Dependence in most ADLs",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Karnofsky score &le;50",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    Karnofsky = 50: Requires considerable assistance and frequent medical care.",
"    <br/>",
"    Karnofsky &lt;50: Unable to care for self; requires equivalent of institutional or hospital care; disease may be progressing rapidly.",
"    <div class=\"footnotes\">",
"     FEV1: forced vital capacity in one second; PaO2: arterial oxygen tension; PaCO2: arterial carbon dioxide tension; FAST 7-C: Functional Assessment Staging 7-C; ARB: angiotensin receptor blocker; ACE-inhibitor: angiotensin converting enzyme inhibitor; INR: international normalized ratio; ADL: activities of daily living.",
"    </div>",
"    <div class=\"reference\">",
"     Sources:",
"     <br/>",
"     <ol>",
"      <li>",
"       The NHO medical guidelines for non-cancer disease and local medical review policy: hospice access for patients with diseases other than cancer. Hosp J 1999.",
"      </li>",
"      <li>",
"       Centers for Medicare &amp; Medicaid Services. Local Coverage Determination (LCD) for Hospice Determining Terminal Status (L32015)",
"       <a href=\"file://www.cms.gov/medicare-coverage-database/shared/handlers/highwire.ashx?url=file://www.cms.gov/medicare-coverage-database/details/lcd-details.aspx@@@LCDId$$$32015***ContrId$$$236***ver$$$11***ContrVer$$$2***CntrctrSelected$$$236*2***Cntrctr$$$236***name$$$CGS+Administrators,+LLC+(15004,+HHH+MAC)***LCntrctr$$$236*2***bc$$$AgACAAIAQAAA***&amp;session=a2qgjyiqqk1bgt454ny2dr55&amp;kq=1056876468\" target=\"_blank\">",
"        file://www.cms.gov",
"       </a>",
"       (Accessed on January 10, 2013).",
"      </li>",
"     </ol>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_51_19262=[""].join("\n");
var outline_f18_51_19262=null;
var title_f18_51_19263="Nomogram of hour-specific total bilirubin in term infants";
var content_f18_51_19263=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F70863&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F70863&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 542px\">",
"   <div class=\"ttl\">",
"    Nomogram of hour-specific serum total bilirubin (STB) concentration in healthy term and near-term newborns",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 522px; height: 350px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The red, blue, and green lines denote the 95th, 75th, and 40th percentiles, respectively. Risk zones are designated according to percentile: high (STB &ge;95th), high intermediate (95th &gt;STB &ge;75th), low intermediate (75th &gt;STB &ge;40th), and low (STB &lt;40th). Infants with values in the high risk zone are at increased risk for the development of clinically significant hyperbilirubinemia requiring intervention.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from Subcommittee on Hyperbilirubinemia. Management of Hyperbilirubinemia in the Newborn Infant 35 or More Weeks of Gestation. Pediatrics 2004; 114:297. Copyright &copy; 2004 The American Academy of Pediatrics.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_51_19263=[""].join("\n");
var outline_f18_51_19263=null;
